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ABSTRACT 
 
Total Knee Arthroplasty (TKA) is one of the most commonly performed procedures in 
the United States every year.  In 2014 alone, approximately three-quarters of a million were 
performed at a cost of nearly $40 billion.  These figures are only expected to grow.  Obesity is 
one factor influencing this growth.  Obese patients are becoming a larger portion of those having 
TKA procedures and face different risks and benefits when doing so.  Some have suggested that 
TKA be restricted in the obese population to either control spending or because obese patients do 
not see the same outcomes as nonobese patients.  Given the substantial budget impact, it is 
important to understand the differences faced by obese patients.   
This dissertation uses meta-analysis, cost-effectiveness analysis, and agent-based 
modeling to inform decision making about obese patients and TKA.  The meta-analysis resolves 
some uncertainty in the current literature around complication and implant survival rates in 
individuals with different obesity classifications.  Then, the cost-effectiveness analysis explores 
the relative costs and benefits of the TKA procedure by obesity class.  Finally, a trend model is 
built in an agent-based framework to examine the volume of TKA procedures and the budget 
impact for the entire US population under different potential future scenarios.   
These results show that even though obese patients do face higher rates of complications 
than their nonobese counterparts, this alone does not rule out TKA as a reasonable option for 
those patients.  Even in the heaviest patients, TKA is cost-effective.  The budget impact for 
restricting access to obese patients is minimal due to the offsetting rise in costs of living with 
osteoarthritis without surgical intervention.  There are potential policy solutions to the large 
xiii 
 
expenditure on TKA and certain areas need further investigation before guidelines should be 
changed.  Obesity does matter when considering TKA policies and outcomes, but outright bans 
on TKA in obese patients may not be the best policy solutions.  
  
1 
 
Introduction 
 
 
Total Knee Arthroplasty (TKA) is the most common inpatient surgery (excluding 
maternal and neonatal procedures) with 752,941 performed in 2014 alone at a rate of 237 per 
100,000 (Healthcare Cost and Utilization Project (HCUP), 2017).  This rate was virtually 
unchanged for 2015, the last year with data available (Healthcare Cost and Utilization Project 
(HCUP), 2017).  According to a 2014 report, it is also in growing demand with the second 
greatest rate of increase among inpatient operative procedures having an average annual growth 
rate of 4.9% between 2003 and 2012 (Fingar, Stocks, Weiss, & Steiner, 2014).  One controllable 
driver of this increased demand is obesity (Fehring, Odum, Griffin, Mason, & McCoy, 2007).  
Obesity is a risk factor for developing osteoarthritis (OA), the primary condition that leads to 
TKA,  increasing risk by a factor of 3-4 (Webb, et al., 2004) which in turn contributes to the 
increased share of TKA patients who are obese nearly doubling between 1990 and 2005 
(Fehring, Odum, Griffin, Mason, & McCoy, 2007). The share of TKA patients who are obese is 
also double the share of the general population who are obese (Fehring, Odum, Griffin, Mason, 
& McCoy, 2007).  Taken together, TKA procedures are a significant and growing portion of the 
health care budget and rising obesity rates are both driving the rise in TKA and changing the 
makeup of the TKA population.  It is less clear what effect this trend towards heavier patients is 
having on outcomes of the popular procedure.   
Obesity is a major public health concern that now affects over 1/3 of the US population 
(Ogden, Carroll, Fryar, & Flegal, 2015).  The definition of obesity varies in the current literature 
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and this variation may explain some of the lack of consensus on whether obesity alone leads to 
poor surgical outcomes in TKA.  Obesity can be classified in several ways, the most popular 
being to use Body Mass Index (BMI).  BMI is simply defined as the body mass in kilograms 
divided by the square of height in meters.  Obesity is almost always treated categorically (i.e. 
normal, overweight, obese), but the underlying value is continuous, a simple relationship 
between height and weight.  The most familiar treatment of obesity is a binary variable in chart 
reviews or lists of comorbidities meaning the person is either above BMI 30 or not.  Another 
important cutoff is morbid obesity defined as BMI ≥ 40, which now encompasses more than 5% 
of the US population (National Institute of Diabetes and Digestive and Kidney Diseases, 2012).  
The World Health Organization (WHO) classification system uses three smaller classifications 
of obesity by dividing the obese class in two halves: Class I with 30 ≤ BMI < 35, Class II with 35 
≤ BMI < 40, and Class III with BMI ≥ 40, identical to morbid obesity (Centers for Disease 
Control and Prevention, 2016).  It is important to remember that because of the continuous 
nature of the underlying BMI value that an obese person with BMI of 30 may be more like the 
overweight group (25 ≤ BMI < 30), than an obese person with BMI of 39 than the categorical 
variable might otherwise suggest.   
The TKA literature currently offers conflicting evidence on whether obese patients have 
poorer outcomes or whether to restrict surgical intervention in this patient population or some 
segment of it.  Due to the growing share of obese patients receiving TKA, this is a popular 
subject in the literature, yet no clear consensus has been reached (Rodriguez-Merchan, 2015) 
(Alvi, et al., 2015) (Wallace, et al., 2014) (D'Apuzzo, Novicoff, & Browne, 2015) (Abdel, Ast, 
Lee, Lyman, & Gonzalez Della Valle, 2014) (Napier, et al., 2014) (Belmont, Goodman, 
Waterman, Bader, & Schoenfeld, 2014) (Baker, et al., 2013) (Issa, et al., 2013) (Issa, et al., 2013) 
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(Liabaud, Patrick, & Geller, 2013) (Collins, Walmsley, Amin, Brenkel, & Clayton, 2012) 
(Jarvenpaa, Kettunen, Soininvaara, Miettinen, & Kroger, 2012) (Yeung, et al., 2011) (Jarvenpaa, 
Kettunen, Kroger, & Miettinen, 2010) (Krushell & Fingeroth, 2007) (Amin, et al., 2006) (Foran, 
et al., 2004) (Spicer, et al., 2001) (Chesney, Sorth, Sales, Elton, & Brenkel, 2008) (Johnson, 
Worland, Keenan, & Norambuena, 2003) (Bordini, et al., 2009).  When morbid obesity is used in 
the analysis, there is much more agreement in the literature that outcomes are worse for these 
patients (Amin, et al., 2006) (D'Apuzzo, Novicoff, & Browne, 2015) (Issa, et al., 2013) (Krushell 
& Fingeroth, 2007).  Despite a variety of approaches and methodologies, the literature finds little 
common ground.   
As the share of TKA patients who are obese grows, the question of whether obesity is a 
predictor of poor outcomes or even a disqualifying condition for surgery grows in importance for 
both individual patients and as a broader policy concern (Amin, et al., 2006) (Collins, Walmsley, 
Amin, Brenkel, & Clayton, 2012).   A clear answer to the question of how obesity affects various 
outcomes is essential if policy makers are to develop guidelines in a systematic way.  Attempts 
to establish guidelines or restrict access to TKA have been deemed arbitrary and judged to be 
solely based on financial considerations rather than patient care.  In 2005, a local health trust in 
the United Kingdom (UK) banned knee replacement in any patient with a BMI over 30 unless all 
other options were exhausted and daily life was affected by the joint (Coombes, 2005).  In this 
case, while clinicians supported the move based on the risk factors in this population, the motive 
is openly financial in a health system trying to close a budget deficit with a local National Health 
Service (NHS) official quoted as calling the move “unashamedly financial” while also admitting 
it was “unlikely to make big savings”  (Carvel, 2005).  An official from the national (UK) 
Department of Health noted in response to this policy, that “Any actions that trusts take to 
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manage to reduce deficits should not lower the quality of care provided to NHS patients” 
indicating a more nuanced process is desirable (Carvel, 2005).  In 2016, other NHS trusts also 
adopted a total restriction for routine surgeries, specifically including TKA, in obese patients 
until they lost 10% of body weight.  Again, the motive is stated to be mainly financial with the 
NHS official referring to “severe pressure” when discussing cutting off payments for those not 
following the new policy, but this blanket ban has provoked more pushback from clinicians 
(Bodkin, 2016).   In the American setting, the conversation includes more nuanced questions.  
These focus on areas like requiring weight loss before surgery in obese patients, how to 
effectively communicate the increased risk profile to patients, the ethics of withholding care 
from an otherwise eligible candidate, and who pays for any increased costs or burdens (Wooten 
& Curtin, 2016), (Martin, Jennings, & Dennis, 2017), (Li, et al., 2017), (Stickles, Phillips, Brox, 
Owens, & Lanzer, 2001), (Incavo & Derasari, 2014), (Kremers, Visscher, Kremers, Naessens, & 
Lewallen, 2014), (Gillespie & Porteous, 2007), (Bronson, et al., 2014). The American 
perspective takes a more individual focus on whether the surgery is worthwhile for that specific 
patient, including obesity as one factor in that calculus, rather than an evaluation of whether 
limited resources are used effectively at the system level as in the UK setting.   
The literature is divided then in both what it measures in terms of outcomes, but also in 
what should be done with those results.  Even though the morbidly obese have higher 
complication rates with some reasonable certainty, this does not lead to a consensus on whether 
this should preclude operations in the population.  Due to its high demand, the cost implications 
of TKA mean that policy decisions are important at the national level.  Having a clear evidence 
base to work from is therefore important.  One option for developing this evidence base is a cost-
effectiveness analysis.  This approach can provide a structure for the differing costs and benefits 
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across groups and place TKA in a broader healthcare context in terms of value for limited 
healthcare dollars.   
The cost implications of refusing TKA to obese patients could be staggering.  An analysis 
from 2012 showed that approximately 10% of all hospital stays involving operations paid for by 
either Medicare or private insurance were for TKA  (Fingar, Stocks, Weiss, & Steiner, 2014) and 
there was a 13.8% increase in the discharge rate from 2007-2011  (Dreyer, Zhang, & Udow-
Phillips, 2014).  This translates into an estimated $38.5 billion USD in charges in 2011 alone 
(Dreyer, Zhang, & Udow-Phillips, 2014).  The cost for TKA varies across and within markets, 
but nationally, the mean charge for a TKA is $54,158 (Dreyer, Zhang, & Udow-Phillips, 2014).  
The expectation is for continued growth as the population ages and becomes more obese.  This 
makes it important to understand whether obese populations are in fact benefiting from this 
procedure and if TKA in obese populations is a valuable use of health care resources.  The UK 
restrictions are explicitly focused on reducing expenditures in a cash-strapped system.  The 
United States healthcare system, while different in many ways, is also not immune to budget 
constraints.  Predicting volume and the commensurate costs is a valuable tool for budgeting of 
financial outlays and other resources like surgical capacity.   
This dissertation adds to this policy conversation in several ways.  First, the lack of 
consensus in the literature is addressed with a meta-analysis of implant failure rates and 
complications by obesity classifications.  Next, a formal cost-effectiveness analysis (CEA) is 
undertaken focusing on TKA in different obesity classifications.  Third, an agent-based model 
(ABM) is built to examine the trend in demand for TKA and several what-if scenarios relating to 
obesity are applied.  The application of operations research and decision science techniques to 
this policy area can begin to remove some of the haphazard application of restrictions and reduce 
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the ad hoc nature of the evidence base.  For instance, the NHS official quoted above admitted 
uncertainty about seeing any budget savings despite the entire purpose of the guideline being a 
reduction of the financial burden of TKA.  The ABM is able to easily quantify the budget impact 
in a variety of guideline scenarios with a reasonable level of confidence in the estimates.  The 
impacts can be anticipated before policies are enacted thereby saving unnecessary disruption to 
patient care and upset among clinicians over policies that may not even achieve their goals.  
More generally, the modeling process can generate a framework for thinking about the issue that 
that helps to organize available information which in itself can be a useful exercise.  The need for 
parameter values can draw attention to a lack of consensus in the literature and point to a need 
for meta-analysis or new studies about important topics.  The act of developing a conceptual 
model and thinking through the entire process can point to unanticipated consequences of a 
policy decision that may be left out of more ad hoc decisions.  In the case of TKA, the question 
at first seems to impact only the patients themselves and orthopedic surgery departments, but the 
conceptual model makes clear that those restricted patients remain with OA and this must be 
accounted for when considering a new policy.  Thus, rheumatology and primary care 
departments are also impacted.  Systems thinking provides policy insights and helps draw all 
stakeholders into the process.  Finally, such techniques also provide evidence and concrete 
rationales to help dispel any upset over changes.  Pointing to a CEA can help defend a policy 
against claims of unfairness in decision making processes as well as help to avoid biased 
decision making in the first place by forcing a different way of thinking about the issues.  Policy 
making, then, can begin on a more solid footing, perhaps increasing uptake of proposed 
guidelines as appropriate.   
  
7 
Chapter II of this dissertation details the meta-analysis undertaken to rationalize the 
disparate literature on outcomes of TKA by obesity classifications.  The literature has a wide 
variety of outcomes of interest, obesity designations, study designs, and sample size.  The meta-
analysis focuses on four outcomes of particular interest clinically: wound complications, venous 
thromboembolisms (VTE), deep infections, and survival of the implant.  These parameters are 
also important in the development of the models used in Chapter III and IV.  The lack of 
consensus in the literature is less pronounced when meta-analytic techniques are applied, but 
there are several areas that require more investigation in future research.   
To address the arbitrary nature of existing guidelines, a cost-effectiveness analysis was 
performed using a compartmental model in Chapter III.  The model follows the existing 
framework for the conceptual model from Losina, et al. (Losina, et al., 2009) to integrate the 
obesity findings into the existing literature on the cost-effectiveness of TKA.  The parameters 
developed in Chapter II inform the risks associated with the different obesity classifications.  
This model formalizes the costs and benefits involved for different groups and provides metrics 
to examine the tradeoffs involved.  The results reinforce the existing belief that TKA is generally 
cost-effective.  The obesity results suggest that the lack of consensus around guidelines 
restricting access to TKA for obese patients is warranted. 
Finally, a trend model is built using an ABM framework to incorporate other sources of 
heterogeneity into the population including time related trends in obesity, demand, and an aging 
population.  This model is then used to examine several scenarios related to various guidelines as 
well as changes in population behavior relating to obesity and desire for TKA.  The ABM 
follows the compartmental model in Chapter III as closely as possible in both form and 
parameterization.  While the CEA focuses on individual level decisions, the ABM considers the 
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US population overall.  The trend model closely follows the historical trajectory from 2000 until 
2015 and provides an estimated volume for the subsequent 20 years.  The model results focus on 
volume and budget impacts under the various scenarios considered.  As expected from the results 
in Chapter III, the adoption of guidelines restricting access to TKA in obese populations is not 
clear cut.  The results around changes in obesity patterns and modification of TKA uptake are 
more surprising.   
The dissertation as a whole moves from a literature lacking consensus on whether 
outcomes are less favorable in obese patient populations and what to do with those poorer 
outcomes if they exist to a formal evaluation of the impact of obesity on TKA in terms of 
outcomes, budget impact, and projected volume.  The dissertation makes use of several 
techniques new to this policy area.  Literature reviews exist in the TKA complication domain, 
but formal meta-analytic techniques have not previously been applied to isolate the role of 
obesity in changed outcomes in TKA.  Cost-effectiveness has looked at TKA generally as well as 
to examine the role of provider volume on outcome, but this is the first to include obesity in the 
analysis.  The treatment of deep infections is also more detailed in this model than previous 
efforts.  Finally, the application of an agent-based model to serve as an environment to explore 
what-if scenarios is a novel approach.  The calibration necessary to do this also advanced new 
technique to ensure a well-matched synthetic population.    
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Does Obesity Lead to Poorer Outcomes in Total Knee Arthroplasty?  A Meta-Analysis 
 
Background 
Many studies have attempted to discover whether obesity leads to poorer surgical 
outcomes using various measures and study designs.  Despite a large number of such studies, no 
consensus has been reached.  Outcomes under consideration in existing literature include the 
failure rate of the implant (possibly due to faster deterioration due to increased stress on the 
joint), complications due to poorer overall health of obese patients, and various other markers of 
surgical improvement like functional knee score or range of motion after surgery.  The most 
popular outcomes in the literature are the failure rate of implants and various complications, both 
short and long term.   
The lack of consensus in the literature may have to do with several characteristics of the 
studies currently available.  Small studies may be underpowered especially in the higher BMI 
range (Bordini, et al., 2009) (Krushell & Fingeroth, 2007) (Foran, et al., 2004).  Two possibilities 
for the lack of power relate to the use of the binary obese designation that is readily available in 
charts and thus popular in retrospective studies.  First, while this is convenient, it may lack 
accuracy if obese patients are not assigned obesity as a comorbidity in the chart or weights are 
out of date when assigning status.  These clerical errors could mean that the nonobese control 
group actually contains many obese patients.  The second issue with the binary designation is to 
do with a simple sharp divide into obese and nonobese.  Because BMI is a continuous value, any 
categorization may conceal differences or a tipping point in the underlying population.  It is 
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possible that mild obesity is protective, part of the obesity paradox, while morbid obesity is 
problematic and that mixing all obese patients in a single group obscures the true nature of the 
relationship between BMI and complication rates.   If the actual inflection point for obesity 
causing poorer outcomes is somewhere towards the middle of this divide, perhaps examining the 
existing literature with a finer classification system, including BMI as continuous value if 
possible, will provide clearer answers on the role of obesity on outcomes in TKA.   Another 
reason for the disagreement in the literature is the wide variety of the complications considered 
and follow-up periods used.  Failure rates are considered from 1 year to 15+ (Collins, Walmsley, 
Amin, Brenkel, & Clayton, 2012) (Foran, et al., 2004).  Complications range from general body 
systems like cardiovascular to specific like VTE.  This lack of consensus on even what 
complications are under consideration contributes to the lack of a clear conclusion in the 
literature.  Finally, study designs range from case studies to retrospective chart review to long 
term prospective trials all with varying degrees of inclusion criteria.   
This review and meta-analysis of the literature on complications and revisions for TKA 
will examine the effect of obesity using several classification levels including binary obesity and 
the more granular WHO classification to help identify how obesity impacts a standardized set of 
outcomes and provide information to guide decision makers who are interested in understanding 
whether the impact of obesity on outcomes is great enough to merit establishing clinical 
exclusion criteria.  The other goal is to examine a smaller subset of complications that are of 
most interest to orthopedic surgeons.   Other literature reviews in this area are limited and focus 
either on a single outcome or are more qualitative in nature while this paper takes a full meta-
analytic approach to a comprehensive set of outcomes.   
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Methods 
Literature Search 
A PubMed search with Medical Subject Headings (MeSH) terms was conducted to find 
all articles published relating obesity to total knee replacement outcomes.  To be included in this 
review, the studies needed to have a nonobese control group for comparison purposes and the 
studies had to report outcomes of TKA stratified by the obesity designation of the patients under 
study.  This excluded articles where the TKA outcomes were ancillary.  After this initial 
refinement, four rounds of evaluation were conducted to ensure that papers included in the meta-
analysis were a) focused on the entire population, b) from countries with health care systems 
comparable to the United States, c) original research and d) well-designed studies.  These 
restrictions reduced the original sample from 260 prospective studies to 23.  Secondarily, a 
snowball search was done using the literature reviews uncovered in the original search.  This 
process generated a total of 26 papers for review (Figure II-1).   
Figure II-1 Literature Search Review Steps 
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The literature review began with a PubMed search using two MeSH terms: “obesity” and 
“Arthroplasty, Replacement, Knee”.  Entry terms for “Arthroplasty, Replacement, Knee” include 
appropriate variants for nomenclature combinations and total and partial procedures.  This was 
further restricted to English only, but without publication date restrictions.  This yielded 260 
papers.   
The titles were then examined for any dealing with specific subpopulations, those 
focused on partial replacements, and any papers that were not original research.  Some were also 
excluded based on obesity-related outcomes of TKA not being the primary focus, such as 
studying anaesthesia techniques in obese patients undergoing joint replacements.  After the title 
search, 168 papers remained leaving 65%.   
Next, the country of the study population was extracted from PubMed.  Only countries 
classified as High Income by the World Bank were included.  It was believed that other countries 
would have fundamentally different health care systems and thus lack comparability across 
studies.  Only 6 papers were excluded on this measure, retaining 96%.  The excluded studies 
were conducted in China, Taiwan, Korea, and the Dominican Republic.   
The abstracts were reviewed in the next stage of selecting articles.  The search terms 
yielded a variety of papers including opinions, comments, and original research of which only 
original research findings were retained.  Articles where obesity-related outcomes of TKA were 
not the primary objective of the paper were excluded.  Another major exclusion was those that 
did not in fact have a comparison between nonobese and some obese classification in the study 
design.  Studies that focused on specific procedures or implants were also excluded as were 
exclusively bilateral operations.  This round yielded 83 papers or 51% retention.   
  
13 
Lastly, the full text was read with the same criteria.  Again, a sizable portion of those 
excluded were those without control groups or where the effect of obesity on TKA outcomes was 
ancillary.  Several were discarded when total joint replacements numbers rather than total knee 
replacements were reported.  Others were discarded as being older studies with short follow-ups.  
Short term follow-up defined as 1 year or less and old being defined as operations performed 
prior to 2000.  Long term follow-up studies were retained even with older procedures as the 
follow-up period requires time.  Samples of convenience like the 50 heaviest patients seen at the 
hospital or those lacking control groups, for example, were excluded.  This left 23 papers or 
28%.  This was an overall retention of 9%.   
As a final step, the 9 literature reviews discovered in the initial search were examined for 
any papers missed in the original search strategy.  Of the citations in these reviews, an additional 
3 were discovered fitting the search criteria.  Given the low yield, further snowball search was 
not done on the 23 retained papers.   
The 26 papers were then reviewed for a final quality check.  Using the criteria laid out in 
Egger (Egger, Davey-Smith, & Altman, 2001), eighteen categories were graded on a three-point 
scale: good, fair, bad (Table A-1).  The criteria cover sample selection, follow-up period, 
outcome variable definition, prognostic variable selection, analysis methods, and treatment 
subsequent to inclusion.  No papers had any categories judged bad.  The categories most likely to 
see fair grades were dealing with treatment subsequent to inclusion or sample description.  For 
treatment, this is mainly due to lack of detail in specific implant or surgical technique given in 
papers especially those from large claims databases.  For the sample, some papers provide sparse 
demographic details and many of the single institution papers while representative of that patient 
Literature                        
Review                                       
(3) 
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population and well mixed in terms of gender and age, may not be representative of a larger 
national sample such as those studies that used claims data.  
Data Collection 
The final collection of 26 papers was then searched for any data points relating to 
survival of the implant or complications.  During the initial search, the type of outcome data was 
not considered as part of exclusion criteria to avoid bias.  During data collection, only the papers 
where the raw numbers were available were used.  The full text as well as any tables or graphs 
were searched for this information.  Two student reviewers conducted a second search.  Conflicts 
in either inclusion or the specific values was decided by a third-party familiar with the project 
guidelines.  Further details are available in Appendix A.   
The two outcomes of interest are survival curves and complication rates.  Due to the 
differences in presentation of the data, the extraction methods differed and are explained below.   
Survival Curves 
Survival curves were mainly presented in two ways in the literature.  The graph of the 
curve itself was presented or a simple number was given.  In the case of numbers, any that had a 
mixed age of implant survival at single time point were ignored.  For instance, Pfefferle et al. 
collected information on patients who had surgery from 1998-2013 and reported revisions done 
as of March 26, 2013 as a single figure for survival (Pfefferle, Gil, Fening, & Dilisio, 2014).  
This was not included.  For graphical presentations, Web Plot Digitizer was used to obtain the 
value at each year of survival independent of reporting increments used in the paper (Rohatgi, 
2017).   This was done to maximize the information compatibility across papers.   
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Complications 
Complications of specific interest were wound, deep infection, and VTE.  This group of 
complications was chosen as being of most interest to orthopedic surgeons as well as being the 
complications obesity most likely impacts (Hallstrom, 2017).  They are also directly connected 
to the TKA procedure itself rather than more systemic issues related to health or surgery in 
general.  Other groups of complications frequently mentioned in the literature were also 
examined.  These were major and minor complications, surgical and medical complications, and 
overall complications.  These groups were selected because they were a common theme across 
the literature, but they are not universal or particularly well defined.  For example, the grouping 
of overall complications is meant to include any and all complications experienced, but if a study 
only reports complications of specific types ignoring rare or less specific complications in the 
report this will underestimate overall complications.  Some papers chose to report complications 
by body system rather than individually.  This schema may include major and minor 
complications meaning none can be included in either the major or minor counts for this study.  
If the grouping was used directly in a paper that number as a total was used.  If not, individual 
complications that fit the category were summed.  Any complications reported in groups were 
carefully considered to avoid double counting specific complications and to not include 
inappropriate complication types to fit into the defined category.     
Only data presented in raw form was included, which excluded papers that only reported 
odds ratios developed from logistic regression.  In most categories, this was one or no papers and 
at most two per category of complication.  No two papers adjusted for all the same things and the 
papers that reported in the dominant format of contingency table had no adjustment.  Thus, for 
comparability these were excluded at the data collection phase.   
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Statistical Methods 
Survival Curves 
With the collected data points taken at each year of follow-up, a weighted average was 
taken.  The weight was the size of the studies as determined by the number of knees not patients.  
This weighted average was then graphed by BMI class using Microsoft Excel (Microsoft, 2016).   
Complications 
For complications, two ratios were calculated.  A pooled odds ratio and a pooled relative 
risk were both undertaken using a fixed effects model using the inverse variance method.   This 
approach favors larger studies with more weight in the point estimate (Sterne & Egger, 2001).  
Odds ratios and relative risk are both measures of association between an outcome and an 
exposure, but they address this relationship differently.  The rationale for reporting both ratios is 
practical.  Odds ratio is the dominant effect size reported in the existing literature, but relative 
risk is a more useful and intuitive number for understanding the probability of adverse effects 
based on obesity.  The population of studies were carefully chosen to be of a homogenous 
underlying population.  Any papers focusing on specific subpopulations were excluded as were 
countries with a different economic status.  There is no theoretical basis to judge these studies to 
be examining heterogenous populations.  However, for some categories, the heterogeneity tests 
did indicate some level of concern.  This has been taken to be a result of the small sample size of 
some studies.  Thus, a fixed effect model was used.  The inverse variance method of pooling was 
selected based on including study quality in a quantifiable way.  By weighting the studies with 
the smallest standard error most heavily, the high-quality studies are given the most impact 
(Barendregt & Doi, 2016).  This method also allows a balance between the claims data and case 
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control study designs.  Lastly, a Peto model was determined to be inappropriate given the large 
effect sizes present.    
Results 
Survival Curves 
The survival of the implant over time, the years past primary surgery without a revision 
operation, was combined from all studies reporting survival rates.  The data from 9 studies was 
combined as described above.  These aggregated survival rates over 20 years is displayed by 
different levels of BMI in Figure II-2.  These curves show no significant difference between 
obesity classes through the first decade.  Only a single study did longer follow-up.  Foran et al. 
display a significant decline in survivorship after 10 years for all patients (Foran, et al., 2004).  
Of interest is the group with BMI over 30 is significantly better than nonobese in the period up to 
18 years.  While not included in the pooled results, the mixed duration survival numbers reported 
in the literature show similar results.  A statistical difference is reported in Pfefferle, but it is of 
negligible practical difference (Pfefferle, Gil, Fening, & Dilisio, 2014).  Spicer and Bordini 
reported no difference (Spicer, et al., 2001), (Bordini, et al., 2009).  It is important to note that 
the number of studies and knees at each varies each year for each category with at most 6 studies 
and 684 knees to a low of a single study and 32 knees (Table A-2).   
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Figure II-2 Implant Survival by Obesity Class 
 
Complications 
For complications, the pooled relative risk and odds ratio, both relative to the nonobese 
population (BMI <30) for various categorical designs are reported in Table II-1.  Key findings 
are discussed below for specific complication types. 
Wound 
When looking at wound complications, obesity tends to increase the risk.  While both 
Class I and Class III are significantly different from nonobese at 95% confidence level, the risk 
is more than double in Class I over Class III with OR of 3.748 and 1.605 respectively.  It is also 
important to note that if this analysis focuses instead on just obesity defined as BMI between 30 
and 40 the risks are higher than the nonobese, but not statistically significant.   Obesity defined 
as any BMI greater than 30 more closely resembles Class I than Class III.  Figure II - 3 shows 
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the forest plots for the pooled relative risks of wound complications in each of the six obese 
categories under study.   
Figure II-3 Forest Plots for Wound Complications by Obesity Class 
 
Deep Infection 
This important complication involves major intervention to resolve and yet it is the least 
attested to in the literature searched.  The point estimates indicate that at the granular level all 
obesity classes show increased risk of deep infection compared to nonobese, but statistically 
significant results were found only in Class III group.  Relatively few studies were available for 
analysis, so perhaps a lower sample size led to the lack of statistically significant results.  Figure 
II - 4 shows the forest plots for the pooled relative risks of deep infections in each of the six 
obese categories under study.   
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Figure II-4 Forest Plots for Deep Infection Complications by Obesity Class 
 
VTE 
In VTE, the higher risks observed for obese patients are statistically significant as 
compared to nonobese controls.  Class I indicates a minor elevation of risk that barely reaches 
significance (OR 1.207, RR 1.200).  No studies specifically studied VTE risk in Class II patients 
alone.   As BMI exceeds 30, the risk is estimated to more than double relative to nonobese 
patients (OR 2.514, RR 2.476).  When looking at obesity defined as BMI 30-40, we find a 
substantial and significant increased risk for this condition in this group (OR 2.106, RR 2.084).  
In the Class III group we see an increased risk approaching 3 (OR 2.957, RR 2.909).  Using a 
binary indicator of obesity could obscure the difference between Class I and heavier patients.  
Figure II - 5 shows the forest plots for the pooled relative risks of VTE in each of the six obese 
categories under study.   
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Figure II-5 Forest Plots for VTE Complications by Obesity Class 
 
Groupings 
The five broad categories of complications investigated (medical, surgical, major, minor, 
and overall) are a more complex story that lack statistical significance in many cases.  Obesity 
appears detrimental to most medical complications, but protective in surgical complications.  The 
major and minor groupings lack power to make general conclusions.  The overall complication 
rate shows conflicting results for different obesity levels.  It is important to note that these 
groupings were selected to reflect some trends in the literature, but they are not necessarily found 
in the papers under study and included in these figures.  Further, few studies reported results in a 
way that allowed for inclusion in these grouped results.  
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Table II-1 Pooled Odds Ratios and Relative Risks for Various Complications 
 
    Obesity Class 
Significant, Increased Risk Nonobese Rate Nonobese Class I   Class II   Class III Obese Obese   Obese 
Significant, Decreased Risk BMI < 30 Rate  BMI < 30 BMI 30-35 BMI 35-40 BMI > 40 BMI > 30 BMI 30-40 BMI > 35 
Wound 0.25%               
Odds Ratio (95% CI)   ref 3.748 (3.148, 4.463) 1.882 (0.908, 3.9) 1.605 (1.211, 2.127) 3.682 (3.128, 4.335) 1.18 (0.621, 2.241) 4.296 (3.516, 5.249) 
Relative Risk (95% CI)   ref 3.623 (3.054, 4.298) 1.832 (0.914, 3.671) 1.604 (1.212, 2.121) 3.552 (3.027, 4.169) 1.175 (0.633, 2.183) 4.132 (3.399, 5.022) 
Total N   112023 9874 211 90337 17736 671 5618 
No. Studies    11 4 2 6 7 2 4 
Deep Infection 1.12%         
Odds Ratio (95% CI)   ref 1.305 (0.453, 3.763) 2.331 (0.577, 9.425) 4.114 (1.376, 12.3) 1.694 (0.878, 3.269) 2.126 (0.663, 6.822) 0.507 (0.187, 1.374) 
Relative Risk (95% CI)   ref 1.307 (0.459, 3.723) 2.305 (0.583, 9.116) 4.001 (1.371, 11.681) 1.681 (0.88, 3.212) 2.107 (0.665, 6.678) 0.51 (0.19, 1.37) 
Total N   1515 522 154 198 1515 592 255 
No. Studies    5 2 1 3 4 1 2 
VTE 0.95%         
Odds Ratio (95% CI)   ref 1.207 (1.036, 1.405) - 2.957 (2.868, 3.05) 2.514 (2.45, 2.579) 2.106 (2.041, 2.174) 1.358 (1.138, 1.622) 
Relative Risk (95% CI)   ref 1.2 (1.035, 1.392) - 2.909 (2.823, 2.998) 2.476 (2.415, 2.539) 2.084 (2.02, 2.15) 1.347 (1.134, 1.599) 
Total N   1323924 9414 0 267197 485889 291914 5343 
No. Studies    8 2 0 4 5 1 2 
Medical  3.09%         
Odds Ratio (95% CI)   ref 0.694 (0.621, 0.776) - 5.043 (4.958, 5.13) 3.537 (3.489, 3.586) 2.892 (2.844, 2.941) 0.48 (0.409, 0.563) 
Relative Risk (95% CI)   ref 0.709 (0.638, 0.788) - 4.492 (4.423, 4.562) 3.282 (3.24, 3.325) 2.735 (2.693, 2.779) 0.497 (0.427, 0.58) 
Total N   1239650 9272 0 177146 488831 294945 5276 
No. Studies    4 1 0 2 4 2 1 
Surgical 4.58%         
Odds Ratio (95% CI)   ref 0.326 (0.279, 0.38) - 1.087 (0.341, 3.458) 0.471 (0.422, 0.526) 0.736 (0.503, 1.077) 0.581 (0.497, 0.68) 
Relative Risk (95% CI)   ref 0.34 (0.292, 0.395) - 1.085 (0.348, 3.385) 0.484 (0.435, 0.538) 0.739 (0.507, 1.076) 0.597 (0.514, 0.693) 
Total N   26857 9272 0 172 19943 3031 2576 
No. Studies    3 1 0 1 3 1 1 
Major 2.00%         
Odds Ratio (95% CI)   ref 0.442 (0.16, 1.218) - 15.197 (0.827, 279.287) 1.067 (0.726, 1.568) - 1.642 (0.68, 3.963) 
Relative Risk (95% CI)   ref 0.462 (0.175, 1.216) - 13 (0.756, 223.501) 1.061 (0.731, 1.54) - 1.566 (0.712, 3.44) 
Total N   2803 142 0 41 2401 0 67 
No. Studies    3 1 0 1 2 0 1 
Minor 2.56%         
Odds Ratio (95% CI)   ref - - 1.002 (0.233, 4.312) 1.781 (1.285, 2.467) - - 
Relative Risk (95% CI)   ref - - 0.956 (0.239, 3.829) 1.747 (1.274, 2.395) - - 
Total N   2617 0 0 91 2192 0 0 
No. Studies    3 0 0 2 1 0 0 
Overall 9.76%         
Odds Ratio (95% CI)   ref 0.695 (0.64, 0.754) 0.83 (0.274, 2.519) 1.661 (1.013, 2.722) 0.712 (0.667, 0.76) 1.04 (0.855, 1.266) 0.54 (0.483, 0.605) 
Relative Risk (95% CI)   ref 0.723 (0.671, 0.778) 0.845 (0.309, 2.314) 1.623 (1.036, 2.543) 0.733 (0.69, 0.778) 1.038 (0.86, 1.252) 0.575 (0.519, 0.638) 
Total N   28047 9494 57 416 21086 3833 5343 
No. Studies    10 3 1 5 7 3 2 
Discussion 
Several themes emerge from the results.  One is that we generally see that obese patients 
have more complications than nonobese patients.  Obese patients appear to be at higher risk of 
wound infections, deep infections, and VTEs when compared to nonobese patients following 
TKA.  All definitions of obesity show higher risks of complications than nonobese patients, but 
some estimates of increased risk are not statistically significant.  In addition, there is variability 
in increased risk for different definitions or categories of obesity. 
It would be expected that if there was a detrimental effect of obesity in outcomes of TKA 
that a dose-response type effect would be observed with more dramatic obesity classification 
leading to more dramatic risk increases.  We do not observe this.   
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One possible reason for the lack of dose-response effect is that, regardless of study design 
and controls, obese patients face different surgical criteria already (Kolata, 2016), (Yates, 2016).  
This would mean any observational design will fail to detect the true relationship between 
obesity and outcomes.  If less healthy Class I patients are allowed surgery when Class III patients 
face more rigorous general health criteria before the patient can proceed to surgery, we would 
expect ancillary complications to be higher in the overall less healthy, but lighter group.  Another 
manifestation of this explanation is found in the survival results.  The endpoint used is not 
actually a failed implant but a revision operation.  If obese patients are not given the option of 
reoperation, then they would not appear in this curve as a failure biasing the results towards no 
difference.   
Another explanation for these somewhat counterintuitive results is that even if the 
selection is unbiased that the treatment plan or execution is different.  This could explain why the 
risk of wound complications is highest in Class I patients.  If following the current literature that 
Class III is a problem, but not simple obesity, these Class I patients may not be instructed as 
stringently on wound care or may see less intensive watching than their heavier counterparts.   
An important consideration for these results is that by design they are unadjusted.  In the 
literature search, papers that only reported adjusted odds ratios were discarded and in papers that 
reported both the contingency table and odds ratio only the contingency table’s raw numbers 
were used.  This makes combining across papers appropriate given every paper adjusted for 
different things.  It does however mean that any effect of age or comorbidities not addressed by a 
case control design is left in these figures.  Papers that reported both adjusted odds ratios and raw 
numbers do not show a clear pattern of difference with some adjusted risks being much lower 
than the raw numbers suggest (Dowsey & Choong, 2009), others having nearly identical results 
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in the adjusted and unadjusted risks, (D'Apuzzo, Novicoff, & Browne, 2015), and others having 
unadjusted risks half that suggested in the adjusted figure (Dowsey & Choong, 2009).   
It is also apparent from examining both individual and grouped complications that 
granularity and agreement on which complications are of interest also matters.  Studies that focus 
on grouped complications may find less of an effect of obesity than those examining specific 
complications of interest.  This may be providing a false security to obese patients and their 
surgeons about their true risk profile.  That is not to say groupings of complications are not of 
interest, but some effort should be made to design future groups to be more compatible with 
prior studies.  Many studies were unable to be included in this meta-analysis because only 
grouped outcomes were reported and they were not defined either well enough to determine 
specific complications included or were entirely novel and unable to be grouped with any other 
studies.  It is entirely possible that these seemingly conflicting results are really in agreement at a 
more granular level of single complications, but the different grouping systems yield different 
overall risk assessments.   
The use of groups deserves further comment.  As the results above suggest, using 
common and simple-sounding categories (such as “medical” and “surgical”) can be problematic.  
Firstly, the differing reporting style means that many of the studies that were otherwise of high 
quality could not be considered in this analysis because the complication outcome was entirely 
unable to be collapsed into a standard category or individual complication.  Secondly, another 
issue, especially relating to the overall complication rate, has to do with which complications 
were included in the studies.  Some chose a specific set to look for in charts that were deemed of 
interest or relevant to the procedure, but others chose to include any complication that occurred.  
These yielded two distinct types of “overall complication” numbers that are not measuring the 
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same thing.  In the same vein, some of the studies included in the “overall complication” results 
reported an overall number themselves while others are the sum of the individual complications 
reported in the papers that did not report overall rates on their own.  Third, these groups may 
reflect something beyond obesity-related complications.  A feedback loop may exist between 
major complications and surgical complications and surgeon quality, but surgeon quality may be 
a factor in which patients they choose to operate on.  Much more clearly defined categories and 
complications to include needs to be agreed upon before these grouped results are considered for 
use in decision-making.   
Future Research 
Future research related to the effect of obesity on outcomes of TKA would benefit from 
several changes.   One would be moving away from a binary obesity classification culled from a 
single comorbidity and move towards measured BMI reported at a minimum using the WHO 
classification system or even a continuous BMI variable.  It is clear that different classes behave 
differently in almost every complication examined.  Adopting this more detailed approach may 
provide clarity to the debate in the literature about whether obesity increases the risk of 
complications currently observed or if there are certain obesity thresholds that are important to 
complication risk.   
In the same spirit, more attention should be paid to consistent definitions of 
complications.  Grouping complication by body system or severity or root cause is useful 
information, but without specific complication data the study is rendered less helpful in future 
meta-analyses.  It may also be obscuring risk for some groups.   
Finally, an effort should be made for more detailed description of patient selection and 
treatment protocols.  While a randomized trial withholding care or inducing obesity is not 
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possible, the standard matching on demographics may not suffice.  Even matching or controlling 
for comorbidities may not suffice if these characteristics are evaluated differently in obese and 
nonobese populations.   Treatment descriptions, if they exist, generally focus on type of implant 
or surgical approach used, but outcomes depend on the immediate follow-up period as well, 
which is nearly never described.  While the claims data approach is an excellent way to add 
power and increase demographic generalizability, it may be obscuring key details on this 
account.  Any designs that are not observational are to be pursued towards this end.  A natural 
experiment using the NHS trusts that withheld TKA in some populations may be one possible 
setting for such a study.  
It is also important that future research continues to report on both findings and non-
findings in this area.  Currently, no publication bias appears to exist as no consensus has yet been 
reached so individual studies are equally likely to report higher risk for obese patients as not.  
This is to be commended and continued.   
Clinical Applications 
Obese patients do face higher complication rates.  This is most evident in looking at 
single complications.  The grouped complications should not be used in evaluating risk at the 
current time.  Careful attention should be paid to the postoperative regimen and aftercare 
instructions in all patients not just the morbidly obese.  Informal heuristics may be ensuring that 
only the healthiest Class III patients are offered surgery while less healthy nonobese patients are 
routinely offered surgery.  Therefore, it is important that the clinician does not consider only 
obesity in making treatment plans.     
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Methodological Advances 
This study is the first formal meta-analytic evaluation of the impact on outcomes in TKA   
due to obesity.  The focus on finer WHO classification for obesity is also a new approach.  These 
techniques allow a fuller understanding of obesity ‘s impact on outcomes while making use of 
existing work.  
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A Cost-Effectiveness Analysis of Total Knee Arthroplasty in Obese Populations 
 
Background 
The current literature has found some suggestions that the outcomes are different in obese 
populations but has not addressed quantitatively whether that is enough to withhold TKA.  The 
meta-analysis in Chapter II also finds differences in complication rates.  The previous studies 
have examined isolated factors including surgical time and certain complication rates.  Rather 
than looking at simple differences in complication rates or patient satisfaction and extrapolating 
to a guideline, an analysis that combines all the available information in a systematic way and 
quantifies the value of TKA obtained in subpopulations based on their BMIs is needed.  This 
study examines the entire experience holistically over time.   
One approach to this broader policy question of whether obese patients should be offered 
elective TKA surgery is a cost-effectiveness framework.  In this way, we can evaluate both the 
costs and benefits of proposed policies, such as a guideline restricting TKA to nonobese patients.  
CEA incorporates the value of treatment and a more long-term perspective than the simple cost-
saving approach used in the UK in attempts to balance NHS trust budgets.  Studies addressing 
complication rate differences amongst obesity groups have considered obesity guidelines to 
restrict access, but there has never been a formal examination of the cost-effectiveness of general 
guidelines.   
While TKA in general has been judged cost-effective, no one has addressed this question 
specifically in obese populations.  A cost-effectiveness analysis will incorporate both costs and 
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quality of life information specific to patient obesity classifications to address this nascent policy 
issue.  Current implementations of a ban as done in the UK are based on purely financial 
calculations, as admitted by the trusts involved in the UK guidelines, which raises the specter of 
unfairly rationing care at the expense of patient care.  This study will attempt to answer whether 
TKA in obese populations is a worthwhile use of resources to society.   
Methods 
Overview of Model 
To perform the CEA of TKA in obese populations, a Markov model was developed in 
Microsoft Excel 2016 and Visual Basic for Applications was used to perform sensitivity analysis 
(Microsoft, 2016).  The basic model design, including the choice of health states, follows a 
similar model by Losina, et al. as closely as possible (Losina, et al., 2009).  While Losina, et al. 
sought to understand the impact of hospital volume on patients, this model will instead examine 
the effect of obesity severity in patient outcomes.  The overall patient journey from no surgery to 
final outcome is unchanged in the conceptual model.  The choice to replicate the model design 
allows for cross model validation, furthers a single conceptual model of the progression from 
disease to knee replacements and outcomes in the literature, and eases verification of the model 
implementation  (Rand & Wilensky, 2006).  This analysis seeks to understand the role of obesity 
as defined in the WHO classification system.  In this scheme, obesity has three classes based on 
BMI: : Class I with 30 ≤ BMI < 35, Class II with 35 ≤ BMI < 40, and Class III with BMI ≥ 40, 
also known as morbid obesity (Centers for Disease Control and Prevention, 2016).  The model 
therefore examines four groups of patients based on obesity status: those who are not obese 
(BMI < 30) and the three obesity classes.  This replaces classifications of hospital volume and 
generic patient risk used in Losina, et al.  The model also follows standard cost-effectiveness 
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practice using a 3% discount rate (Gold, Siegel, Russell, & Weinstein, 1996) for both future 
costs and health related quality of life using a societal perspective.    
CEA Terminology  
Several definitions specific to the cost-effectiveness domain are explained below.  The 
incremental cost-effectiveness ratio (ICER) is a statistic defined as the difference in intervention 
and baseline costs divided by the difference in intervention and baseline QALYs providing a 
ratio of costs and benefits.  This can then be compared to threshold values to assess the cost-
effectiveness of an intervention.  Net Monetary Benefit (NMB) is another summary statistic that 
incorporates the threshold value directly rather than a comparison as in the case of an ICER.  In 
the US, the two commonly held thresholds for an intervention being considered cost-effective are 
$50,000 and $100,000 per QALY (Neumann, Cohen, & Weinstein, 2014).  Thresholds are 
country but not disease specific.  They serve as a benchmark of value for health care dollars 
across the whole of the system to aid in decision making among competing priorities.  An 
intervention is said to be dominant if it is both less expensive and provides more health benefits 
than the status quo.  Conversely, an intervention is dominated if it costs more to implement while 
providing less benefit than the alternative.   
Model Structure 
The model consists of 8 basic health states as shown in Figure III-1.  All patients begin in 
end-stage OA of the knee, significant pain in and changes to the joint.  From OA, patients may 
elect to undergo a TKA, the first of two acute states.  The TKA may either result in a full benefit 
to the patient or no benefit.  Full benefit means that the patient is now seeing an improvement 
over the preoperative state.  No benefit means that the surgery did not improve the health state of 
the patient.  This is a simplification from Losina, et al. where a limited benefit state exists as a 
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precursor to failure.  To accommodate more limited data on obese patients, this model collapsed 
those two states into a single full benefit state.  For those who initially had a positive outcome, 
failure is still possible.  Those who are in the no benefit state may choose to undergo a revision 
procedure, the second acute state.  Revision leads to similar outcome states as those seen in the 
primary TKA.  The final health state is death to which all other health states can transition.   
Figure III-1 Simplified Compartmental Model Flow Chart 
 
The time step of the model is one year.  The two acute surgical states take zero time, but 
a health impact is assessed for passing through this state.  In addition, patients who undergo 
surgery may also experience complications which add both cost and health penalties.  Three 
specific complications are considered: wounds, VTEs, and deep infections.  The last is of special 
interest given the intensity of treatment and possible long-term consequences.  While the wound 
and VTE patients face one-time penalties in cost and Quality Adjusted Life Years (QALYs) for 
the year of the procedure, the deep infection complication patients move to a separate submodel 
for the duration.  Following deep infection, patients permanently face different consequences and 
lower quality of life but follow a similar set of possible transitions.  More specifically, a patient 
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experiencing a deep infection has a second surgery the following year.  There are still two 
possible outcomes of that surgery but the quality of life possible is lower than regular surgeries 
and the probability of each is specific to the deep infection module.  The risk of complications is 
also different in the submodule.  In some scenarios under consideration, OA patients may choose 
to have surgery or not at each time step, in others all patients receive TKA in the first year.  For 
the benefit states, Figure III-1 is a simplification.  The transition to failure is dependent on the 
age of the implant so these states are in fact a tunnel of health states where all patients move out 
of the state entirely or advance one year in the same state.  In a similar way, the decision to 
revise or not is also time dependent with immediate failures undergoing revision more frequently 
than late failures.   
Population 
The model follows a cohort of patients.  All patients begin the model at age 74 to match 
the average overall age of the Medicare population as used by Losina, et al. (Losina, et al., 
2009).  The model is flexible to evaluate other starting ages to incorporate the trend toward 
younger patients.  The population is homogenous in all respects except for obesity.  The four 
obesity groups – nonobese and Class I – III – run through the model separately using class 
specific parameters for some transitions and costs as defined below.   
Alternative Strategies 
The scenarios examined provide TKA to OA patients in different populations by obesity 
group.  The alternative is supportive care for OA.  Evaluation of the TKA strategy is done in two 
ways: in the base case, surgery occurs in the first year.  In an alternative analysis, surgery occurs 
as a staggered patient choice with a percent of patients with OA opting in each year.  The 
staggered start is used only for cross model comparison to Losina, et al. and the immediate TKA 
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for the entire cohort is used for the rest of the analyses.  In both cases, the comparison is between 
TKA and no TKA (OA with supportive care).  The obesity groups considered are nonobese, 
Class I obesity, Class II obesity, and Class III obesity.  Death rates vary by age as well as obesity 
classification.  The obesity classification is unchanged for the duration of the model and the 
years spent as obese are not considered.  Complication rates, surgical success (likelihood of full 
versus no benefit after surgery) and failure rates vary by obesity.  Costs of surgery as well as 
overall quality of life are also dependent on the obesity classification.   
Outcomes 
The outcomes of interest include costs and QALYs, as well as the ICER and NMB.  The 
model tracks the four obesity group outcomes separately.  The overall outcomes are based on a 
weighted average of the four obesity groups where the weights are equal to the current share of 
the general population in each obesity group.  In addition, the model considers two scenarios 
relative to no TKA, staggered TKA for cross model validation and all patients receiving TKA in 
the first year for policy recommendations.  This provides 10 sets of outputs.   
Data 
Parameters fall into several broad categories including the likelihood of surgical 
outcomes for primary and revision TKAs, complication rates, implant failure rates, costs of 
treatment, and health outcomes measured in QALYs.  The data to parameterize the model comes 
from a variety of sources with a focus on large population studies.  Many data sources follow 
Losina, et al. with newer data used if available.  Meta-analyses supplemented where needed 
particularly for complication and failure rates.   
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Transitions Between States 
The primary transitions required for the Markov model (Table III-1) fall into several 
broad categories.  Patient decisions to have TKA procedures are the first group and these rates 
follow existing literature.  The staggered analysis requires a probability that a patient with end 
stage symptomatic knee OA will undergo TKA.  That parameter uses the same parameter as 
Losina, et al which follows Holt, et al. who combine existing literature with observed utilization 
in the US and suggest a third of the symptomatic OA patients undergo surgery each year (Holt, et 
al., 2011).  Both the immediate and staggered models use another patient decision: whether a 
failed surgery results in a revision.  In this, the model follows that of Losina, et al.  If a surgery is 
an immediate failure, all patients undergo revision surgery, but if it fails after the first year, then 
only half seek revision each year (Losina, et al., 2009).  The next group of transitions relates to 
outcomes.  The sources for these parameters are based in the literature.  In Losina, et al., the 
model uses two states of improvement with a substantial improvement deemed full benefit and 
some improvement called limited benefit.  In this model, a single state of full benefit conflates 
these so that any improvement qualifies as full benefit.  Katz, et al. suggests that this figure is 
90% following work done by Fortin, et al. (Katz, et al., 2004) (Fortin, et al., 2002).  Lastly, 
revision outcomes follow a similar approach.  A meta-analysis done by Saleh, et al. using patient 
reported Knee Scores found 77% good or excellent outcomes after revision (Saleh, et al., 2002).  
The final possible transition is that patients in any health state may die.  Age dependent mortality 
rates come from US CDC life tables (Centers for Disease Control and Prevention, 2017).  
Relative risks for obesity are discussed in a later section.   
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Table III-1 Transition Parameters 
Name 
Base Low High Distribution Source (Base/ 
Range & 
Distribution)  
Annual Probability OA has TKA 0.33 0.22 0.44 Normal (0.33, 0.06) 6/6 
Probability of Full Benefit following TKA 0.9 0.1394 1 Beta (0.88, 0.12) 7/10a 
Relative Risk for Nonobese (BMI <30) 1.0287 0.9765 1.0568 Normal (1.03, 0.02) * 
Relative Risk for Class I Obese (BMI 30-35) 0.9464 1.0438 0.894 Normal (0.95, 0.03) * 
Relative Risk for Class II Obese (BMI 35-40) 0.9464 1.0438 0.894 Normal (0.95, 0.03) * 
Relative Risk for Class III Obese (BMI > 40) 0.9464 1.0438 0.894 Normal (0.95, 0.03) * 
Probability of Revision after Early Failure 1 0 1 Beta (0.5, 0.5) 10/+ 
Probability of Revision after Late Failure 0.5 0 1 Beta (0.5, 0.5) 10/+ 
Probability of Full Benefit following Revision 0.77 0.1394 1 Beta (0.88, 0.12) 12/10c 
Relative Risk for Nonobese (BMI <30) 1.0773 0.9369 1.1528 Normal (0.86, 0.05) * 
Relative Risk for Class I Obese (BMI 30-35) 0.8559 1.1178 0.715 Normal (0.86, 0.09) * 
Relative Risk for Class II Obese (BMI 35-40) 0.8559 1.1178 0.715 Normal (0.86, 0.09) * 
Relative Risk for Class III Obese (BMI > 40) 0.8559 1.1178 0.715 Normal (0.86, 0.09) * 
Annual Death Rate 1 1 1 Constant Value of 1 1/Not Tested 
Relative Risk for Nonobese (BMI <30) 1 1 1 Constant Value of 1 3a 
Relative Risk for Class I Obese (BMI 30-35) 1.0158 1.0106 1.021 Lognormal (0.02, 0) 3a 
Relative Risk for Class II Obese (BMI 35-40) 1.0108 1.001 1.0207 Lognormal (0.01, 0) 3a 
Relative Risk for Class III Obese (BMI > 40) 1.0923 1.0763 1.1085 
Lognormal (0.09, 
0.01) 3a 
Probability of Best Case after Deep Infection Surgery 0.5 0 1 Beta (0.5, 0.5) ~/+ 
Relative Risk for Nonobese (BMI <30) 1.0773 0.9369 1.1528 Normal (0.86, 0.05) * 
Relative Risk for Class I Obese (BMI 30-35) 0.8559 1.1178 0.715 Normal (0.86, 0.09) * 
Relative Risk for Class II Obese (BMI 35-40) 0.8559 1.1178 0.715 Normal (0.86, 0.09) * 
Relative Risk for Class III Obese (BMI > 40) 0.8559 1.1178 0.715 Normal (0.86, 0.09) * 
Probability of Revision after Early Failure of Deep 
Infection Surgery 0 0 1 Beta (0.5, 0.5) #/+ 
Probability of Revision after Late Failure of Deep 
Infection Surgery 0 0 1 Beta (0.5, 0.5) #/+ 
#: In the base case, the worst-case scenario is amputation so there is no re-revision possible.   
*: This parameter was unavailable in the literature.  Relative risks of a poor outcome are approximately 2 for obese patients for observed 
parameters.  The relative risks generally range from slightly protective to a relative risk of 4.  This range was used as the basis for the 
unknown value here.  The model is structured as a probability of a good outcome, so calculations were performed to make these 
observations compatible with the probability of the positive outcome of not failing.   
~: Expert opinion for estimate 
+: No information available for this range.  A Beta (0.5,0.5) distribution was used to cover the full probability range with weight in center as 
best guess that explored full probability space.   
1: Centers for Disease Control and Prevention 
3: The Global BMI Mortality Collaboration a: The table data provided was used to construct relative risks and confidence intervals rather 
than the hazard ratios reported in the paper.   
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6: Holt, et al. 
7: Katz, et al. 
10: Losina, et al.  
10: Losina, et al. a: The range used for limited benefit is taken as the complement of the full benefit desired for this model.  The convention 
for defining a beta distribution was used. 
10: Losina, et al. c: The rates given in the literature for success of revision surgery vary widely from less than 50% to nearly 90%.  To 
ensure a wide range was explored, the same range from the primary surgery based in the Losina, et al. model was used here as well. 
12: Saleh, et al.  
Complications 
A meta-analysis (Chapter II) was conducted to evaluate important complications by 
obesity class and those figures are used here to track VTE, wound complications and deep 
infections (Table III-2).  For surgeries subsequent to a deep infection, the rates of wounds and 
VTE are the same but deep infection is ten times more likely.  The meta-analysis results broadly 
indicate higher complication rates for obese patients for the VTEs, wound complications, and 
deep infections considered in the model.   Depending on the exact definition of obesity used, the 
results showed some variability in magnitude and obtainment of statistical significance.  
Counterintuitively, no dose-response effect was observed as obesity increased for which several 
explanations are proposed in the meta-analysis.   
Table III-2 Complication Parameters 
Name 
Base Low High Distribution 
Source (Base/  
Range & 
Distribution)  
VTE 0.0095 0 0.0279 Normal (0.01, 0.01) 4/4 
Relative Risk for Nonobese (BMI <30) 1 1 1 Constant Value of 1 4/4a, b 
Relative Risk for Class I Obese (BMI 30-35) 1.2005 1.0355 1.3918 Lognormal (0.18, 0.08) 4/4a, b 
Relative Risk for Class II Obese (BMI 35-40) 2.0841 2.0202 2.15 Lognormal (0.73, 0.02) 4/4a, b 
Relative Risk for Class III Obese (BMI > 40) 2.9088 0.5472 15.4612 Lognormal (1.07, 0.85) 4/4a, b 
Wound 0.0025 0 0.0466 Normal (0, 0.02) 4/4 
Relative Risk for Nonobese (BMI <30) 1 1 1 Constant Value of 1 4/4a, b 
Relative Risk for Class I Obese (BMI 30-35) 3.6226 0.5798 22.6327 Lognormal (1.29, 0.93) 4/4a, b 
Relative Risk for Class II Obese (BMI 35-40) 1.8316 0.914 3.6706 Lognormal (0.61, 0.35) 4/4a, b 
Relative Risk for Class III Obese (BMI > 40) 1.6036 0.4971 5.173 Lognormal (0.47, 0.6) 4/4a, b 
Deep Infection 0.0112 0 0.0363 Normal (0.01, 0.01) 4/4 
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Relative Risk for Nonobese (BMI <30) 1 1 1 Constant Value of 1 4/4a, b 
Relative Risk for Class I Obese (BMI 30-35) 1.3066 0.076 22.4712 Lognormal (0.27, 1.45) 4/4a, b 
Relative Risk for Class II Obese (BMI 35-40) 2.3052 0.5829 9.1164 Lognormal (0.84, 0.7) 4/4a, b 
Relative Risk for Class III Obese (BMI > 40) 4.0014 1.3707 11.6813 Lognormal (1.39, 0.55) 4/4a, b 
VTE after Deep Infection 0.0095 0 2 Normal (0.01, 0.01) 4c 
Relative Risk for Nonobese (BMI <30) 1 1 1 Constant Value of 1 4c 
Relative Risk for Class I Obese (BMI 30-35) 1.2005 1.0355 1.3918 Lognormal (0.18, 0.08) 4c 
Relative Risk for Class II Obese (BMI 35-40) 2.0841 2.0202 2.15 Lognormal (0.73, 0.02) 4c 
Relative Risk for Class III Obese (BMI > 40) 2.9088 0.5472 15.4612 Lognormal (1.07, 0.85) 4c 
Wound after Deep Infection 0.0025 0 0.0466 Normal (0, 0.02) 4c 
Relative Risk for Nonobese (BMI <30) 1 1 1 Constant Value of 1 4c 
Relative Risk for Class I Obese (BMI 30-35) 3.6226 0.5798 22.6327 Lognormal (1.29, 0.93) 4c 
Relative Risk for Class II Obese (BMI 35-40) 1.8316 0.914 3.6706 Lognormal (0.61, 0.35) 4c 
Relative Risk for Class III Obese (BMI > 40) 1.6036 0.4971 5.173 Lognormal (0.47, 0.6) 4c 
Subsequent Deep Infection 0.1122 0.0871 0.1373 Normal (0.11, 0.01) 4d 
Relative Risk for Nonobese (BMI <30) 1 1 1 Constant Value of 1 4d 
Relative Risk for Class I Obese (BMI 30-35) 1.3066 0.076 22.4712 Lognormal (0.27, 1.45) 4d 
Relative Risk for Class II Obese (BMI 35-40) 2.3052 0.5829 9.1164 Lognormal (0.84, 0.7) 4d 
Relative Risk for Class III Obese (BMI > 40) 4.0014 1.3707 11.6813 Lognormal (1.39, 0.55) 4d 
4: Guiney  
4: Guiney a: Inverse Variance Heterogeneity method used to parameterize the model over the values reported in this paper.  This 
method accounts for more sources of heterogeneity which widens the confidence intervals to ensure the model encompasses the 
full range of values.   
4: Guiney b: Using the reported confidence intervals, a lognormal distribution was fitted.   
4: Guiney c: Unchanged from main model 
4: Guiney d: Following expert opinion, the reoccurrence rate is ten times the primary rate. 
 
Implant Failure Rates 
Patients who initially have a positive outcome may still face implant failure over time.  
Each year after surgery, the probability of failure changes (Table III-3).  The relative risks 
applied based on obesity follow in Table III-4.   The meta-analysis conducted in Chapter II is the 
source for these annual rates in primary and revision surgeries.  Failure rates subsequent to a 
deep infection are estimated at 50% each year.  The ranges and relative risks are not year specific 
and are derived from the literature (Losina, et al., 2009) (Kerkhoffs, et al., 2012). 
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Table III-3 Annual Failure Parameters 
Name 
Base Low High Distribution 
Source (Base/  
Range & 
Distribution)  
TKA Failure - Year 1 0.0051 0 0.0764 Constant Value of 0 4, 10b 
TKA Failure - Year 2 0.0107 0 0.0764 Constant Value of 0 4, 10b 
TKA Failure - Year 3 0.0129 0 0.0764 Constant Value of 0 4, 10b 
TKA Failure - Year 4 0.0128 0 0.0764 Constant Value of 0 4, 10b 
TKA Failure - Year 5 0.0151 0 0.0764 Constant Value of 0 4, 10b 
TKA Failure - Year 6 0.0181 0 0.0764 Constant Value of 0 4, 10b 
TKA Failure - Year 7 0.0291 0 0.0764 Constant Value of 0 4, 10b 
TKA Failure - Year 8 0.0423 0 0.0764 Constant Value of 0 4, 10b 
TKA Failure - Year 9 0.0608 0 0.0764 Constant Value of 0 4, 10b 
TKA Failure - Year 10 0.0578 0 0.0764 Constant Value of 0 4, 10b 
Revision Failure - Year 1 0.0028 0 0.1673 Constant Value of 0 4, 10d 
Revision Failure - Year 2 0.0033 0 0.1673 Constant Value of 0 4, 10d 
Revision Failure - Year 3 0.0082 0 0.1673 Constant Value of 0 4, 10d 
Revision Failure - Year 4 0.0122 0 0.1673 Constant Value of 0 4, 10d 
Revision Failure - Year 5 0.0122 0 0.1673 Constant Value of 0 4, 10d 
Revision Failure - Year 6 0.0139 0 0.1673 Constant Value of 0 4, 10d 
Revision Failure - Year 7 0.0166 0 0.1673 Constant Value of 0 4, 10d 
Revision Failure - Year 8 0.0172 0 0.1673 Constant Value of 0 4, 10d 
Revision Failure - Year 9 0.038 0 0.1673 Constant Value of 0 4, 10d 
Revision Failure - Year 10 0.0603 0 0.1673 Constant Value of 0 4, 10d 
Failure After Deep Infection - Year 1 0.5 0 1 Constant Value of 0 ~, + 
Failure After Deep Infection - Year 2 0.5 0 1 Constant Value of 0 ~, + 
Failure After Deep Infection - Year 3 0.5 0 1 Constant Value of 0 ~, + 
Failure After Deep Infection - Year 4 0.5 0 1 Constant Value of 0 ~, + 
Failure After Deep Infection - Year 5 0.5 0 1 Constant Value of 0 ~, + 
Failure After Deep Infection - Year 6 0.5 0 1 Beta (0.5, 0.5) ~, + 
Failure After Deep Infection - Year 7 0.5 0 1 Beta (0.5, 0.5) ~, + 
Failure After Deep Infection - Year 8 0.5 0 1 Beta (0.5, 0.5) ~, + 
Failure After Deep Infection - Year 9 0.5 0 1 Beta (0.5, 0.5) ~, + 
Failure After Deep Infection - Year 10 0.5 0 1 Beta (0.5, 0.5) ~, + 
~: Expert opinion for estimate 
+: No information available for this range.  A Beta (0.5,0.5) distribution was used to cover the full probability range with weight 
in center as best guess that explored full probability space.   
4: Guiney  
10: Losina, et al. b: For sensitivity analyses, Losina, et al. followed using single range for all years.   
10: Losina, et al. d: To encompass the idea that revision sees lower success rates, the primary range was modified such that 
it is centered on a value twice as bad as that used in the primary distribution.   
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Table III-4 Obesity Adjustments for Failure Rates 
Name 
Base Low High Distribution 
Source (Base/  
Range & 
Distribution)  
TKA Failure           
Relative Risk for Nonobese (BMI <30) 1 1 1 Constant Value of 1 8a/8b 
Relative Risk for Class I Obese (BMI 30-35) 1.7689 1.1494 2.7635 Lognormal (0.57, 0.22) 8a/8b 
Relative Risk for Class II Obese (BMI 35-40) 1.7689 1.1494 2.7635 Lognormal (0.57, 0.22) 8a/8b 
Relative Risk for Class III Obese (BMI > 40) 1.7689 1.1494 2.7635 Lognormal (0.57, 0.22) 8a/8b 
Revision Failure           
Relative Risk for Nonobese (BMI <30) 1 1 1 Constant Value of 1 8a/8b 
Relative Risk for Class I Obese (BMI 30-35) 1.7729 1.1479 2.7209 Lognormal (0.57, 0.22) 8a/8b 
Relative Risk for Class II Obese (BMI 35-40) 1.7729 1.1479 2.7209 Lognormal (0.57, 0.22) 8a/8b 
Relative Risk for Class III Obese (BMI > 40) 1.7729 1.1479 2.7209 Lognormal (0.57, 0.22) 8a/8b 
Failure After Deep Infection           
Relative Risk for Nonobese (BMI <30) 1 1 1 Constant Value of 1 8a/8b 
Relative Risk for Class I Obese (BMI 30-35) 1.7729 1.1479 2.7209 Lognormal (0.57, 0.22) 8a/8b 
Relative Risk for Class II Obese (BMI 35-40) 1.7729 1.1479 2.7209 Lognormal (0.57, 0.22) 8a/8b 
Relative Risk for Class III Obese (BMI > 40) 1.7729 1.1479 2.7209 Lognormal (0.57, 0.22) 8a/8b 
8: Kerkhoffs, et al. a: Converted the odds ratio from Kerkhoffs, et al. to relative risk using RR = OR/(1-AbsRisk+(AbsRisk*OR)) 
with the Year 5 failure rate as the absolute risk as the original data was over 5-year period.   
8: Kerkhoffs, et al. b: The high and low values used are derived using the same conversion from OR to RR as the base rate.  
To create a distribution, the event data in Figure 4 of Kerkhoffs, et al. were used to calculate a standard error with the formula: 
sqrt (1/event +1/event +1/total +1/total)  
 
Costs 
The costs (Table III -5), where possible, follow Losina, et al.  Following the methodology 
of Losina, et al., the cost of the primary surgery is a combination of a Current Procedural 
Terminology (CPT) code (27447), a Diagnosis-related Group (DRG), and physical therapy costs 
(Losina, et al., 2009).  The 2015 Medicare reimbursement rates were used rather than inflating 
the older costs used by Losina, et al. (Centers for Medicare & Medicaid Services, 2017), 
(Centers for Medicare & Medicaid Services, 2017).  For the physical therapy component, after 
currency conversion, the inflation was done separately based on the figures from the Canadian 
study used by Losina, et al.  This composite figure is the overall cost.  Using population level 
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obesity rates, the cost for the nonobese population was derived from this overall cost.  The cost 
of revision followed a similar pattern.  The CPT code (27487) and DRG changed and the in-
home physical therapy care value was nearly tripled over primary surgery to account for the 
added intensity and duration required, which Losina did not incorporate (Losina, et al., 2009).  
The choice of DRG requires further discussion as it diverges from Losina, et al.  For primary 
surgery, the DRG used was that for uncomplicated joint replacement, 470.  Only major 
complications and comorbidities (MCC) justify the DRG 469 designation and the MCC list does 
not include obesity.  Further, less than 5% of primary joint replacements are billed as 469 
(Fontana, 2017) so the uncomplicated DRG was selected.  In the case of revisions, three DRGs 
exist.  Major complications (466) are again unlikely with less than 10% of joint revisions using 
this designation.  For the remaining joint revisions, there is an almost even split between 467 for 
complications and comorbidities (CC) and 468 for uncomplicated (no MCC or CC).  While the 
CC list includes BMI ≥ 40, the increased reimbursement between 467 and 468 is approximated 
by the obesity multiplier added in this model so DRG 468 was used in all obesity groups and 
independent of complication outcome.  Another reason for these choices is that all five DRGs 
include both hips and knees.  The share of knees in the higher DRG groups relative to the overall 
number reported is unclear and may not be the same as the overall billing pattern.   
For the cost of complications, Losina, et al. uses a generic cost of complications (Losina, 
et al., 2009).  This cost assignment method gives the costs associated with VTEs and wound 
complications.  For deep infections, the model follows a two-stage surgical treatment.   To reflect 
the nature of this complication and treatment plan, the cost of deep infection is the generic 
complication cost plus the cost of revision.  Then, in the submodel for deep infections, the 
second phase surgery occurs, and a second revision cost incurred.  This reflects the time lag and 
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the multiple surgeries.  The figures for treating OA, postoperative care for TKA patients, and 
care for failed surgeries are also simple inflations of Losina, et al. (Losina, et al., 2009). 
Table III-5 Cost Parameters 
Name Base Low High Distribution 
Source (Base/  
Range & 
Distribution)  
TKA  $ 26,046  
 
$13,023   $ 52,091  Lognormal (9.72, 0.35) 10,2/10e, f 
Cost Multiplier for Nonobese (BMI <30) 1 1 1 Constant Value of 1 9a/9b 
Cost Multiplier for Class I Obese (BMI 30-35) 1.03 1.02 1.05 Normal (1.03, 0.01) 9a/9b 
Cost Multiplier for Class II Obese (BMI 35-40) 1.03 1.02 1.05 Normal (1.03, 0.01) 9a/9b 
Cost Multiplier for Class III Obese (BMI > 40) 1.09 1.07 1.12 Normal (1.09, 0.01) 9a/9b 
Revision  $ 52,307  
 
$26,154  
 
$104,615   Lognormal (10.8, 0.35) 10, 2/10g, f 
Cost Multiplier for Nonobese (BMI <30) 1 1 1 Constant Value of 1 9a/9b 
Cost Multiplier for Class I Obese (BMI 30-35) 1.03 1.02 1.05 Normal (1.03, 0.01) 9a/9b 
Cost Multiplier for Class II Obese (BMI 35-40) 1.03 1.02 1.05 Normal (1.03, 0.01) 9a/9b 
Cost Multiplier for Class III Obese (BMI > 40) 1.09 1.07 1.12 Normal (1.09, 0.01) 9a/9b 
VTE  $ 15,296   $ 7,648   $ 30,593  Lognormal (9.58, 0.35) 10h/10f 
Wound  $ 15,296   $ 7,648   $ 30,593  Lognormal (9.58, 0.35) 10h/10f 
Deep Infection  $ 64,907  
 
$32,454  
 
$129,815  Lognormal (10.64, 0.35) 10i/10f 
OA Treatment  $   4,613   $ 2,307   $   9,226  Lognormal (8.38, 0.35) 10h/10f 
Successful TKA care  $      250   $    125   $      500  Lognormal (5.46, 0.35) 10j/10f 
Failed TKA care  $   6,920   $ 3,460   $ 13,840  Lognormal (8.78, 0.35) 10k/10f 
Revision after Deep Infection 
 
$112,532  
 
$56,266  
 
$225,064  Lognormal (11.57, 0.35) 10p/10f 
Cost Multiplier for Nonobese (BMI <30) 1 1 1 Constant Value of 1 9a/9b 
Cost Multiplier for Class I Obese (BMI 30-35) 1.03 1.02 1.05 Normal (1.03, 0.01) 9a/9b 
Cost Multiplier for Class II Obese (BMI 35-40) 1.03 1.02 1.05 Normal (1.03, 0.01) 9a/9b 
Cost Multiplier for Class III Obese (BMI > 40) 1.09 1.07 1.12 Normal (1.09, 0.01) 9a/9b 
VTE after Deep Infection  $ 15,296   $ 7,648   $ 30,593  Lognormal (9.57, 0.35) 10q 
Wound after Deep Infection  $ 15,296   $ 7,648   $ 30,593  Lognormal (9.57, 0.35) 10q 
Subsequent Deep Infection  $ 64,907  
 
$32,454  
 
$129,815  Lognormal (11.02, 0.35) 10q 
Continuing Care for Best Case  $   6,920   $ 3,460   $ 13,840  Lognormal (8.78, 0.35) 10r 
Continuing Care for Worst Case  $ 30,000  
 
$15,000   $ 60,000  Lognormal (10.25, 0.35) @/10f 
@: The figures for aftercare for amputation range from a few thousand to over $60,000 annually mostly to account for fitting and 
maintaining protheses.  The value $30,000 was selected as a middle ground.   
2: Centers for Medicare and Medicaid Services  
9: Kim a: These are percent changes expressed as cost multipliers not relative risks.   
9: Kim b: A normal distribution was fit to the confidence interval reported.   
10: Losina, et al.  
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10: Losina, et al. e: The component pieces are 2015 rates of reimbursement for CPT 27447, 2015 reimbursement for DRG 470, and the 
inflated and converted value to USD 2015 from the Canadian study cited by Losina, et al. for the in-home physical therapy postoperative.   
This sum was then inflated to 2017 dollars. 
10: Losina, et al. f: Following the convention of Losina, et al., a range from 50% to 100% of base costs is used.  A lognormal distribution 
was selected for the probabilistic distribution.    
10: Losina, et al. g: The component pieces are 2015 rates of reimbursement for CPT 27487, 2015 reimbursement for DRG 468, and the 
inflated and converted value from the Canadian study cited by Losina, et al. for the in-home physical therapy postoperative multiplied by 3 
to reflect the more intensive treatment necessitated by revision.   This sum was then inflated to 2017 dollars. 
10: Losina, et al. h: The price given in Losina, et al. is inflated from 2006 to 2017 USD 
10: Losina, et al. i: The complication cost from Losina, et al. is used to address the infection control and then the revision cost is added to 
reflect the first stage of the two-stage deep infection treatment.   
10: Losina, et al. j: The postoperative treatment plan is reduced to include a single radiograph and office visit based on expert opinion. 
10: Losina, et al. k: The 50% increase over OA treatment seen in Losina is applied here. 
10: Losina, et al. p: The component pieces are 2015 rates of reimbursement for CPT 27487, 2015 reimbursement for DRG 468, and the 
inflated and converted value from the Canadian study cited by Losina, et al. for the in-home physical therapy postoperative multiplied by 3 
to reflect the more intensive treatment necessitated by revision.   This sum was then inflated to 2017 dollars.  Then to account for the 
excess costs associated with the deep infection this is increased by 50%.  Finally, to more accurately reflect the two-stage revision 
process a second round of physical therapy is added.   
10: Losina, et al. q: Unchanged from main model  
10: Losina, et al. r: Follows main model for failed TKA 
 
QALYs 
The model uses QALYs to account for health status and impacts (Table III-6).  In the 
spirit of model replication, most QALYs follow Losina, et al. directly.  For OA, the input 
assumption for the utility value is 0.69 and is taken directly from Losina, et al. (Losina, et al., 
2009).  For the condensed health state of full benefit, an average of the two health states in 
Losina, et al., weighted by likelihood of either outcome, generates a QALY of 0.826 (Losina, et 
al., 2009).  Rather than a new QALY valuation, an increment is preferable so, taking the 
difference, the additional QALYs associated with the full benefit of TKA is set at 0.136.  By 
using an incremental value over the OA QALY, sensitivity analyses provide more sensible 
results.  If OA varies independently of the value of a beneficial TKA, it would be possible that a 
full benefit TKA left the patient worse off than OA.  This violates the definition of full benefit 
procedures used in the model.  For this reason, the benefit of TKA was set as an incremental 
benefit above OA state.  Losina, et al. define failure QALYs as a 25% reduction from the 
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preoperative state.  This gives a QALY of 0.5175 (Losina, et al., 2009).  Similarly, a decrement 
is preferable for use in the model and subtraction yields a decrement of 0.1725.   
To account for the discomfort of surgery and the follow-up care, the model incorporates a 
QALY decrement in the year of surgery.  This is taken to be the difference between subsequent 
year QALY and initial year as described in Monreal, et al. (Monreal, Brosa, Diamantopoulos, 
Folkerts, & Imberti, 2013).  For wound and VTE complications the figures from Monreal, et al. 
become decrements by taking the first year QALY and subtracting the complication values.  For 
both of these complications, this is approximately a 0.01 deduction (Monreal, Brosa, 
Diamantopoulos, Folkerts, & Imberti, 2013).  In the case of deep infection, half of the wound 
decrement is added to the revision decrement to signify that a surgery occurs but there was an 
additional discomfort as well.  In the second year, the revision decrement accrues again to reflect 
the second surgery.  For deep revision, the QALY is anchored on the values of a normal revision.  
Even in the best-case, after a deep revision there is still a disability.  To account for this, the 
QALY for best-case scenario is then equivalent to the failed state for a revision surgery.  In the 
worst-case outcome, the QALY is set to 80% of the best-case scenario.   
To account for loss of quality of life for those living with obesity, a decrement was 
developed from two pieces.  WHO obesity classes are generally five BMI wide i.e. 30-35, 35-40.  
An increase of a single unit of BMI results in a decrement of 0.0017  (Hakim, Wolf, & Garrison, 
2002).  Thus, the single unit value is multiplied by half the width of a class (2.5) and this number 
serves as the basis of the QALY decrement for obesity, Class I once, Class II twice that value, 
and Class III trebled.   
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Table III-6 QALY Parameters 
Name Base Low High Distribution Source (Base/ Range & 
Distribution)  
OA   0.69 0.4548 0.9252 Normal (0.69, 0.12) 10/10 
Full Benefit Addition 0.136 0 0.3712 Normal (0.14, 0.12) 10l/10m 
Failed TKA change -0.1725 -0.4077 0 Normal (-0.17, 0.12) 10n/10m 
TKA  0.15 0.0123 0.4145 Beta (1.5, 8.5) 11a/10o 
Revision 0.15 0 0.9001 Beta (0.15, 0.85) 11a/10o 
VTE 0.01 0 0.0808 Beta (0.01, 0.99) 11b/10o 
Wound 0.0133 0 0.152 Beta (0.01, 0.99) 11b/10o 
Deep Infection 0.1567 0.0001 0.9069 Beta (0.16, 0.84) 11c/10o 
Obesity 0.0043 0 0.0084 Normal (0, 0) 5a/5b 
Best Case 0.5175 0.2823 0.7527 Normal (0.52, 0.12) 10r/10m 
Worst Case 0.414 0.1788 0.6492 Normal (0.41, 0.12) & 
Revision after Deep Infection 0.15 0 0.9001 Beta (0.15, 0.85) 10q 
VTE after Deep Infection 0.01 0 0.0808 Beta (0.01, 0.99) 10q 
Wound after Deep Infection 0.0133 0 0.152 Beta (0.01, 0.99) 10q 
Subsequent Deep Infection 0.1567 0 0.9069 Beta (0.16, 0.84) 10q 
&: This is estimated to be 80% of the best-case outcome 
5: Hakim, Wolf, & Garrison a: The WHO classification system generally has a width of 5 BMI for the categories.  The QALY/unit BMI of 
0.017 is thus multiplied by half the width to create a BMI decrement by category of obesity.   
5: Hakim, Wolf, & Garrison b: The class wide decrement was used as the mean of a normal distribution with half the mean used for a 
standard deviation 
10: Losina, et al.  
10: Losina, et al. l: A weighted average is constructed from full and limited benefit states in Losina, et al.  From this, the OA QALY is 
subtracted to convert to an incremental gain. 
10: Losina, et al. m: Following the convention of Losina, et al., a normal distribution is constructed with the mean equal to the base 
parameter and standard deviation of 0.12 
10: Losina, et al. n: A 25% reduction from OA is used following Losina, et al.  This is converted to a decrement.   
10: Losina, et al. o: Following the convention of Losina, et al. a beta distribution is constructed where α is the baseline value and β is equal 
to 1- α 
10: Losina, et al. q: Unchanged from main model  
10: Losina, et al. r: Follows main model for failed TKA 
11: Monreal, et al. a: A decrement was created by taking the difference between ongoing postsurgical value and the year of surgery value 
given by Monreal, et al.  
11: Monreal, et al. b: The specific complication value listed by Monreal, et al. was subtracted from the first-year value to create a 
decrement for the complication 
11: Monreal, et al. c: The wound complication decrement is halved and added to the surgical decrement to approximate the first stage of 
the two-stage deep infection treatment.   
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Obesity Adjustments 
For several of the important parameters in the model, relative risks associated with the 
various obesity classes address the observed differences in certain transitions and outcome 
measures. 
For probabilities of full benefit for each surgery, there is no suitable information available 
in the literature.  Based on the other obesity relative risks, there is most often a doubled risk of a 
poor outcome.  The range seen is a slight protective influence to about 4 times the risk of a poor 
outcome.   
Another obesity adjustment applies to all-cause mortality rate.  A meta-analysis done by 
an international consortium provides the adjustment factors (The Global BMI Mortality 
Collaboration, 2016).  The duration of obesity is not taken into account.  Hazard ratios were 
converted to relative risks and the reference group was changed to nonobese using the raw data 
provided in Table 1 of that paper (The Global BMI Mortality Collaboration, 2016).  The 
confidence intervals required similar transformations.   
Complication rate is a major source of difference between obesity classes.  The relative 
risk for the various complications comes from the meta-analysis conducted in Chapter II.  
Confidence intervals on the relative risk were also constructed with the upper and lower bounds 
used as high and low values for the relative risk from the same source.   
To address the added burden of obesity on costs of the procedure, the model includes a 
multiplier for surgical costs in lieu of the complicated coding rules of changing the DRG.  
Claims data analysis from Kim serves as the basis for this parameter  (Kim, 2010).  Kim found 
an increase in cost over the base price for both Class I and II as well as Class III.  The confidence 
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intervals provided by Kim are used to construct a normal distribution around this percentage 
increase (Kim, 2010).   
Sensitivity Analysis Ranges and Distributions 
In general, the distributions provided in the literature yielded 95% confidence intervals.  
The limits of those intervals were used to create a high and low value for univariate sensitivity 
analysis.  In other cases, the literature supplied the upper and lower bounds and a distribution of 
an appropriate type was fitted.  The beta distribution was used for probabilities to constrain 
values to the proper interval of 0 to 1 and the lognormal distribution for costs to address the long 
tail.  A normal distribution was used for other parameters.   
In transitions, the ranges are as follows.  For OA to TKA, the range used matches that 
followed by Holt, et al. (Holt, et al., 2011).  For any type of surgery to full benefit, the range set 
by Losina, et al. for probability of poor postoperative function is used (Losina, et al., 2009).  A 
beta distribution centered on 0.5 accommodates uncertainty with a wide even range around both 
early and late revision choices by the patient.  Base death rates do not undergo sensitivity 
analysis. 
For complication rates, the meta-analysis in Chapter II provides confidence intervals 
directly.  For purposes of this model, the inverse variance heterogeneity method gives the 
confidence intervals.  This method developed by Doi, et al overcomes some known problems 
with both fixed and random effects models in dealing with heterogeneity in meta-analysis.  
Specifically, it deals with overconfident estimators (Barendregt & Doi, 2016).  Consequently, the 
confidence intervals reported in the meta-analysis of Chapter II do not match those used here.  
This method derives larger confidence intervals because it accounts for several types of 
heterogeneity not addressed in the meta-analysis results.  The point estimates are unchanged 
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from those in Chapter II, but these larger ranges allow for more thorough examination in this 
model.  There is no theoretical reason to believe that heterogeneity is an issue in the meta-
analysis, but the sensitivity analyses can benefit from a wider exploration of relative risks.    
For failure rates, a single adjustment factor was available.  The value given by Losina, et 
al. for failure applies to each year and surgical category (Losina, et al., 2009). 
All cost ranges follow the Losina, et al. suggestion of testing from 50% reduction to 
100% increase (Losina, et al., 2009).  Probabilistic analysis follows a log normal distribution fit 
to match the mean of the distribution to the base value.   
For QALYs, when possible, the model follows Losina, et al.  In general, Losina, et al. 
used normal distributions with standard deviations of 0.12 (Losina, et al., 2009).  The model 
applies the same convention while using the bases as described above as the mean throughout for 
all QALY values.  Except for obesity, QALY decrements also follow the convention of Losina, 
et al. while using the specific decrements from Monreal as baselines (Monreal, Brosa, 
Diamantopoulos, Folkerts, & Imberti, 2013).   For decrements, the convention is to construct a 
beta distribution using the base as α and 1- α as β parameter (Losina, et al., 2009).  For obesity 
decrements, the class decrement was used as the mean of a normal distribution with half the 
mean used for a standard deviation.   
Sensitivity Analysis 
Thorough sensitivity analyses were undertaken using five strategies.  First, a one-way 
sensitivity analysis tested each parameter and relative risk separately at both the low and high 
values.  For these results, tornado graphs display the most impactful parameters.  Next, guided 
by the results of the one-way analysis, the costs of OA treatment compared to the costs of 
postoperative treatment for TKA patients with positive outcomes underwent a two-way 
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sensitivity analysis.  Third, a threshold analysis examined the impact of the size of the increment 
accrued for full benefit of TKA.  Next, scenario analyses were performed in some key areas 
highlighted by either the literature or the one-way analysis: the relationship between OA and 
TKA costs and health states, complications, deep infection, and failure rates.  Best- and worst-
case scenarios were also considered where all parameters were set to favor TKA and OA 
respectively.  To further explore the relationship between OA and TKA costs seen in the two-
way analysis and the QALY increment in the threshold analysis, a scenario analysis expands the 
parameters included to encompass those related to failed procedures as well as the costs and 
decrements associated with the surgery itself.  The literature implicates differential complication 
rates in differences between obesity class outcomes.  To that end, scenarios explored various 
combinations of complication rates and the relative risks of experiencing those complications.  
Given the importance of deep infections and the particularly involved consequences, a set of 
scenarios involving only deep infection rate and relative risk was done as well.  The one-way 
analysis along with the literature indicate failure rates are important.    This scenario led to a 
second threshold analysis where the annual failure rates were considered correlated and a range 
of change between no failure and twice the base rate of failure applied to each parameter.  
Finally, a probabilistic sensitivity analysis was conducted using the distributions described above 
and 10,000 iterations.  Cost-effectiveness acceptability curves are the main outcome of this 
analysis.   
Assumptions 
Several important assumptions underlie the model design.  Most important is the 
assumption that the population is a homogenous cohort of 74-year-olds undergoing a generic 
TKA procedure.  There is no consideration for different implants or surgical approaches, all 
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surgeons are equally competent, and patient demographics play no role in the outcomes.  Second, 
the only comorbidity considered in the model is obesity.  Any other potentially impactful 
comorbidities are not considered.  The distribution of obesity is assumed to be identical in the 
TKA population as it is in the general population.  The model allows for unlimited revisions in 
that any failed revision is allowed future revisions that face identical failure rates to first 
revisions.  A final assumption is that the differential benefit in outcomes posited in the literature 
is implicit.  The gain in QALYs is expected to be the same for all patients even if the starting 
point is lower.  This is addressed by decrementing QALYs for obesity.   
Verification and Validation 
Verification was undertaken in several ways.  The first was debugging the model to 
ensure proper formulas and data connections.  The model structure incorporates error checking 
throughout the build.  Where possible the transitions were built modularly to be transparent and 
intermediate summation was used to ensure that the model maintained a constant population, a 
sign that all transitions were accounted for correctly.  Testing extreme cases in the one-way 
analysis ensured reasonableness.  Finally, the model structure replicates Losina, et al. as closely 
as possible to verify the conceptual model (Losina, et al., 2009).   
Validation also made use of the work of Losina, et al.  The weighted average of the four 
obesity groups where primary TKA could be performed any year in the model was compared to 
results of that paper.  There were very similar costs and QALYs, within 10% for each individual 
piece.  Significant changes were made to the cost of postoperative care for successful procedures 
to reflect a change in treatment recommendations, so the cost is significantly lower in this model 
as is reflected in the ICER.   A UK based trial setting yielded comparable results for the overall 
ICER (Dakin, et al., 2012).  These results are also in line with the generally held belief that TKA 
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is a cost-effective procedure.  Further validation of the model comes from the one-way analysis.  
The direction and scale of movement fit within the expected changes.  Finally, the model and its 
parameters were reviewed by an expert in TKA for face validity.   
Results  
Base Case 
TKA is a cost-effective procedure when using baseline assumptions that all patients 
undergo TKA in the first year as seen in Table III-7.  The overall population sees an ICER of 
$16,273/QALY, an excellent value by US standards.  For nonobese patients, TKA is an even 
better value at $4,932/QALY.  Class I and II see ICERs of $33,891 and $46,379 respectively.  
Class III sees a sharp rise in the ICER to $80,671/QALY.      
Table III-7 Base Case Results 
TKA Status by 
Obesity  
Cost QALY ICER  NMB* 
Relative to No TKA 
Overall      
No TKA  $        49,071  7.31     
TKA   $        65,151  8.30  $        16,273   $        33,326  
Nonobese         
No TKA  $        49,255  7.37     
TKA   $        54,571  8.44  $         4,932   $        48,568  
Class I Obese          
No TKA  $        48,954  7.28     
TKA   $        78,629  8.15  $        33,891   $        14,105  
Class II Obese         
No TKA  $        49,049  7.25     
TKA   $        86,550  8.05  $        46,379   $          2,928  
Class III Obese          
No TKA  $        47,559  6.98     
TKA   $      101,722  7.65  $        80,671   $ (20,592) 
*Net Monetary Benefit where QALYs are valued at $50,000 
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Sensitivity Analysis 
The model is generally robust to parameter changes in the ranges considered when 
looking at TKA for the overall population.  As obesity increases, TKA may no longer be 
consistently cost-effective.  TKA for patients with Class III obesity may become very expensive 
under many different parameter assumptions.  There are several categories of parameters that are 
most likely to weigh against TKA.  Parameters related to OA (whether costs of treatment or 
health status) are important.  The likelihood of successful surgery is also a key parameter to 
consider.  Lastly, deep infection rates are also a major deciding factor in whether TKA is cost-
effective for obese patients.   
One-Way Sensitivity Analysis 
One-way sensitivity analysis shows TKA is consistently cost-effective in the overall and 
nonobese populations.  The model results are more likely to change as obesity class increases.  
This is most evident in the number of parameters that can make TKA look less cost-effective.  In 
the overall population (Figure III-2), only three parameters would make TKA not look cost-
effective at a willingness-to-pay threshold of $100,000 per QALY.  If the initial success of either 
primary and revision surgery are poor, they can push the ICER over the $100,000 threshold.  The 
maximum ICER is in the range of $125,000/QALY, a small amount relative to those observed in 
heavier groups.  More interesting is the third parameter, the value of the utility increase from OA 
to full benefit after the surgery.  In this case, when the value is at its lowest (no benefit over OA) 
TKA is dominated.  Despite lower costs of continuing care, it is still necessary that health 
improves over the initial health state for TKA to be of value thus when this parameter is zero, 
TKA is dominated in all obesity groups.  This relationship is explored further in other analyses.  
For the nonobese population (Figure III-3), when parameters are at their least favorable to TKA, 
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the ICER of TKA never exceeds $100,000 per QALY and sometimes TKA may even become 
dominant.  The exception is the utility increment of TKA benefit as noted above.  In Class I 
obesity (Figure III-4), the situation is similar to the overall population with the addition that the 
utility associated with OA parameter can cause the ICER to exceed the $100,000 threshold.  
However, if the relative risk of deep infection is at its highest, TKA is dominated.  Moving into a 
heavier population, Class II obesity (Figure III-5) sees six parameters capable of making the 
ICER for TKA exceed $100,000 per QALY.  In addition to those seen in Class I, the decrement 
for having a revision surgery and the rate of deep infection can raise the ICER above $100,000 
per QALY.  Finally, in Class III obesity (Figure III-6), nineteen parameters can make TKA 
exceed this threshold.   
It is also of interest to note that while the same parameters drive much of the change 
across these population groups that the magnitude of impact increases with obesity.  A change in 
an important parameter in the nonobese makes TKA slightly more than the threshold at its worst, 
but in the Class III group that same change pushes the ICER into the millions of dollars.  There 
are not only more parameters that matter in decision making, but those parameters also matter 
more.   
Looking at the ten most impactful parameters in each obesity group and the overall 
population, only 16 unique parameters appear out of 248 possible.  Six of those appear in all five 
lists.  One interesting parameter that rises to importance in the overall population and even 
dominance in the nonobese is age.  As the starting age of the population falls, the cost-
effectiveness improves.  This is most likely because there is more lifespan left to benefit from 
improved health.  The trend toward younger patients is beneficial despite the increased 
likelihood of revision due to age of the implant.     
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The tornado graphs of the top ten most impactful parameters for each population group as 
well as the overall population are shown below (Figures III-2-6).  Each parameter’s range is 
centered about the baseline value (dashed line) for that population and the red line shows the 
$100,000 threshold.  Full results are available in Appendix B.   
Figure III-2 Tornado Graph of Top Ten Impactful Parameters for the Overall Population 
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Figure III-3 Tornado Graph of Top Ten Impactful Parameters for the Nonobese Population 
 
Figure III-4 Tornado Graph of Top Ten Impactful Parameters for the Class I Obese Population 
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Figure III-5 Tornado Graph of Top Ten Impactful Parameters for the Class II Obese Population 
 
Figure III-6 Tornado Graph of Top Ten Impactful Parameters for the Class III Obese Population 
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Two-Way Sensitivity Analysis 
The relationship between OA and postoperative health and costs was of import in the 
univariate analysis so further investigation using a two-way analysis explored this relationship.   
The cost of OA treatment and the cost of continuing care after successful TKA were 
compared at various levels.  For OA, the range was the same used in the univariate analysis 
(50%-200% of baseline).  For successful TKA, the range was considerably wider.  This reflects 
the much larger value used by Losina, et al. in their study while maintaining the base line value 
used in this model which reflects newer practice patterns of minimal contact once the implant is 
deemed a success.  In that spirit, the range used is no cost for annual follow up care to the 
midpoint of the OA range which is roughly equal to baseline OA spending.     
The results of the analysis are presented below using five tables, one for the overall 
population (Table III-8) followed by one for each obesity group (Tables III-9-12).   The rows are 
different annual OA costs and the annual costs of continuing care for successful postoperative 
TKA are the columns.  By applying conditional formatting such that red values have ICERs over 
the $100,000 threshold, yellow values are between the $50,000 and $100,000 thresholds and into 
green for values under the $50,000 threshold including zeroes for dominant combinations, the 
relationship between these two major cost components can be visualized.  The base value of the 
continuing care of successful TKA is $250 per year and the annual cost of OA has a base value 
of $4613.20 and the red font represent these key values.     
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Table III-8 ICERs for Two-Way Sensitivity Analysis in the Overall Population 
 Overall Population 
  Annual Cost of Continuing Care for Successful TKA 
  $0  $250  $500  $1,000  $1,500  $2,000  $2,500  $3,000  $3,500  $4,000  $4,500  $5,000  $5,500  $6,000  
A
n
n
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al
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st
 o
f 
O
A
 T
re
at
m
en
t 
$2,307  $38,894  $41,103  $43,312  $47,730  $52,148  $56,566  $60,984  $65,402  $69,820  $74,239  $78,657  $83,075  $87,493  $91,911  
$2,500  $36,812  $39,021  $41,230  $45,648  $50,066  $54,484  $58,903  $63,321  $67,739  $72,157  $76,575  $80,993  $85,411  $89,829  
$3,000  $31,430  $33,639  $35,848  $40,266  $44,684  $49,102  $53,520  $57,938  $62,356  $66,774  $71,192  $75,610  $80,028  $84,446  
$3,500  $26,047  $28,256  $30,465  $34,883  $39,301  $43,720  $48,138  $52,556  $56,974  $61,392  $65,810  $70,228  $74,646  $79,064  
$4,000  $20,665  $22,874  $25,083  $29,501  $33,919  $38,337  $42,755  $47,173  $51,591  $56,009  $60,427  $64,845  $69,263  $73,681  
$4,500  $15,282  $17,491  $19,700  $24,119  $28,537  $32,955  $37,373  $41,791  $46,209  $50,627  $55,045  $59,463  $63,881  $68,299  
$5,000  $9,900  $12,109  $14,318  $18,736  $23,154  $27,572  $31,990  $36,408  $40,826  $45,244  $49,662  $54,080  $58,498  $62,916  
$5,500  $4,518  $6,727  $8,936  $13,354  $17,772  $22,190  $26,608  $31,026  $35,444  $39,862  $44,280  $48,698  $53,116  $57,534  
$6,000  $0  $1,344  $3,553  $7,971  $12,389  $16,807  $21,225  $25,643  $30,061  $34,479  $38,897  $43,315  $47,733  $52,151  
$6,500  $0  $0  $0  $2,589  $7,007  $11,425  $15,843  $20,261  $24,679  $29,097  $33,515  $37,933  $42,351  $46,769  
$7,000  $0  $0  $0  $0  $1,624  $6,042  $10,460  $14,878  $19,296  $23,714  $28,132  $32,550  $36,968  $41,386  
$7,500  $0  $0  $0  $0  $0  $660  $5,078  $9,496  $13,914  $18,332  $22,750  $27,168  $31,586  $36,004  
$8,000  $0  $0  $0  $0  $0  $0  $0  $4,113  $8,531  $12,949  $17,367  $21,785  $26,203  $30,621  
$8,500  $0  $0  $0  $0  $0  $0  $0  $0  $3,149  $7,567  $11,985  $16,403  $20,821  $25,239  
$9,000  $0  $0  $0  $0  $0  $0  $0  $0  $0  $2,184  $6,602  $11,020  $15,438  $19,856  
$9,226  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $4,165  $8,583  $13,001  $17,419  
 
Table III-9 ICERs for Two-Way Sensitivity Analysis in the Nonobese Population 
 Nonobese (BMI < 30) 
  Annual Cost of Continuing Care for Successful TKA 
  $0  $250  $500  $1,000  $1,500  $2,000  $2,500  $3,000  $3,500  $4,000  $4,500  $5,000  $5,500  $6,000  
A
n
n
u
al
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f 
O
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$2,307  $25,701  $27,785  $29,868  $34,035  $38,202  $42,368  $46,535  $50,702  $54,868  $59,035  $63,202  $67,368  $71,535  $75,702  
$2,500  $23,785  $25,869  $27,952  $32,119  $36,285  $40,452  $44,619  $48,785  $52,952  $57,119  $61,286  $65,452  $69,619  $73,786  
$3,000  $18,832  $20,915  $22,998  $27,165  $31,332  $35,498  $39,665  $43,832  $47,998  $52,165  $56,332  $60,499  $64,665  $68,832  
$3,500  $13,878  $15,961  $18,045  $22,211  $26,378  $30,545  $34,711  $38,878  $43,045  $47,211  $51,378  $55,545  $59,712  $63,878  
$4,000  $8,924  $11,008  $13,091  $17,258  $21,424  $25,591  $29,758  $33,924  $38,091  $42,258  $46,424  $50,591  $54,758  $58,925  
$4,500  $3,971  $6,054  $8,137  $12,304  $16,471  $20,637  $24,804  $28,971  $33,137  $37,304  $41,471  $45,637  $49,804  $53,971  
$5,000  $0  $1,100  $3,184  $7,350  $11,517  $15,684  $19,850  $24,017  $28,184  $32,350  $36,517  $40,684  $44,850  $49,017  
$5,500  $0  $0  $0  $2,396  $6,563  $10,730  $14,897  $19,063  $23,230  $27,397  $31,563  $35,730  $39,897  $44,063  
$6,000  $0  $0  $0  $0  $1,609  $5,776  $9,943  $14,110  $18,276  $22,443  $26,610  $30,776  $34,943  $39,110  
$6,500  $0  $0  $0  $0  $0  $822  $4,989  $9,156  $13,323  $17,489  $21,656  $25,823  $29,989  $34,156  
$7,000  $0  $0  $0  $0  $0  $0  $35  $4,202  $8,369  $12,536  $16,702  $20,869  $25,036  $29,202  
$7,500  $0  $0  $0  $0  $0  $0  $0  $0  $3,415  $7,582  $11,749  $15,915  $20,082  $24,249  
$8,000  $0  $0  $0  $0  $0  $0  $0  $0  $0  $2,628  $6,795  $10,962  $15,128  $19,295  
$8,500  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $1,841  $6,008  $10,175  $14,341  
$9,000  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $1,054  $5,221  $9,388  
$9,226  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $2,978  $7,144  
 
Table III-10 ICERs for Two-Way Sensitivity Analysis in the Class I Obese Population 
 Class I Obesity (BMI 30-35) 
  Annual Cost of Continuing Care for Successful TKA 
  $0  $250  $500  $1,000  $1,500  $2,000  $2,500  $3,000  $3,500  $4,000  $4,500  $5,000  $5,500  $6,000  
A
n
n
u
al
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o
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 o
f 
O
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at
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$2,307  $59,446  $61,846  $64,246  $69,047  $73,847  $78,648  $83,448  $88,249  $93,049  $97,850  $102,650  $107,451  $112,251  $117,052  
$2,500  $57,102  $59,502  $61,902  $66,703  $71,503  $76,304  $81,104  $85,905  $90,705  $95,506  $100,306  $105,107  $109,907  $114,708  
$3,000  $51,042  $53,442  $55,842  $60,643  $65,443  $70,244  $75,044  $79,845  $84,645  $89,446  $94,246  $99,047  $103,847  $108,648  
$3,500  $44,982  $47,382  $49,783  $54,583  $59,384  $64,184  $68,985  $73,785  $78,586  $83,386  $88,187  $92,987  $97,788  $102,588  
$4,000  $38,922  $41,323  $43,723  $48,523  $53,324  $58,124  $62,925  $67,725  $72,526  $77,326  $82,127  $86,927  $91,728  $96,528  
$4,500  $32,863  $35,263  $37,663  $42,464  $47,264  $52,065  $56,865  $61,666  $66,466  $71,267  $76,067  $80,868  $85,668  $90,469  
$5,000  $26,803  $29,203  $31,603  $36,404  $41,204  $46,005  $50,805  $55,606  $60,406  $65,207  $70,007  $74,808  $79,608  $84,409  
$5,500  $20,743  $23,143  $25,544  $30,344  $35,145  $39,945  $44,746  $49,546  $54,347  $59,147  $63,948  $68,748  $73,549  $78,349  
$6,000  $14,684  $17,084  $19,484  $24,284  $29,085  $33,885  $38,686  $43,486  $48,287  $53,087  $57,888  $62,688  $67,489  $72,289  
$6,500  $8,624  $11,024  $13,424  $18,225  $23,025  $27,826  $32,626  $37,427  $42,227  $47,028  $51,828  $56,629  $61,429  $66,230  
$7,000  $2,564  $4,964  $7,364  $12,165  $16,965  $21,766  $26,566  $31,367  $36,167  $40,968  $45,768  $50,569  $55,369  $60,170  
$7,500  $0  $0  $1,305  $6,105  $10,906  $15,706  $20,507  $25,307  $30,108  $34,908  $39,709  $44,509  $49,310  $54,110  
$8,000  $0  $0  $0  $45  $4,846  $9,646  $14,447  $19,247  $24,048  $28,848  $33,649  $38,449  $43,250  $48,050  
$8,500  $0  $0  $0  $0  $0  $3,587  $8,387  $13,188  $17,988  $22,789  $27,589  $32,390  $37,190  $41,991  
$9,000  $0  $0  $0  $0  $0  $0  $2,327  $7,128  $11,928  $16,729  $21,529  $26,330  $31,130  $35,931  
$9,226  $0  $0  $0  $0  $0  $0  $0  $4,384  $9,185  $13,985  $18,786  $23,586  $28,387  $33,187  
 
Table III-11 ICERs for Two-Way Sensitivity Analysis in the Class II Obese Population 
 Class II Obesity (BMI 35-40) 
  Annual Cost of Continuing Care for Successful TKA 
  $0  $250  $500  $1,000  $1,500  $2,000  $2,500  $3,000  $3,500  $4,000  $4,500  $5,000  $5,500  $6,000  
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$2,307  $74,148  $76,710  $79,272  $84,396  $89,520  $94,645  $99,769  $104,893  $110,017  $115,142  $120,266  $125,390  $130,514  $135,639  
$2,500  $71,605  $74,167  $76,729  $81,853  $86,977  $92,102  $97,226  $102,350  $107,474  $112,599  $117,723  $122,847  $127,971  $133,096  
$3,000  $65,030  $67,592  $70,154  $75,278  $80,402  $85,527  $90,651  $95,775  $100,899  $106,024  $111,148  $116,272  $121,396  $126,521  
$3,500  $58,455  $61,017  $63,579  $68,703  $73,828  $78,952  $84,076  $89,200  $94,325  $99,449  $104,573  $109,697  $114,822  $119,946  
$4,000  $51,880  $54,442  $57,004  $62,129  $67,253  $72,377  $77,501  $82,626  $87,750  $92,874  $97,998  $103,123  $108,247  $113,371  
$4,500  $45,305  $47,867  $50,430  $55,554  $60,678  $65,802  $70,927  $76,051  $81,175  $86,299  $91,424  $96,548  $101,672  $106,796  
$5,000  $38,730  $41,293  $43,855  $48,979  $54,103  $59,227  $64,352  $69,476  $74,600  $79,724  $84,849  $89,973  $95,097  $100,221  
$5,500  $32,156  $34,718  $37,280  $42,404  $47,528  $52,653  $57,777  $62,901  $68,025  $73,150  $78,274  $83,398  $88,522  $93,647  
$6,000  $25,581  $28,143  $30,705  $35,829  $40,954  $46,078  $51,202  $56,326  $61,451  $66,575  $71,699  $76,823  $81,948  $87,072  
$6,500  $19,006  $21,568  $24,130  $29,255  $34,379  $39,503  $44,627  $49,752  $54,876  $60,000  $65,124  $70,249  $75,373  $80,497  
$7,000  $12,431  $14,993  $17,555  $22,680  $27,804  $32,928  $38,052  $43,177  $48,301  $53,425  $58,549  $63,674  $68,798  $73,922  
$7,500  $5,856  $8,419  $10,981  $16,105  $21,229  $26,353  $31,478  $36,602  $41,726  $46,850  $51,975  $57,099  $62,223  $67,347  
$8,000  $0  $1,844  $4,406  $9,530  $14,654  $19,779  $24,903  $30,027  $35,151  $40,276  $45,400  $50,524  $55,648  $60,773  
$8,500  $0  $0  $0  $2,955  $8,080  $13,204  $18,328  $23,452  $28,577  $33,701  $38,825  $43,949  $49,074  $54,198  
$9,000  $0  $0  $0  $0  $1,505  $6,629  $11,753  $16,877  $22,002  $27,126  $32,250  $37,374  $42,499  $47,623  
$9,226  $0  $0  $0  $0  $0  $3,652  $8,776  $13,900  $19,025  $24,149  $29,273  $34,397  $39,522  $44,646  
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Table III-12 ICERs for Two-Way Sensitivity Analysis in the Class III Obese Population 
 Class III Obesity (BMI >40) 
  Annual Cost of Continuing Care for Successful TKA 
  $0  $250  $500  $1,000  $1,500  $2,000  $2,500  $3,000  $3,500  $4,000  $4,500  $5,000  $5,500  $6,000  
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$2,307  $113,185  $116,089  $118,993  $124,802  $130,611  $136,419  $142,228  $148,036  $153,845  $159,653  $165,462  $171,270  $177,079  $182,887  
$2,500  $110,215  $113,119  $116,024  $121,832  $127,641  $133,449  $139,258  $145,066  $150,875  $156,683  $162,492  $168,301  $174,109  $179,918  
$3,000  $102,538  $105,442  $108,346  $114,155  $119,963  $125,772  $131,580  $137,389  $143,197  $149,006  $154,814  $160,623  $166,431  $172,240  
$3,500  $94,860  $97,764  $100,669  $106,477  $112,286  $118,094  $123,903  $129,711  $135,520  $141,328  $147,137  $152,945  $158,754  $164,562  
$4,000  $87,182  $90,087  $92,991  $98,799  $104,608  $110,417  $116,225  $122,034  $127,842  $133,651  $139,459  $145,268  $151,076  $156,885  
$4,500  $79,505  $82,409  $85,313  $91,122  $96,930  $102,739  $108,547  $114,356  $120,165  $125,973  $131,782  $137,590  $143,399  $149,207  
$5,000  $71,827  $74,731  $77,636  $83,444  $89,253  $95,061  $100,870  $106,678  $112,487  $118,295  $124,104  $129,913  $135,721  $141,530  
$5,500  $64,150  $67,054  $69,958  $75,767  $81,575  $87,384  $93,192  $99,001  $104,809  $110,618  $116,426  $122,235  $128,043  $133,852  
$6,000  $56,472  $59,376  $62,281  $68,089  $73,898  $79,706  $85,515  $91,323  $97,132  $102,940  $108,749  $114,557  $120,366  $126,174  
$6,500  $48,794  $51,699  $54,603  $60,411  $66,220  $72,029  $77,837  $83,646  $89,454  $95,263  $101,071  $106,880  $112,688  $118,497  
$7,000  $41,117  $44,021  $46,925  $52,734  $58,542  $64,351  $70,159  $75,968  $81,777  $87,585  $93,394  $99,202  $105,011  $110,819  
$7,500  $33,439  $36,343  $39,248  $45,056  $50,865  $56,673  $62,482  $68,290  $74,099  $79,907  $85,716  $91,525  $97,333  $103,142  
$8,000  $25,762  $28,666  $31,570  $37,379  $43,187  $48,996  $54,804  $60,613  $66,421  $72,230  $78,038  $83,847  $89,655  $95,464  
$8,500  $18,084  $20,988  $23,893  $29,701  $35,510  $41,318  $47,127  $52,935  $58,744  $64,552  $70,361  $76,169  $81,978  $87,786  
$9,000  $10,406  $13,311  $16,215  $22,023  $27,832  $33,641  $39,449  $45,258  $51,066  $56,875  $62,683  $68,492  $74,300  $80,109  
$9,226  $6,930  $9,834  $12,739  $18,547  $24,356  $30,164  $35,973  $41,781  $47,590  $53,398  $59,207  $65,015  $70,824  $76,632  
 
 For the overall population, even in the worst pairing for TKA, TKA does not exceed the 
$100,000 threshold.  Examining by obesity classification, the tables tell a similar story with a 
decreasing number of combinations being dominant and an increasing share exceeding that 
threshold.  In the nonobese population, few combinations are not cost-effective at $50,000 and 
none exceed $100,000 with many others being dominant.  The least cost-effective occur in the 
upper right where postoperative care for successful TKA is very (perhaps unrealistically) 
expensive and cost of OA treatment is minimal.  Conversely, TKA is dominant when OA is 
expensive and continuing care is minimal as found to the lower left.  In Class I, these numbers 
shift towards the worst and less realistic situations for TKA exceeding the $100,000 as well as 
fewer being dominant in the opposite corner.  For Class II, this pattern continues with a larger 
area around the extreme corner failing at the highest threshold and smaller area at the opposite 
extreme being dominant.  In Class III, TKA does not fare as well when costs turn against TKA.  
It is no longer possible to see TKA as dominant.  Regardless, looking at areas where Class III is 
most cost-effective, it is easy to think of situations where these conditions exist, high intensity 
health care users where successful surgery seems probable.  It is much harder to imagine 
situations in the opposite direction where treating OA is minimal cost but TKA expenses for 
continuing care will be more than 20 times the base value.   
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This last group also illustrates the importance of the relative relationship between OA and 
TKA as well as what is still missing in this two-way analysis.  In the top left corner of the Class 
III table, TKA continuing care is no cost, there is no additional cost beyond the initial surgery 
and any complications for patients remaining in the successful TKA state.  Patients who never 
return to the surgeon after the immediate postoperative appointments because they and their 
implant are doing well would accrue no costs for continuing care.  This fairly likely situation is 
still not cost-effective until OA treatment costs over $3,000 annually.  The simple costs of OA 
and postoperative treatments are less important than the relationship between them and should 
not be considered in isolation.   
Utility Threshold Analysis 
A threshold analysis for the incremental improvement in quality of life after successful 
TKA surgery relative to living with OA was done to further explore the effects of the 
relationship between OA and successful TKA.  In this analysis, the magnitude of this 
improvement of quality of life following successful TKA relative to OA was varied between no 
change and 0.37.  The baseline value of utility for living with OA is 0.69 and is maintained 
throughout this analysis.  The maximum possible utility for any patient is 1 so the increment size 
is constrained when it pushes the total utility over this boundary of perfect health.   
There are two interesting ways to examine the effect of this maximum benefit size for 
successful TKA.  The first is to look at just the change in incremental utility for TKA relative to 
no TKA.  The incremental QALY graph (Figure III-7) shows the additional utility gained per 
year by someone in the successful TKA state relative to living with OA on the horizontal axis.  
The vertical axis shows the difference in QALYs over the patient life span between TKA and no 
TKA.  Each line depicts one population group.  The other is to look at the overall outcome of 
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interest, the ICER (Figure III-8).  In that graph, the horizontal axis is the same, but the vertical is 
the incremental cost-effectiveness ratio (which is the incremental cost [which remains unchanged 
in this analysis] divided by the incremental QALYs that are examined alone in the previous 
graph).   
Figure III-7 Incremental QALYs by Obesity Class 
 
Looking at just the incremental QALYs illustrates two things.  The first is the previously 
discussed maximum benefit ceiling.  For all population groups, at 0.31 the incremental benefit 
flattens out.  This is because while OA is at baseline, the maximum improvement possible is the 
gap between perfect health and OA (1-0.69 = 0.31).  The lines reach this maximum at different 
levels of incremental benefit in lifetime QALYs due to other factors in the model such as the 
obesity penalty and different complication rates assessing QALY penalties.  At the other end of 
the spectrum, every obesity classification as well as the nonobese can result in net losses in 
lifetime QALYs when the benefit of successful TKA is low enough.  This result may appear 
surprising.  However, this parameter is not the only one determining overall lifetime QALYs.  To 
experience the benefit of successful TKA, a patient must first face the surgery itself (a decrement 
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of 0.15 for that first year).  Additionally, patients face complications which may also lower 
quality of life experienced in both the short and long term for deep infections.  Implants may also 
fail which is a worse health state than OA.  Revisions may also occur with a further surgical 
decrement and accompanying risks.  The higher quality of life associated with a successful 
surgery must outweigh all these risks and experiences.  For each obesity group there is a floor at 
which the benefit of the best outcome does not outweigh the rest of the process.  The 
accompanying table (Table III-13) displays those floors.     
Figure III-8 ICERs by Obesity Class 
 
The graph of ICERs demonstrates another key factor in the overall results.  While the 
cost portion of the ICER is unchanged in this analysis, the ratio is significantly impacted by the 
change in benefit relative to the OA utility.  This graph shows the ICERs in a reasonable window 
of willingness to pay (WTP).  To the left the impact of this single parameter on the overall 
results is clear from the rate at which the ICER is falling.  The difference in benefit needed to 
move between dominated and cost-effectiveness at reasonable thresholds is small.  The effect of 
the same increase in benefit at larger benefit levels is minimal.   
 $-
 $25,000
 $50,000
 $75,000
 $100,000
 $125,000
 $150,000
0 0.05 0.1 0.15 0.2 0.25 0.3 0.35
In
cr
em
en
ta
l C
o
st
-E
ff
ec
ti
en
es
s 
R
at
io
 
($
/Q
A
LY
) 
TK
A
 v
 N
o
 T
K
A
Additional annual utility gained relative to OA for succesful TKA
ICERs
Overall Nonobese Class I Class II Class III
  
62 
Table III-13 below shows the increase in utility associated with successful TKA relative 
to OA required for TKA to not be dominated by no TKA along with the increase required to be 
cost-effective at the two most common thresholds used in the US setting.  As seen on the graphs, 
Class III patients require a much larger benefit to reach a cost-effectiveness threshold that is 
considered appropriate in the US.  The baseline value is 0.136 which is just beyond the 
increment required to reach $50,000 per QALY.  The nonobese group on the other hand only 
requires a third of that value to be cost-effective at the same threshold.  This difference in 
required benefit highlights the differences between groups.  While the same net benefit is had 
from the surgery, the overall risk profile limits the overall impact surgery has on heavier groups.  
The best-case scenario needs to have greater impact for the heavier groups to get enough benefit 
from surgery to be worthwhile.   
Table III-13 Minimum Utility Benefit of TKA Required at Baseline 
Population Group 
Not Dominated 
Cost-effective at WTP 
$100,000  $50,000  
Overall 0.036 0.053 0.068 
Nonobese 0.030 0.035 0.040 
Class I 0.045 0.076 0.100 
Class II 0.051 0.090 0.120 
Class III 0.061 0.120 0.180 
 
Scenario Analysis 
OA and Postoperative Costs and QALYs 
This scenario extends the two analyses conducted to work jointly among all the 
parameters on the postoperative side including procedure costs in addition to the continuing care 
as well as combining the effects of costs and QALYs simultaneously.  Table III-14 presents these 
results. 
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First, biasing all costs against TKA by setting TKA costs to their highest values and 
simultaneously setting OA cost to its lowest, the nonobese population is cost-effective at the 
$100,000 level.  None of the obese classes would be considered cost-effective.  Next, the 
scenario was reversed to bias all costs in favor of TKA.  In this scenario, all subpopulations and 
the overall population show TKA as dominant.  The two-way analysis showed that, at the 
extreme favorability for just two of the costs, dominance was likely.  This extends that to Class 
III by incorporating all the costs faced on the operative side.   
Similarly, biasing all QALY measures against TKA, the results are as suggested by the 
threshold analysis in Table III-13.  In all obesity groups and overall, TKA is dominated.  The 
cost remains unchanged, but the QALYs show no improvement over the no TKA scenario.  In 
the reverse case, the large gains in health while costs are unchanged make the extra expense well 
worth the cost in all groups.    
Combining the costs and QALYs, when OA is favored all groups see TKA dominated.  
When TKA is favored, all groups see TKA dominant.   
The full picture of postoperative health and costs extends the earlier analyses by showing 
that the relative relationship between OA and postoperative experience are more important than 
the absolute values.   
Table III-14 CEA Results of OA and TKA Scenarios 
TKA Status 
 by Obesity  
Cost QALY ICER  NMB* 
TKA Status  
by Obesity  
Cost QALY ICER  NMB* 
TKA Favored OA Favored 
Relative to No TKA Relative to No TKA 
Overall         Overall         
Costs Only         Costs Only         
No TKA  $ 98,142  7.31     No TKA  $ 24,536  7.31     
TKA   $ 33,670  8.30 
 
Dominant  
 
$113,878  TKA  
 
$128,112  8.30 $  104,822  $  (54,171) 
QALY Only         QALY Only         
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No TKA  $ 49,071  4.81     No TKA  $ 49,071  9.82     
TKA   $ 65,151  7.52  $   5,940  
 
$119,261  TKA   $ 65,151  9.66 
 
Dominated  $  (23,868) 
Cost & QALY         Cost & QALY         
No TKA  $ 98,142  4.81     No TKA  $ 24,536  9.82     
TKA   $ 33,670  7.52 
 
Dominant  
 
$199,812  TKA  
 
$128,112  9.66 
 
Dominated  
 
$(111,365) 
Nonobese         Nonobese         
Costs Only         Costs Only         
No TKA  $ 98,510  7.37     No TKA  $ 24,628  7.37     
TKA   $ 27,953  8.44 
 
Dominant  
 
$124,441  TKA  
 
$107,805  8.44 $    77,182  $  (29,293) 
QALY Only         QALY Only         
No TKA  $ 49,255  4.86     No TKA  $ 49,255  9.88     
TKA   $ 54,571  7.79  $   1,809  
 
$141,624  TKA   $ 54,571  9.76 
 
Dominated  $  (11,068) 
Cost & QALY         Cost & QALY         
No TKA  $ 98,510  4.86     No TKA  $ 24,628  9.88     
TKA   $ 27,953  7.79 
 
Dominant  
 
$217,496  TKA  
 
$107,805  9.76 
 
Dominated  $  (88,930) 
Class I Obese          Class I Obese          
Costs Only         Costs Only         
No TKA  $ 97,909  7.28     No TKA  $ 24,477  7.28     
TKA   $ 40,492  8.15 
 
Dominant  
 
$101,197  TKA  
 
$154,904  8.15 $  148,957  $  (86,647) 
QALY Only         QALY Only         
No TKA  $ 48,954  4.78     No TKA  $ 48,954  9.77     
TKA   $ 78,629  7.15  $ 12,538   $ 88,668  TKA   $ 78,629  9.57 
 
Dominated  $  (39,628) 
Cost & QALY         Cost & QALY         
No TKA  $ 97,909  4.78     No TKA  $ 24,477  9.77     
TKA   $ 40,492  7.15 
 
Dominant  
 
$175,759  TKA  
 
$154,904  9.57 
 
Dominated  
 
$(140,380) 
Class II Obese         Class II Obese         
Costs Only         Costs Only         
No TKA  $ 98,098  7.25     No TKA  $ 24,525  7.25     
TKA   $ 45,346  8.05 
 
Dominant   $ 93,181  TKA  
 
$168,957  8.05 $  178,628  
 
$(104,004) 
QALY Only         QALY Only         
No TKA  $ 49,049  4.75     No TKA  $ 49,049  9.75     
TKA   $ 86,550  7.01  $ 16,587   $ 75,539  TKA   $ 86,550  9.50 
 
Dominated  $  (49,786) 
Cost & QALY         Cost & QALY         
No TKA  $ 98,098  4.75     No TKA  $ 24,525  9.75     
TKA   $ 45,346  7.01 
 
Dominant  
 
$165,792  TKA  
 
$168,957  9.50 
 
Dominated  
 
$(156,718) 
Class III Obese         Class III Obese         
Costs Only         Costs Only         
No TKA  $ 95,119  6.98     No TKA  $ 23,780  6.98     
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TKA   $ 54,680  7.65 
 
Dominant   $ 74,009  TKA  
 
$195,805  7.65 $  256,221  
 
$(138,456) 
QALY Only         QALY Only         
No TKA  $ 47,559  4.56     No TKA  $ 47,559  9.41     
TKA  
 
$101,722  6.57  $ 26,976   $ 46,227  TKA  
 
$101,722  9.10 
 
Dominated  $  (69,749) 
Cost & QALY         Cost & QALY         
No TKA  $ 95,119  4.56     No TKA  $ 23,780  9.41     
TKA   $ 54,680  6.57 
 
Dominant  
 
$140,828  TKA  
 
$195,805  9.10 
 
Dominated  
 
$(187,613) 
*Net Monetary Benefit where QALYs are valued at $50,000 
 
All Complications 
Complication rates are frequently discussed in the literature as a reason to withhold 
surgery in obese patients or at least something to consider when deciding whether surgical 
intervention is appropriate.  Complications were considered in three ways: base rates, relative 
risks, and rates and risk together (Table III-15).   
When only the base rates of complications were considered at their lowest value, TKA 
becomes dominant in the nonobese population.  Even Class III becomes very cost-effective with 
an ICER under $25,000/QALY.  At the opposite extreme, the overall population is still cost-
effective but not at $50,000 and neither is Class I obesity.  Class II and III obesity are not cost-
effective even at the higher $100,000 threshold with Class III showing an untenable $1.5 
Million/QALY.   
The real debate though may not be what the base rate is, but the impact of obesity on the 
complication rate.  To that end, relative risks for each obesity group for each complication were 
also considered at high and low values.  When all are set to low values, the results are similar to 
low base rates.  All population groups are cost-effective at $50,000.  The overall value is not 
cost-effective at even the $100,000 level when all relative risks are set to high.  Class II and III 
obesity are very much not cost-effective with Class III almost a million dollars per QALY.  Class 
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I is actually dominated.  This is not surprising because for Class I obesity, the upper bound for 
the relative risk is set to 22.  The much wider range on this relative risk is a result of limited 
literature that deals with deep infection rates. 
Combining these scenarios, when the base rate and the relative risks are both low, for 
overall population we see cost savings and even Class III is very cost-effective.  At the opposite 
end of the range, TKA is dominated in all obese groups and overall.  TKA remains highly cost-
effective in the nonobese population.   
Table III-15 CEA Results of Complication Rates Scenarios 
TKA Status  
by Obesity  
Cost QALY ICER  NMB* 
TKA Status  
by Obesity  
Cost QALY ICER  NMB* 
Complication Low Complication High 
Relative to No TKA Relative to No TKA 
Overall         Overall         
Base Rates Only         Base Rates Only         
No TKA 
 
$49,071  7.31     No TKA $ 49,071  7.31     
TKA  
 
$55,257  8.39 $    5,738  
 
$47,720  TKA  $ 91,735  8.10 $     54,109  $ (3,240) 
Relative Risks Only         Relative Risks Only         
No TKA 
 
$49,071  7.31     No TKA $ 49,071  7.31     
TKA  
 
$60,774  8.34 $ 11,394  
 
$39,654  TKA  
 
$112,854  7.94 $   101,460  $ (32,350) 
Base & Risks         Base & Risks         
No TKA 
 
$49,071  7.31     No TKA $ 49,071  7.31     
TKA  
 
$55,257  8.39 $    5,738  
 
$47,720  TKA  
 
$248,935  7.13 
 
Dominated  
 
$(209,160) 
Nonobese         Nonobese         
Base Rates Only         Base Rates Only         
No TKA 
 
$49,255  7.37     No TKA $ 49,255  7.37     
TKA  
 
$48,036  8.51 
 
Dominant  
 
$58,202  TKA  $ 71,339  8.31 $     23,529   $   24,845  
Relative Risks Only         Relative Risks Only         
No TKA 
 
$49,255  7.37     No TKA $ 49,255  7.37     
TKA  
 
$54,571  8.44 $    4,932  
 
$48,568  TKA  $ 54,571  8.44  $      4,932   $   48,568  
Base & Risks         Base & Risks         
No TKA 
 
$49,255  7.37     No TKA $ 49,255  7.37     
TKA  
 
$48,036  8.51 
 
Dominant  
 
$58,202  TKA  $ 71,339  8.31 $     23,529   $   24,845  
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Class I Obese          Class I Obese          
Base Rates Only         Base Rates Only         
No TKA 
 
$48,954  7.28     No TKA $ 48,954  7.28     
TKA  
 
$68,311  8.25 $ 19,992  
 
$29,055  TKA  
 
$107,673  7.95 $     87,896  $ (25,316) 
Relative Risks Only         Relative Risks Only         
No TKA 
 
$48,954  7.28     No TKA $ 48,954  7.28     
TKA  
 
$69,163  8.24 $ 20,992  
 
$27,926  TKA  
 
$275,015  6.69 
 
Dominated  
 
$(255,447) 
Base & Risks         Base & Risks         
No TKA 
 
$48,954  7.28     No TKA $ 48,954  7.28     
TKA  
 
$68,311  8.25 $ 19,992  
 
$29,055  TKA  
 
$685,859  4.08 
 
Dominated  
 
$(796,567) 
Class II Obese         Class II Obese         
Base Rates Only         Base Rates Only         
No TKA 
 
$49,049  7.25     No TKA $ 49,049  7.25     
TKA  
 
$68,412  8.22 $ 19,956  
 
$29,151  TKA  
 
$135,977  7.70 $   191,648  $ (64,249) 
Relative Risks Only         Relative Risks Only         
No TKA 
 
$49,049  7.25     No TKA $ 49,049  7.25     
TKA  
 
$73,303  8.18 $ 26,106  
 
$22,199  TKA  
 
$143,622  7.58 $   281,498  $ (77,775) 
Base & Risks         Base & Risks         
No TKA 
 
$49,049  7.25     No TKA $ 49,049  7.25     
TKA  
 
$68,412  8.22 $ 19,956  
 
$29,151  TKA  
 
$325,494  6.33 
 
Dominated  
 
$(322,366) 
Class III Obese         Class III Obese         
Base Rates Only         Base Rates Only         
No TKA 
 
$47,559  6.98     No TKA $ 47,559  6.98     
TKA  
 
$70,474  7.92 $ 24,425  
 
$23,994  TKA  
 
$188,803  7.08 
 
$1,450,938  
 
$(136,377) 
Relative Risks Only         Relative Risks Only         
No TKA 
 
$47,559  6.98     No TKA $ 47,559  6.98     
TKA  
 
$80,746  7.83 $ 39,195  $ 9,149  TKA  
 
$170,837  7.14 $   761,469  
 
$(115,183) 
Base & Risks         Base & Risks         
No TKA 
 
$47,559  6.98     No TKA $ 47,559  6.98     
TKA  
 
$70,474  7.92 $ 24,425  
 
$23,994  TKA  
 
$626,850  5.51 
 
Dominated  
 
$(653,056) 
*Net Monetary Benefit where QALYs are valued at $50,000 
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Deep Infection 
In the one-way analysis, the only complication to appear in the most important 
parameters list for any of the subpopulations is deep infection.  A scenario similar to the 
complications was done to isolate the effect of this single complication as a result (Table III-16).   
When the deep infection rate is low, TKA is cost-saving in the nonobese population.  All 
three obesity classes now have ICERs well under the $50,000 threshold.  If instead deep 
infection is set at its highest rate, the nonobese cease to be cost-saving, but do remain cost-
effective with an ICER under $50,000.  Class I obesity is acceptable at $100,000 level, but BMI 
greater than 35 is no longer cost-effective.  Class III sees an ICER over a million dollars.   
Looking instead at the relative risks of deep infection, overall and each of the obesity 
groups are cost-effective even at $50,000.  Conversely, when relative risks are high, the overall 
figure is not even cost-effective at $100,000.  Class II and III are not cost-effective at any 
reasonable level.  Class I, as with all complications, is dominated driven by the high value tested 
for deep infection in this group.   
When both the base rate and the relative risks are considered simultaneously, low values 
show the same pattern to base rate alone being low because this is equivalent to no complications 
occurring.  When both are set to high, all three obesity classes and the overall population show 
TKA as dominated.  
Table III-16 CEA Results of Deep Infection Rates Scenarios 
TKA Status 
by Obesity  
Cost QALY ICER  NMB* 
TKA Status  
by Obesity  
Cost QALY ICER  NMB* 
Deep Infection Low Deep Infection High 
Relative to No TKA Relative to No TKA 
Overall         Overall         
Base Rates Only         Base Rates Only         
No TKA 
 
$49,071  7.31     No TKA $ 49,071  7.31     
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TKA  
 
$55,630  8.39 $    6,085  
 
$47,334  TKA  $ 85,967  8.11       46,549   $     2,735  
Relative Risks Only         Relative Risks Only         
No TKA 
 
$49,071  7.31     No TKA $ 49,071  7.31     
TKA  
 
$60,868  8.34 $ 11,486  
 
$39,557  TKA  
 
$112,361  7.94 $   100,614  $ (31,838) 
Base & Risks         Base & Risks         
No TKA 
 
$49,071  7.31     No TKA $ 49,071  7.31     
TKA  
 
$55,630  8.39 $    6,085  
 
$47,334  TKA  
 
$213,093  7.15 
 
Dominated  
 
$(172,065) 
Nonobese         Nonobese         
Base Rates Only         Base Rates Only         
No TKA 
 
$49,255  7.37     No TKA $ 49,255  7.37     
TKA  
 
$48,283  8.51 
 
Dominant  
 
$57,946  TKA  $ 68,562  8.31 $     20,527   $   27,722  
Relative Risks Only         Relative Risks Only         
No TKA 
 
$49,255  7.37     No TKA $ 49,255  7.37     
TKA  
 
$54,571  8.44 $    4,932  
 
$48,568  TKA  $ 54,571  8.44  $      4,932   $   48,568  
Base & Risks         Base & Risks         
No TKA 
 
$49,255  7.37     No TKA $ 49,255  7.37     
TKA  
 
$48,283  8.51 
 
Dominant  
 
$57,946  TKA  $ 68,562  8.31 $     20,527   $   27,722  
Class I Obese          Class I Obese          
Base Rates Only         Base Rates Only         
No TKA 
 
$48,954  7.28     No TKA $ 48,954  7.28     
TKA  
 
$68,841  8.24 $ 20,547  
 
$28,506  TKA  
 
$100,100  7.95 $     75,895  $ (17,451) 
Relative Risks Only         Relative Risks Only         
No TKA 
 
$48,954  7.28     No TKA $ 48,954  7.28     
TKA  
 
$69,401  8.24 $ 21,244  
 
$27,677  TKA  
 
$273,639  6.69 
 
Dominated  
 
$(254,012) 
Base & Risks         Base & Risks         
No TKA 
 
$48,954  7.28     No TKA $ 48,954  7.28     
TKA  
 
$68,841  8.24 $ 20,547  
 
$28,506  TKA  
 
$616,549  4.14 
 
Dominated  
 
$(724,653) 
Class II Obese         Class II Obese         
Base Rates Only         Base Rates Only         
No TKA 
 
$49,049  7.25     No TKA $ 49,049  7.25     
TKA  
 
$69,041  8.22 $ 20,614  
 
$28,500  TKA  
 
$124,412  7.71     163,263  $ (52,283) 
Relative Risks Only         Relative Risks Only         
No TKA 
 
$49,049  7.25     No TKA $ 49,049  7.25     
TKA  
 
$73,379  8.17 $ 26,189  
 
$22,121  TKA  
 
$143,482  7.58     280,981  $ (77,629) 
Base & Risks         Base & Risks         
No TKA 
 
$49,049  7.25     No TKA $ 49,049  7.25     
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TKA  
 
$69,041  8.22 $ 20,614  
 
$28,500  TKA  
 
$290,112  6.35 
 
Dominated  
 
$(285,777) 
Class III Obese         Class III Obese         
Base Rates Only         Base Rates Only         
No TKA 
 
$47,559  6.98     No TKA $ 47,559  6.98     
TKA  
 
$71,278  7.92 $ 25,296  
 
$23,163  TKA  
 
$166,146  7.09 
 
$1,053,501  
 
$(112,959) 
Relative Risks Only         Relative Risks Only         
No TKA 
 
$47,559  6.98     No TKA $ 47,559  6.98     
TKA  
 
$81,390  7.83 $ 39,975   $ 8,484  TKA  
 
$167,449  7.15 $   730,309  
 
$(111,681) 
Base & Risks         Base & Risks         
No TKA 
 
$47,559  6.98     No TKA $ 47,559  6.98     
TKA  
 
$71,278  7.92 $ 25,296  
 
$23,163  TKA  
 
$351,718  5.69 
 
Dominated  
 
$(368,859) 
*Net Monetary Benefit where QALYs are valued at $50,000 
 
Failure Rates 
Failure rates are likely to be correlated across time so were tested as sets to capture this 
(Table III-17).  In the one-way analysis, the later failure rates sometimes appeared as a top 
parameter of interest in some of the obesity classes and deserve further investigation.  Three 
scenarios were considered at both high and low values.  These values are derived from the 
bounds of 95% confidence intervals around the base to cover the full spectrum of likely values.  
The first is the failure rate for each year in both primary and revision procedures.  Second, only 
failure rates of the primary surgery were considered.   Third, only failure rates for revision were 
considered with revision done normally and subsequent to a deep infection considered at once.   
When all failure rates were set to lowest value, TKA is dominant in all obesity 
subpopulations and overall except Class III.  Conversely, when all failure rates were set to 
highest value, TKA is dominated in all groups.   
More interesting is when just TKA failure rates are considered.  Because there is little 
opportunity for revision when the primary rarely fails, results are quite comparable to the results 
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when all failure rates are changed.  When failure rates are low, only Class III obesity fails to be 
cost-saving and even that is highly cost-effective.  When TKA failure rates are all set to high 
values, TKA is no longer cost-effective for any group at $50,000 and only nonobese has an ICER 
less than $100,000.  This reflects the importance placed on the initial failure rate of TKA shown 
in all groups in the one-way analysis.   
Looking just at revision, the results for low failure rates are quite favorable for TKA.  
The nonobese group is cost-saving and the three obesity classes are all cost-effective at $50,000.  
When the revision failure rate is high, TKA in obese groups instead are dominated because the 
health toll of multiple surgeries and increased exposure to complications plus the added costs of 
those repeated surgeries drops the QALY below the no TKA values while increasing costs.  The 
nonobese population sees an ICER of over $100,000/QALY and overall ICER is over 
$200,000/QALY.   
Table III-17 CEA Results of Implant Failure Rates Scenarios 
TKA Status 
 by Obesity  
Cost QALY ICER  NMB* 
TKA Status  
by Obesity  
Cost QALY ICER  NMB* 
Failure Rates Low  Failure Rates High 
Relative to No TKA Relative to No TKA 
Overall         Overall         
Primary and Revision         Primary and Revision         
No TKA 
 
$49,071  7.31     No TKA $  49,071  7.31     
TKA  
 
$34,505  8.54 
 
Dominant  
 
$76,039  TKA  
 
$376,883  5.47 
 
Dominated  
 
$(420,242) 
Primary Only         Primary Only         
No TKA 
 
$49,071  7.31     No TKA $  49,071  7.31     
TKA  
 
$38,383  8.52 
 
Dominant  
 
$71,111  TKA  
 
$117,630  7.83 $   134,119  $  (43,000) 
Revision Only         Revision Only         
No TKA 
 
$49,071  7.31     No TKA $  49,071  7.31     
TKA  
 
$53,880  8.38 $    4,492  
 
$48,718  TKA  
 
$137,059  7.64 $   270,490  $  (71,723) 
Nonobese         Nonobese         
Primary and Revision         Primary and Revision         
No TKA 
 
$49,255  7.37     No TKA $  49,255  7.37     
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TKA  
 
$31,447  8.63 
 
Dominant  
 
$80,875  TKA  
 
$346,702  5.75 
 
Dominated  
 
$(378,519) 
Primary Only         Primary Only         
No TKA 
 
$49,255  7.37     No TKA $  49,255  7.37     
TKA  
 
$33,829  8.62 
 
Dominant  
 
$77,932  TKA  
 
$103,249  8.00 $     85,857  $  (22,550) 
Revision Only         Revision Only         
No TKA 
 
$49,255  7.37     No TKA $  49,255  7.37     
TKA  
 
$47,288  8.50 
 
Dominant  
 
$58,497  TKA  
 
$110,353  7.92 $   110,845  $  (33,538) 
Class I Obese          Class I Obese          
Primary and Revision         Primary and Revision         
No TKA 
 
$48,954  7.28     No TKA $  48,954  7.28     
TKA  
 
$37,091  8.49 
 
Dominant  
 
$72,263  TKA  
 
$424,482  5.04 
 
Dominated  
 
$(487,268) 
Primary Only         Primary Only         
No TKA 
 
$48,954  7.28     No TKA $  48,954  7.28     
TKA  
 
$42,075  8.45 
 
Dominant  
 
$65,718  TKA  
 
$134,887  7.65 $   231,847  $  (67,401) 
Revision Only         Revision Only         
No TKA 
 
$48,954  7.28     No TKA $  48,954  7.28     
TKA  
 
$62,264  8.28 $  13,279  
 
$36,805  TKA  
 
$180,996  7.22 
 
Dominated  
 
$(134,997) 
Class II Obese         Class II Obese         
Primary and Revision         Primary and Revision         
No TKA 
 
$49,049  7.25     No TKA $  49,049  7.25     
TKA  
 
$40,714  8.41 
 
Dominant  
 
$66,727  TKA  
 
$434,644  4.94 
 
Dominated  
 
$(500,924) 
Primary Only         Primary Only         
No TKA 
 
$49,049  7.25     No TKA $  49,049  7.25     
TKA  
 
$48,023  8.37 
 
Dominant  
 
$57,294  TKA  
 
$146,617  7.51 $   362,847  $  (84,123) 
Revision Only         Revision Only         
No TKA 
 
$49,049  7.25     No TKA $  49,049  7.25     
TKA  
 
$66,867  8.20 $  18,713  
 
$29,791  TKA  
 
$188,859  7.13 
 
Dominated  
 
$(145,647) 
Class III Obese         Class III Obese         
Primary and Revision         Primary and Revision         
No TKA 
 
$47,559  6.98     No TKA $  47,559  6.98     
TKA  
 
$49,063  8.04 $    1,424  
 
$51,296  TKA  
 
$457,829  4.64 
 
Dominated  
 
$(527,166) 
Primary Only         Primary Only         
No TKA 
 
$47,559  6.98     No TKA $  47,559  6.98     
TKA  
 
$59,993  7.98 $  12,472  
 
$37,409  TKA  
 
$170,761  7.06 
 
$1,512,011  
 
$(119,127) 
Revision Only         Revision Only         
No TKA 
 
$47,559  6.98     No TKA $  47,559  6.98     
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TKA  
 
$77,221  7.82 $  35,598  
 
$12,000  TKA  
 
$202,081  6.80 
 
Dominated  
 
$(163,514) 
*Net Monetary Benefit where QALYs are valued at $50,000 
 
 A best- and worst-case scenario analysis was also conducted.  Unsurprisingly, the best 
case shows TKA dominant in all groups and the worst case shows it dominated in all groups.   
Threshold Analysis for Failure Rates 
The failure rates scenario analysis suggested that failure rates deserve more attention.  
The scenario treated each year alike, but this analysis maintains the differences between rates by 
the number of years postoperative.  The assumption that the rates are correlated is also 
maintained.  For this analysis, the failure rates for primary and revision surgeries are multiplied 
by a factor ranging from 0 for no failure to 2 for a 100% increase in the failure rates.   
Figure III-9 shows the ICERs relative to the multipliers across a reasonable range of 
WTP.  The impact of failure rates as well as the difference between obesity groups is clear.  
Class III obesity is never cost-saving even when failure rates are zero.  The nonobese group is 
cost-saving until nearly 80% of baseline rate.  TKA for individuals in Class I and II obesity 
remain dominant until approximately 25% and 15% respectively.  At the opposite end of the 
range, even when failure rates double, the nonobese population is still cost-effective.  Class III 
obesity cannot tolerate even a 15% increase in failure rates if it is to remain cost-effective.  Class 
I and II can both see more than 50% increase and remain cost-effective at $100,000/QALY.   
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Figure III-9 ICERs by Obesity Class for Failure Rate Multipliers 
 
The margin of error in parameters for Class III obesity is once again much finer than 
other groups.  Nonobese is again more robust to changes in parameter valuation.   
Probabilistic Sensitivity Analysis 
A probabilistic sensitivity analysis was conducted using Monte Carlo simulation to 
explore the impact of uncertainty in multiple parameters simultaneously.  The model was run 
using the probability distributions described above for 10,000 iterations.  Then cost-effectiveness 
acceptability curves were constructed (Figure III-10).  The acceptability curve displays the 
percent of simulation iterations that would be preferred at various levels of WTP for a QALY.  
The x-axis is these WTP values.  There are two things to note about the model design.  The 
overall population figure is an average of the four obesity groups not a distinct model setting.  
Second, each iteration makes a single draw from each parameter distribution so that each obesity 
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group faces the same value for that iteration excepting the relative risks that are unique to each 
subgroup.   
Figure III-10 Acceptability Curves by Obesity Class  
 
Looking at just the overall population, about 25% of the time TKA is dominated and 40% 
of the time it is dominant.  Using a WTP of $50,000, TKA is preferred about two thirds of the 
time.  Increasing the WTP to $100,000, about 72% of the time TKA is preferred.   
Looking at the specific obesity groups similar results are found across all groups as 
detailed in Table III-18.  In each obesity class about 34% of the time TKA is dominated and 
TKA is dominant about 20%.  Using a WTP of $50,000 about 60% of the time TKA is preferred 
and this increases to 64% when the WTP rises to $100,000.   
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Table III-18 Key Values for Probabilistic Sensitivity Analysis  
     Willingness to Pay    
  Dominant $                       50,000  $         100,000  Dominated 
Overall 39% 68% 71% ~27% 
Nonobese 27% 65% 67% ~31% 
Class I 20% 60% 64% ~34% 
Class II 21% 61% 64% ~34% 
Class III 20% 60% 64% ~34% 
 
The parameter related to the utility gained following successful TKA alone accounts for 
much of the probability that TKA would be dominated.  This parameter has a wide distribution.  
The probability distribution for the incremental utility associated with postoperative success is 
frequently less than the threshold of being dominated (Table III-13).  If all other parameters were 
kept at their base values, Table III-19 shows the probability that TKA would be dominated solely 
due to the QALYs gained from TKA not being high enough.  Finally, the last column shows that 
the incremental utility parameter explains 60-80% of the iterations where TKA is dominated.  
The remaining dominated iterations are explainable by the other ways that the overall QALYs 
can be lowered e.g. increased failure rates driving more revisions and poorer outcomes, higher 
penalties for surgeries and complications, and higher likelihood of those complications.    
Table III-19 Probability of TKA Domination and QALY Increment of Successful TKA  
Population Dominated Predicted by Incremental Utility Gained by Successful TKA Share explained 
Overall ~27% 20.23% 76% 
Nonobese ~31% 18.85% 60% 
Class I ~34% 22.41% 66% 
Class II ~34% 23.94% 71% 
Class III ~34% 27.15% 80% 
 
The similarity across obesity classifications for the PSA seems to contradict the 
univariate results where many more parameters had much larger effects in higher obesity classes.  
However, the threshold analysis of the incremental utility gain over OA can explain this apparent 
  
77 
contradiction.  That single parameter has such a large influence that any impact of other 
parameters is often subsumed in the dominated simulations.  With that single parameter 
explaining about two-thirds of the dominated simulations, many of the sensitivity analyses 
showing high ICERS disappear into the dominated runs.  Because of this strong influence by the 
incremental utility from successful TKA, only 2% of iterations are both not dominated and above 
acceptable thresholds.  All variation seen in the univariate analysis on other parameters can only 
express differences in this small number of the iterations.  The extreme ICERs seen in the 
univariate analyses, especially in Class III obesity, disappear when combined with perturbations 
in the overall quality of life benefit of successful TKA.    
Also of note, the overall population is less likely to be dominated because it is a weighted 
average of the subpopulations rather than an independent analysis.  A common set of parameters 
is used for each obesity group so in order to be dominated, all four obesity groups must have 
been assigned unfavorable relative risks simultaneously.  In this average population result, the 
more favorable relative risks in some groups may compensate for even the most unfavorable 
relative risk and base rate combinations in another.    
Discussion 
The analyses show that the cost-effectiveness of TKA varies across the spectrum of BMI, 
with a range from very cost-effective in the nonobese population to Class III obesity requiring 
the higher US threshold of $100,000 to be considered cost-effective.  These results fit in the 
general thought that TKA is a very cost-effective procedure, but that obesity, especially higher 
levels of obesity, may undermine that.  Even at the worst, Class III obesity with an ICER of 
$80,671 is much more cost-effective than Vioxx was in the treatment of arthritis relative to other 
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NSAID and Vioxx was widely prescribed before its withdrawal from the market on safety 
grounds (Maetzel, Krahn, & Naglie, 2003).   
The question of whether TKA should be withheld in obese patients or in some subset of 
obese patients is of great interest and has been implemented for budgetary reasons in some 
places.  The results of this study indicate that obese patients do benefit from TKA even with 
lower functionality scores, but that the absolute benefit is low and drives TKA in a Class III 
obese population to be of marginal cost-effectiveness.  If restriction of TKA to obese patients is 
based on budgetary caution, perhaps there is a rationale for implementing such guidelines.  The 
model shows the higher BMI categories have extremely large consequences compared to less 
obese populations.  These could be costly errors.  It is also important to consider that the share of 
the population in these higher obesity classes is also increasing so the overall budgetary 
implications will only grow as the population shifts.   
Patient satisfaction surveys after TKA indicate 10-30% of patients are not satisfied with 
their outcomes (Bourne, Chesworth, Davis, Mahomed, & Charron, 2010).  The authors also 
examined specific factors that predicted dissatisfaction including complications, low 
improvement after surgery, and unmet expectations (Bourne, Chesworth, Davis, Mahomed, & 
Charron, 2010).  These are all factors that contribute to the occurrence of dominated results in 
the PSA.  The role of unmet patient expectations observed in the patient surveys and the 
important effect of the QALY increment for successful TKA on whether TKA is dominated hold 
an interesting parallel.  Managing patient expectations or discouraging surgery for those with 
unrealistic expectations may improve both patient satisfaction scores and improve resource 
allocation by limiting the patient population to those who will get the most benefit.  Patients who 
believe that a TKA will return them to perfect health with no limitations will never meet that 
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goal, regardless of how well the procedure goes.  When patients expect too much, satisfaction 
scores will be low.  The expectations can either be managed or patients who are not anticipated 
to see much improvement can be denied surgery as not worth the risk for the expected gains.  
The QALY increment’s importance works in a similar way.  When the QALY gain for a 
successful TKA is low, the surgery is not worth the risk and costs, no matter how many 
successful surgeries occur.   
Class III or morbid obesity is the most frequent target of guidelines withholding 
treatment based on increased complications or decreased benefit after the procedure.  While it is 
true that this population does have increased complications and decreased benefits, that alone is 
not enough to argue from a cost-effectiveness standpoint to issue such a guideline.  The 
interaction of those facts with the other influential aspects of the situation needs consideration.  
The overall number of QALYs gained may be smaller but there is still an incremental benefit 
that may offset the increased cost of the TKA procedure.  If cost-effectiveness is meant to be an 
impartial judgment, then by this standard even the patients with the highest BMIs are still cost-
effective at the $100,000 threshold.  The two-way sensitivity analysis further this argument 
showing that with just an average expectation of benefit, this group will be cost-effective at the 
even lower threshold of $50,000.  It does not take much to make this worthwhile.  The threshold 
analysis does indicate that the required improvement is larger than for nonobese patients, but that 
alone should not be disqualifying so long as that floor is expected to be exceeded.   
Complication rates may be what is behind the focus on Class III obesity.  This group does 
face increased, sometimes greatly, risk compared to nonobese groups, but not necessarily more 
than less obese groups.  The complication rates are shown to matter a great deal in the scenario 
analysis and deep infection especially as evidenced by the one-way analysis.  The results of the 
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meta-analysis indicate that the data on these specific complications by obesity class could be 
improved to tighten up the relative risks associated with obesity and improve the results of this 
study.  This is particularly true of deep infection and Class I obesity as shown by TKA being 
dominated when relative risk is set to high as discussed above.  The conclusions are tentative, but 
these are clearly important parameters that require more specific obesity focused research.     
Future Research 
Complication rates and the relative risk by obesity needs further exploration as discussed 
above.  These parameters proved important across the board in the univariate analysis and the 
scenario analyses further demonstrated that the extreme values could change the decision 
regarding TKA.   
Another group of parameters that also need further investigation are failure rates.  First, 
these failure rates are taken from implant survival analysis which are better described as revision 
rates rather than failure rates.  This measure does not account for patients who choose not to 
undergo a subsequent procedure or those who are not even offered such surgery.  The 
stratification by obesity classification is also not explored in the literature on failure rate to any 
great extent.  These two factors may also interact if heavier patients are less likely to be offered 
revision for instance.  The scenario and threshold analyses indicate that failure rates can alter the 
recommendation for or against TKA and so this is a key area to explore.   
Another major area for further study is the ethics of guidelines and withholding treatment 
from certain groups.  The difference in reaction from the two NHS bans illustrate the need for 
this exploration.  In the earlier decision, the procedure was not banned in patients but only to be 
used as a last resort.  In the later decision, the ban was absolute until a weight loss goal had been 
met.  The results of this study indicate that at any level there is still benefit to the procedure and 
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may be cost-effective at any weight.  There may be other related benefits to losing weight, but 
whether that should be tied to the ability to have surgery is debatable.  There is also the question 
of whether this decision is really a financial cover for moralizing against obesity.   
A final major area for further study is found in the next chapter which examines 
population level dynamics and budget impact of TKA in growing obese populations. 
Clinical Applications 
The evidence against TKA in obese patients as a group is scant, but in specific 
circumstances the procedure may not be the best decision.  The results of the sensitivity analysis 
suggest a few key values to consider when considering surgery for an obese patient.  First, the 
heavier a patient the more improvement relative to current health is needed to make surgical 
intervention worthwhile.  A nonobese patient who is clinically expected to improve enough to 
start walking unaided is likely to benefit from TKA.  That same expectation in a morbidly obese 
patient may not be sufficient to offset the costs and the increased risk of complications.  While 
nonobese and obese patients expect to see the same relative level of improvement to their quality 
of life, nonobese patients can still be cost-effective with much smaller improvements.  Heavier 
patients who for whatever reasons are expected to see a below average improvement are unlikely 
to be good surgical candidates.   
In terms of complications, any suspicion that deep infection is more likely than average is 
a major caution especially in the Class I obese population where the relative risk is least well 
defined.  Deep infections are a costly and time-consuming complication that can easily prevent 
TKA from being cost-effective.  When other risk factors for deep infection are present extra care 
should be taken before offering the TKA.   
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Failure rates are similar to deep infection.  Class III obese patients where failure rate is 
suspected to be higher than average should be offered nonsurgical alternatives.  Only a 15% 
increase in failure rate can be tolerated in this group before TKA no longer remains cost-
effective.   
No blanket ban is supported by this analysis, but certain patients will not be cost-
effective.  Focusing on likelihood to gain at least an average level of health improvement, no 
other risk factors for deep infections, and no increased risk for implant failure are good places to 
focus attention when evaluating an obese patient for TKA.   
Methodological Advances 
This is the first CEA done in TKA for obese populations.  It adds to the conversation that 
TKA is a good value for money, but also puts the increased complication rates for obese patients 
into perspective.  The conceptual model is also an advancement on the current literature.  The 
importance of deep infection complications is more fully incorporated by using the submodule to 
address the lifetime differences of patients experiencing this involved complication.    
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Total Knee Arthroplasty and Obesity: Predicting Trends From 2015 To 2035 and an 
Examination of Guidelines Restricting Access in Obese Populations with an Agent-Based 
Model 
 
Background 
There is broad agreement that  demand is growing for TKA procedures (Kurtz S. , Ong, 
Lau, Mowat, & Halpern, 2007), (Kurtz S. M., Ong, Lau, & Bozic, 2014).  Age and obesity seem 
to be important drivers of this increased demand (Fehring, Odum, Griffin, Mason, & McCoy, 
2007), (Wilson, Schneller, Montgomery, & Bozic, 2008), (Losina, Thornhill, Rome, Wright, & 
Katz, 2012), (Weinstein, et al., 2013), (Derman, Fabricant, & David, 2014), (Iorio, et al., 2008), 
(Odum, Springer, Dennos, & Fehring, 2013).   The aging of the population cannot be modified.  
This leaves obesity as a possible lever to control the costs of and demand for TKA.    
There are several ways that the future volume of TKA procedures and the budget and 
health impacts of that volume relate to obesity.  First, if the future volume of TKA depends at 
least in part on whether those obese patients are to be offered surgery, then total volume, budget 
and health impacts are directly impacted by obesity.  If surgical intervention for OA is restricted 
for these obese patients, the volume of TKA procedures will be lower in future than the current 
trend would suggest.  Second, the obesity in the population can be modified such as a public 
health campaign that broadly reduces obesity.  This could change the TKA volume predictions 
given that so many patients are obese even compared to the population.  Last, obesity is one 
factor that could change the decision making around surgical uptake.  For instance, surgical 
device development tracks could be reprioritized.  The focus could shift to making implants 
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more suited to obese patients’ particular needs because of increasing obesity in the population or 
instead to focus on implants that are more durable and long-lasting resulting in fewer revisions 
for implant failure in younger patients.  The trend model in this chapter will be exposed to each 
of these areas to explore the impact obesity has on TKA.   
Understanding future volume and the drivers underlying the trend is an essential element 
in policy making.  This demand has two important sets of consequences – budget impact and 
medical staff planning.  These areas both require projections of volume that incorporate potential 
future conditions to help policy makers plan in these important domains. 
The share of health care spending on TKA is already quite large and only predicted to 
grow.  Health care dollars are a finite resource that should be allocated in a way that provides 
value for the money spent.  Understanding the budget impact for obese patients access to TKA is 
important for future planning.  The existing financial calculations seem focused on the lower 
benefit to obese patients compared to the nonobese population.  Because obesity is a modifiable 
risk factor, unlike age, the thinking is that cost savings are had by reducing the risk factor before 
surgery is allowed to proceed.  This approach does not focus on the broader systemic question of 
whether withholding surgery has a positive budget impact given that the lack of surgical access 
does not mean the cost of treating the underlying disease and disability is zero.   
Another consideration is that as demand grows, orthopedic surgeons will be needed in 
larger numbers to absorb this demand.  Workforce planning is also a long-term project.  
Residents need to be trained now if demand continues to rise in order to accommodate all the 
future patients.  Understanding future demand can also suggest the risk factor modification to 
focus on with primary prevention such as obesity reduction programs. 
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A trend model was developed to address the planning issues and to explore the effects of 
various policy levers related to obesity, including implementing the restrictions on TKA for 
obese populations.  The trend model develops a synthetic population and is parameterized to fit 
the historical data on TKA volume and population characteristics.  The future volume is 
predicted under existing trends.  Then, guidelines restricting access to TKA for obese groups are 
implemented in the simulation.  Third, the pattern of obesity in the population’s effect on TKA is 
explored.  Lastly, the propensity of patients to undergo TKA is changed.  In all these 
environments, the impact to health care budget, volume predictions, and health outcomes are 
considered with an eye toward policy decisions.   
Methods 
Overview 
A trend model was constructed in AnyLogic using an ABM framework (The AnyLogic 
Company, 2018).  The model begins with a population of 250,000 agents representative of the 
United States population in 1995.  Agents are assigned age, gender, an obesity class, and OA 
status based on historic conditions.  The model runs for 40 years until 2035.  The basic model 
design, including the choice of health states, follows a similar model by Losina, et al. as closely 
as possible (Losina, et al., 2009) including the same modifications to Losina, et al. used in the 
compartmental model in Chapter III insofar as possible. The overall patient journey from no 
surgery to final outcome is unchanged in the conceptual model, but this model begins with 
healthy patients who progress first to OA then to possible surgery.   
An ABM was selected to easily incorporate heterogeneity into the population under 
study.  This framework uses a population of low-level agents, individual patients, and allows 
them to make individual choices that shape the top-level behavior observed (TKA uptake).  Each 
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agent follows a set of behavior independently that allows macrolevel outcomes to emerge.  This 
more closely aligns with how patients and providers generate discharges for TKA in the real 
world than other modeling paradigms.  Given the patient’s individual characteristics, disease 
progresses.  There is then a decision made, in consultation with their medical providers, about 
whether to pursue surgical intervention.  Again, based on their individual characteristics different 
outcomes are more or less likely.  The ABM also allows for interaction by the agents with their 
environment.  In this model, that will include the presence or absence of guidelines restricting 
agents to certain classes of obesity.   
This trend model will be used to address several different questions.  First, the trend 
model will be used to predict TKA discharges from 2015-2035 assuming current conditions 
persist.  Second, guidelines restricting access to primary TKA surgeries depending on obesity 
level will be considered.  This will directly address the proposed restrictions and consider the 
budgetary impact as well as applying cost-effectiveness measures to the results.  Third, another 
means to reduce the growing demand for TKA is to change the trajectory for obesity in the 
population as, according to a large registry, much of the increased volume in younger patients is 
not among healthy active patients but is instead obesity related (UMass Medical School 
Communications Staff, 2013).  The trend model will be applied to a world where obesity trends 
are modified to understand the effect of larger changes in the population at large on TKA 
discharges.  Last, TKA rates may change due to changes in medical science like a new 
nonsurgical intervention for OA of the knee or limited surgical capacity.  To that end, the uptake 
of the procedure will be modified in the trend model.   
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Model Structure 
The model consists of 9 basic health states as shown in Figure IV-1.  The population now 
includes a healthy state, a key difference from Figure III-1 and the 8 health states in the 
compartmental model of Chapter III.  From healthy, some patients develop OA.  The remaining 
transitions are the same as described in the Methods section of Chapter III.   
Figure IV-1 Simplified ABM Flow Chart  
  
As with the compartmental model, the time step of the model is one year.  The ABM is 
designed to use discrete time in this implementation to maintain similarity to the Markov process 
used in the compartmental model.   As before, the two acute surgical states take zero time, but a 
health impact is assessed for passing through this state.  In addition, patients who undergo 
surgery may also experience complications which add both cost and health penalties.  Deep 
infections are still treated differently from other complications, but they are not moved out of the 
population in the ABM as they were in the compartmental implementation.  OA patients may 
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choose to have surgery or not at each time step based on demographic characteristics.  Unlike the 
compartmental model, the four obesity groups – nonobese and Class I – III – run through the 
model together using class specific parameters.  The overall numbers are not weighted averages, 
but the overall population in the model.   
Population 
The model follows a cross-section of patients starting in 1995.  The model begins with 
agents matching the age and gender distribution according to Census estimates in that year and 
no birth occurs in the model (Day, 1996).  Race is not considered in this model as the racial 
component of OA in the knee, surgical uptake patterns, or outcomes is not well explored in the 
literature.  The overall population is a closed cohort, however, the portion of the population 
likely to use TKA is an open cohort as the younger ages in 1995 come of age.   
Obesity is not considered until agents reach the age of 20 to reflect that BMI is used 
differently in children (Centers for Disease Control and Prevention, 2018).  On model creation, 
for agents over the age of 20, 1995 obesity estimates were used to assign an obesity class for the 
model outset.  In subsequent years of the model, the changing obesity prevalence observed since 
1995 is reflected in the model’s obesity design.   The likelihood of an agent changing obesity 
classes in the model reflects the changes in obesity seen in National Health and Nutrition 
Examination Survey (NHANES) data (Flegal, Carroll, Ogden, & Johnson, 2002), (Wang & 
Beydoun, 2007), (Ogden, Carroll, & Curtin, Prevalence of Overweight and Obesity in the United 
States, 1999-2004, 2006), (Ogden, Carroll, McDowell, & Flegal, 2007), (Flegal, Carroll, Ogden, 
& Curtin, Prevalence and Trends in Obesity Among US Adults, 1999-2008, 2010), (Flegal, 
Carroll, Kit, & Ogden, 2012), (Ogden, Carroll, Kit, & Flegal, 2014), (Flegal, Kruszon-Moran, 
Carroll, Fryar, & Ogden, 2016).  Throughout the model, adults may change obesity class by 
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becoming more obese.   There is no decrease in obesity class for two reasons.  First, fluctuation 
is already accounted for in a reasonable range.  Depending on height, each of these BMI classes 
is approximately 30 pounds.  Second, even after TKA, most patients do not lose weight despite 
the theoretical ability to do so because of increased activity and mobility (Hospital for Special 
Surgery, 2014), (Schwartsmann, et al., 2017).  Both age and gender are considered in 
determining obesity status.   
OA is not considered until agents reach the age of 40 to reflect long term studies of OA 
population estimates (Murphy & Helmick, 2012).  Similar to obesity, those over the age of 40 
are assigned an OA status to match the prevalence in the population in 1995.  As with obesity, 
age and gender are considered in determining OA risk.  Obesity is an additional risk factor 
included in the model.  Throughout the model, healthy agents may acquire OA.   
Model Purpose 
The scenarios examine providing TKA to patients in different populations by obesity 
group.  The first purpose is to predict the volume of TKA until 2035 and the role that obese 
patients have in driving that.  The obesity groups considered are nonobese with BMI < 30, Class 
I with 30 ≤ BMI < 35, Class II with 35 ≤ BMI < 40, and Class III with BMI ≥ 40.  Many of the 
model parameters are dependent on obesity classification to this end.  Evaluation of the TKA 
strategy is surgery occurring as a staggered patient choice with a percent of patients with OA 
opting in each year based on their demographic characteristics.  OA itself is partially determined 
by obesity.  Death rates vary by age and gender as well as obesity classification.  Complication 
rates, surgical success (likelihood of full versus no benefit after surgery) and failure rates vary by 
obesity.  Costs of surgery as well as overall quality of life are also dependent on the obesity 
classification.   
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Next, several what-if scenarios are constructed to understand some possible ways to 
impact volume and burden of TKA.  First, guidelines restricting access to TKA in obese 
populations are considered.  Specifically, the budget implications and the effect on volume by 
excluding these populations are examined.  Second, the upward trend in TKA volume anticipated 
by most may be dampened or heightened depending on the trend in the obesity prevalence in the 
population and this will also be considered.  Third, the volume trend is considered in light of 
TKA uptake changes.  Uptake is a combination of supply and demand pressures in the broader 
environment.  Demand may be reduced based on new medical treatments for OA or economic 
considerations by the patient, but supply may also be impacted if the population desirous of 
surgery outstrips the providers available to operate on them.  For purposes of this model, both 
these changes can be treated as a change in the propensity for OA patients to receive a TKA.  As 
with the obesity trend, the uptake trend is considered at heightened and dampened level and the 
budget and volume impacts are of special interest.   
Outcomes 
The outcomes of interest focus on the number of procedures performed annually from 
2015 -2035 in the United States.  The role of obesity class is broken out for special analysis.  
This procedure volume is also translated into an overall budget impact to understand the 
financial implications of the uptake of TKA.   
Data 
Because the conceptual model is the same in the ABM and the compartmental model in 
Chapter III, the data needed to parameterize the models are nearly identical.  With few 
exceptions, the parameters used are identical between the two models.  Exceptions are noted 
below and details of the parameters are not repeated.   
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Transitions Between States 
There are three transitions that see different parameters in the ABM.  First, the ABM 
introduces a healthy state that does not exist in the compartmental model.  So, the first new 
parameter is disease development relating to the transition between the healthy and OA states.  
This is done following relative risks for age, gender, and obesity status from a large study on OA 
and a large systematic review for OA risk factors (Zhang, et al., 2011), (Silverwood, et al., 
2015).  In the compartmental model, the main analysis assumed everyone had a TKA the same 
year and relied on the value used in Losina, et al. for replicating the staggered surgery for 
validation.  The ABM though requires a probability that a patient with end stage OA will in fact 
undergo TKA in a given year to match historic data on volume, a key parameter in the ABM 
implementation.  For this now key transition a combination of historic data and calibration, 
which is further discussed below, is used.  The final changed transition is that to do with death.  
The ABM has heterogeneity in agents not present in the compartmental model.  Rather than 
CDC death rates by age, the ABM uses age and gender dependent mortality rates from US CDC 
life tables (Centers for Disease Control and Prevention, 2017).  The relative risks for obesity are 
the same but applied to a different base rate.  Otherwise, transition probabilities are unchanged, 
and details are found in Table III-1.     
Complications 
Complication rates see no changes in the ABM implementation from that of Table III-2.   
Implant Failure Rates 
Implant failure rates are also unchanged from the compartmental implementation and 
details are found in Tables III-3 and 4.   
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Costs  
The costs follow the same parameters as the compartmental model.  The minor change is 
to do with how deep infections are treated in the model.  There is no submodel where deep 
infections are removed from the population in the ABM.  The idea is the same, however.  The 
year after a deep infection, the cost of the second phase surgery is assessed.  Otherwise, refer to 
Chapter III for details.   
QALYs 
QALYs remain the same as those described in Chapter III and detailed in Table III-6.   
Obesity Adjustments 
Obesity Adjustments follow the methods described in Chapter III.   
Population Construction and Verification 
Construction 
The model uses a representative US population reflecting trends and demographics for age, 
gender, obesity classification and OA status.  This begins with the 1995 US Census estimate for 
age and gender makeup by converting population estimates into a joint probability for age and 
gender (Day, 1996).  A total population of 250,000 agents is constructed and simulated following 
this distribution.  Next, an obesity classification is assigned to all agents 20 years or older based 
on age and gender.  This follows the 1994 NHANES obesity data  (Flegal, Carroll, Ogden, & 
Johnson, 2002), (Wang & Beydoun, 2007), (Ogden, Carroll, & Curtin, Prevalence of Overweight 
and Obesity in the United States, 1999-2004, 2006), (Ogden, Carroll, McDowell, & Flegal, 
2007), (Flegal, Carroll, Ogden, & Curtin, Prevalence and Trends in Obesity Among US Adults, 
1999-2008, 2010), (Flegal, Carroll, Kit, & Ogden, 2012), (Ogden, Carroll, Kit, & Flegal, 2014), 
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(Flegal, Kruszon-Moran, Carroll, Fryar, & Ogden, 2016).  The beginning values for 1995 are in 
Table IV-1 below.   
Table IV-1 Obesity Prevalence in 1995 
Obesity Class Male Female 
20-39 40-59 60+ 20-39 40-59 60+ 
Nonobese - BMI < 30 82.020% 72.008% 73.914% 76.112% 67.255% 69.931% 
Class I Obesity - BMI 30-35 14.114% 15.077% 14.385% 6.731% 14.032% 24.127% 
Class II Obesity - BMI 35-40 0.375% 10.293% 11.314% 12.725% 12.743% 0.832% 
Class III Obesity - BMI >= 40 3.491% 2.622% 0.386% 4.432% 5.969% 5.110% 
 
In each subsequent year, agents may move into a heavier weight class.  NHANES data is 
available in every odd year from 1999-2013.  In some years, Class I and II are not available 
separately.  A transition probability was fitted for each of the six age/gender groups for 
advancing an obesity class annually.  These trend parameters were optimized using Excel to best 
fit the available data points from NHANES in this 14-year period.  The NHANES figures are 
reported in three age groups by gender.  For each of the six groups, all data points available were 
arranged by obesity class and year for a total of 19.  A simple simulation was designed to set the 
probability that a person in one group will move to the next highest obesity class for a set of 
three for each of the six groups.  Excel’s Solver add-in determined the three values that 
minimized the mean squared error between the NHANES data and the simulation results across 
all 19 data points.  This was done independently for each of the six groups.  The trend of annual 
transitions to higher BMI groups within each group is considered constant over the time under 
study (Table IV-2).  Childhood obesity statistics are less available and BMI is less useful in 
children, so the model considers all patients under 20 to be nonobese.  This, however, does not 
reflect the nature of obesity in the population.  To account for this, in the year an agent reaches 
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age 20 an initial prevalence boost is modeled by immediately assigning a portion to Class I 
Obesity.   
Table IV-2 Obesity Transitions 
Obesity Class 
Male Female 
20 20-39 40-59 60+ 20 20-39 40-59 60+ 
Nonobese - BMI < 30 8.770% 1.137% 1.005% 0.912% 16.877% 0.939% 0.831% 0.825% 
Class I Obesity - BMI 30-35   2.770% 0.011% 0.000%   0.000% 0.009% 3.415% 
Class II Obesity - BMI 35-40   2.181% 1.642% 2.637%   2.373% 2.354% 1.601% 
Number denotes the probability of exiting that class into the next higher classification as optimized by Solver 
 
 For OA, relative risks based on a large OA study and systematic review were used as the basis 
of a simple simulation.  The base category used was a nonobese 40-year-old male.  Because OA 
cannot exist prior to age 40 in the model, prevalence and incidence are the same for 40-year-olds.  
Murphy and Helmick report an incidence of 1 in 1,000 for symptomatic knee OA in 40-49-year-
old males  (Murphy & Helmick, 2012).  The base probability of having OA is then set at 0.001.  
The odds ratio from a logit model in the study was converted to 1.525 relative risk of being 
female and similarly obesity (BMI ≥ 30) has a relative risk of 2.13.  For each year of age over 
40, an additional probability of 0.056 is added to the base.  The initial prevalence in 1995 for 
those over age 40 and the relative risks are shown in Table IV-3.  These parameters are also the 
basis of assigning OA from healthy for the rest of the model.  OA prevalence may be increasing 
but we assume the risk factors underlying that change have not changed.  OA rises predictably as 
the population makeup relative to age, gender, and obesity status change following the same 
parameters.   
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Table IV-3 Osteoarthritis Parameters 
Name 
Value 
Prevalence Nonobese 40-year-old Male 0.001 
Additional Risk for year over age 40 0.056 
Relative Risk – Female  1.525 
Relative Risk – Obese - BMI > 30 2.130 
 
Verification 
The population demographics were verified against historic data to ensure that the 
population retains the appropriate mix for the United States population from 1995 up to 2015.  
Census estimates were used for verifying the age and gender makeup of the population as time 
progressed.  The 2010 Census and the 2015 estimate based on the 2010 Census were used for 
comparison data (U.S. Census Bureau, Population Division, 2016).  Because of the closed cohort 
design, certain age segments of the population cease to be present in the model over time.  In 
2010, this is 0-15-year-olds and in 2015 it is 0-20-year-olds.  To account for this, a joint 
probability of age and gender was calculated after eliminating the dropped age groups from the 
Census figures.  These joint probabilities were multiplied by the current number of living agents 
in the model at the same time points to generate the expected number of agents in each age 
gender group.  These expected values were then compared to the actual observed size of the 
population in those age gender groups.  The age distribution for each gender closely follows the 
age distribution in the Census (See Appendix C). 
Next, the obesity distribution in the population was compared against NHANES data and 
trends in obesity.  The last year available that included Class I and Class II obesity reported 
individually is 2011.  The 1995 starting obesity distribution is compared against the 1995 starting 
figures in the model, the 2003 NHANES data to get a middle point estimate and then 2011 as the 
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last point all three groups appear.  The obesity prevalence by group is also well matched (See 
Appendix C).   
Finally, the OA prevalence was verified.  OA prevalence is difficult to estimate with 
precision as symptomatic versus radiographic versus doctor diagnosed figures vary widely.  
Figures available also often include all joints not the knee specifically and sometimes even all 
types of arthritis not just osteoarthritis.  Verification for OA prevalence was done in two ways to 
accommodate this uncertainty.  First, an examination of the trends and relative risk of OA was 
considered.  The share of the population over age 40 suffering from OA is the metric in this 
verification.  The prevalence remains relatively stable over the course of the 40 years which fits 
the expectation that while risk factors for OA do not change the underlying population that has 
them does.  This should leave a relatively stable prevalence in the middle age and older portion 
of the population despite the population aging overall, but obesity is rising driving some upward 
trend.  Throughout, the prevalence of OA in female is approximately 1.5 times higher than men 
and obese is approximately twice the nonobese prevalence.  Both are close to the relative risks 
observed in the large population studies described above.  The second verification test is also 
based on the assumption of relative stability.  In 1995, the only year with an age standardized 
population available, prevalence is roughly 5%.  This is a match for the estimate found in the 
Framingham study for symptomatic OA of the knee (Zhang & Jordan, 2010).  Thus, with a stable 
trend and a starting point equivalent to Framingham that result from a relative risk model derived 
from a large-scale study of OA, the rates of OA in the model can be deemed suitably 
representative of the US population.  Further detail is available in Appendix C.  
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Model Output  
The AnyLogic model output undergoes extensive data processing.  The AnyLogic model 
is run on 10,000 agents 25 times for each scenario for a total population of 250,000 agents per 
scenario.  Each model run creates an Excel file containing the patient demographics, the surgical 
and complication events, and the patient state information each year.  This information is 
combined into a single scenario file with a structure appropriate for analysis using PivotTables in 
Excel by using the pandas library in Python.  Excel files were generated for each scenario.  
Those scenario files are then used as the basis for the final output which is organized by outcome 
of interest.  Extensive data validation was undertaken at each step in the process to ensure data 
fidelity.  Further details are provided in Appendix D.   
Cross Model Validation 
The model structure itself was validated in several ways.  First, the model structure is 
designed to follow Losina, et al.  The compartmental model also did this in Chapter III.  The 
structure of the ABM was tested directly by comparing output with the compartmental model 
using a population cohort of 10,000 74-year-olds with OA.  The ABM was run once for each of 
the four obesity groups, with and without TKA, for a period of 25 years and the undiscounted 
costs and QALYs streams were compared to the compartmental results over the same time.  
These are the same conditions used in the compartmental design.  In all 8 scenarios, the results 
were quite similar (See Appendix E).  The average over the 25 years in costs is within 5% and 
for QALYs within an average of 10%.  The model structure that defines agent behavior then is 
sound.   
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Calibration 
The final model design aspect is the probability that a patient with OA of the knee will 
choose to have TKA in a given year.  This probability is allowed to vary based on patient 
characteristics related to age and gender and incorporates the underlying trend towards more 
TKAs observed in the population.  This TKA uptake probability encompasses more than the 
simple choice of the patient to have surgery.  To have a TKA, a healthy person must first develop 
OA, the patient must then seek medical care for the OA which incorporates access to, 
affordability of, and availability of health care services.  Third, it includes the willingness of a 
surgeon to offer TKA as a viable medical procedure for that patient.  This includes any medical 
or social conditions that would make the patient a bad surgical risk as well as patient severity of 
OA.  Lastly, it includes the patient wanting to take a surgical intervention for whatever reasons 
of personal circumstances.  This uptake probability then encompasses both supply and demand 
constraints on whether an individual patient undergoes a TKA.   
TKA uptake is designed in the model as a baseline probability for uptake as well as trend 
parameters to capture the increasing demand for TKA in younger patients (45-64) as well as the 
portion of trend that is not attributable to age and obesity shifts in the population (Ravi, et al., 
2012).  Finally, to capture the differing preferences and suitability for surgery among age and 
gender groups multiplicative factors are applied to that trend line.  These factors use males age 
45-64 as the reference group.   The general equation for uptake is 𝐵𝑎𝑠𝑒𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 ∗
(1 + 𝑇𝑟𝑒𝑛𝑑)𝑌𝑒𝑎𝑟−1995 ∗ 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒𝑅𝑖𝑠𝑘𝑠, where the trend and relative risks applied dependent on 
the age and gender group.   
The calibration of these parameters was done against TKA discharges from the 
Healthcare Costs and Utilization Project (HCUP) database (Healthcare Utilization Project, 2018).  
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The data on discharges for the ICD-9 code for Total Knee Replacement (81.54) from the 
inpatient setting in the years 1997 – 2014 was available for use as the target values for the model.  
The revision code and its inclusion criteria changed in the middle of this period and was 
therefore ignored for calibration purposes.  Discharge data is not available for 2015.  Data is 
available in the following age groups: under 1, 1-17, 18-44, 45-64, 65-84, and older than 85.  
Data is also available for female, male, and overall number of discharges.  Because only a small 
number of less than 45-year-olds receive TKA at all and most are not due to OA these groups are 
ignored in this analysis.  For 2012-2014, data is also available jointly for the same age groups 
and gender.   
Population estimates for the US by age, gender and obesity were required annually for 
the calibration period.  The model starts with a population of 250,000 agents representative of 
the entire US population on age, gender, and obesity.  When available, CDC Wonder data was 
used for population statistics as that is what HCUP uses to estimate populations (Centers for 
Disease Control and Prevention, 2016).  This was supplemented, when necessary.  Census 
Bureau figures were chosen when available and alternatively from a website based on otherwise 
unavailable Census estimates (Centers for Disease Control and Prevention), (US Census 
Bureau), (Population Pyramid, n.d.).  When age groups of five years were used in the source, 
population was assumed to be evenly distributed across the individual ages.  Obesity assignment 
for the population was allocated according to the obesity distribution observed in the model 
population for the age and gender group for each year.  The total US population discharge 
estimates were constructed by scaling the model results up to the US population size.  The 
number of primary discharges is divided by the number of agents living to obtain the incidence 
probability and then this is multiplied by the size of the US population at that point for that 
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population subgroup.  Thus, if 100 primary surgeries occurred while 1,000 agents were living 
that year and the US population was 50,000, then those 100 primary surgeries in the model 
would equate to 5,000 procedures in the US population as a whole.   
The HCUP population estimates for the age brackets, genders, and totals for 2000-2014 
were used to allow for a burn in period.  In the model, there was no initial prevalence of 
individuals having had TKA, so a burn-in period of 5 years was used to allow the initial 
population to reach a steady level of rates of TKA procedures.  In addition, the rates of TKA for 
sub-populations defined by age and sex were used in the three years they are available.  This led 
to a total of 108 datapoints available for calibration (See Appendix F).  Standard errors are not 
provided by HCUP for the joint age and gender datapoints.   
Due to randomness in the stochastic model, logarithmic regression was used to smooth 
the trend line of predicted discharge levels for calibration purposes.  This also provided 95% 
confidence intervals around the predicted trend line.  The same approach was used to create 
confidence intervals for the joint age and gender HCUP estimates.  A logarithmic model was 
chosen as the best fit for the data points with adjusted R2 well above 0.9 and because it 
accommodates the increasing rate of discharge observed in the population.   
An iterative process was used to select the final parameter set.  Parameters were adjusted 
based on the previous iteration’s fit according to the calibration criteria selected.  The calibration 
made use of three different objectives to determine best fit using a holistic approach.  For all 
three objectives, the age and gender groups were considered together.  The 12 age, gender, 
age/gender groups and overall data reporting categories were given equal importance for 
goodness of fit measures.  The primary objective was to maximize the number of years within 
each category for which the confidence intervals from the simulation trend line and confidence 
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intervals from HCUP overlapped.  A secondary criterion was to maximize the number of data 
points where the trend line was inside the HCUP confidence intervals.  This narrower definition 
helped to tighten the calibration to the data without being overly constraining initially.  Finally, a 
visual inspection of the trend lines was employed as an objective to verify the two lines were 
generally similarly oriented.  The conventional approach would have been to minimize the mean 
squared errors (MSE) of the 12 age by gender groups or the sum of those 12 figures as a total 
MSE.  The MSEs were calculated across iterations within each group and as a sum of all 12 for a 
total MSE.  However, this approach was noisy and less informative for parameter selection than 
the objectives used.  The final parameter set selected does in fact have the lowest total MSE for 
over all the iterations examined.  By keeping the individual years as part of the decision making, 
the size and direction of adjustments between iterations were easier to discern.   Additionally, 
calibration parameters impact multiple groups at the same time adding interactions between the 
MSE figures that are not easy to parse when looking at the MSE for a whole data group rather 
than years.  Further details are available in Appendix F.      
Model Assumptions 
There are some important assumptions relating to parameter choice and model structure.  
While obesity is frequently discussed in the literature as a driving force behind the increased 
volume of TKAs and a possible negative outcome predictor, there is not a great deal of obesity-
specific information.  The relative risks of complications are built on a literature review of 
available data.  The calibration is done without regard to obesity in the HCUP data so estimates 
of diverted TKAs must bear that in mind.  TKA uptake only considers obesity in an oblique way 
in that surgical offers by physicians may be more limited to those groups, but this is not modeled 
directly.  Comorbidities that may influence that offer of surgery are also only considered in this 
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same parameter.  Any effect of comorbidities other than obesity are ignored in the complication 
or outcomes entirely.   
The model also simulates a general TKA procedure.   There is no consideration of 
approaches or implant types.  Any variability in physician expertise or hospital volume that may 
influence outcomes are also not considered.  Most importantly, once a patient has a TKA there is 
no difference in trajectory of the process outside of obesity-related complication rates and costs.  
Revisions are done at the same rate regardless of age.  These are all important considerations, but 
there is a lack of detailed data related to obesity to parameterize these factors, so these 
considerations were not included in the model design.   
Bilateral or second knee replacements are also not considered.  A patient could have 
exactly one primary surgery and revisions only on that knee.  Further, revisions are capped at 3 
in this model.  It is possible that more could be done in practice, but without some cap patients in 
the model showed up to 8 procedures in their lifetimes which seems highly unlikely in practice.     
As previously discussed, TKA uptake is a composite likelihood function of both patients 
and providers preferences that get packaged into a single likelihood.  This means that supply and 
demand cannot be parsed from this output.  There is also no crowd out or competition from other 
patients for surgical appointments with surgeons or for surgeons to get operative time in a 
crowded hospital.  Insofar as that effects surgical choices being presented to a patient, that is 
represented in surgical uptake for purposes of this model.  Willingness to operate on less healthy 
patients does not deny surgical resources to other patients in this model but may drive some part 
of decision making in practice.   
OA risk factors are assumed to be time invariant.  Prevalence may change in the 
population due to demographics, but the drivers are assumed unchanged.  Any injury or 
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occupational based risk factors are also considered out of scope leaving only age, gender, and 
obesity included here.  This is why socioeconomic factors and race are not part of the model.  It 
is also why only those over 45 are considered in calibration.  These are not well understood or 
documented in the literature for the role in TKA or OA development.   
A further assumption has to do with agent behavior respective to the larger environment.  
Regardless of the environment, patient motivations do not change.  It is possible that an obese 
patient facing an absolute choice of no surgery or losing weight will in fact lose weight to 
become eligible.  This is not currently observed to be the case, but the presence of a guideline 
may change that behavior.  As the magnitude of such a potential change is unknowable, this 
behavior is not modeled.    
Insurance status was not considered in the model design.  The main reason is that most 
patients are over 65 and thus Medicare eligible making insurance status a moot point.  A second 
reason is for simplicity and parameter availability.  The behavior of uninsured patients may well 
be different.  OA does partially depend on occupational hazards.  Those same manual labor type 
occupations that increase the risk of OA may systematically affect insurance status and 
willingness/ability to forgo work to seek surgical intervention.  The socioeconomic factors are 
complex and intertwined with insurance status, type of job, and obesity.  For this reason, 
insurance status was left out of the model.     
Results  
The results from the various scenarios are presented below.  The model is based on a 
stochastic process and some random variation is to be expected.  Unlike with the calibration 
procedure above no smoothing was performed on the following results.   
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Calibration 
The annual probability for any OA patient to undergo a TKA in any given year is 
calibrated as described above using 7 parameters to incorporate demographic and trend 
conditions as well as an underlying base probability.  Initial parameter values were selected 
based on relative risks calculated from the HCUP data and iteratively changed to find the best fit 
to the observed volume.  The final parameter set (Table IV-4) has 97% overlapping confidence 
intervals and 71% model means contained in HCUP confidence intervals.  A visual inspection 
reveals the trend lines appear to have a similar trajectory as the HCUP observed volume.  The 
OA to TKA rate parameter used in the CEA in Chapter III is 0.33 is large compared to the base 
value used here for TKA uptake of 0.03.  The origin of the 0.33 is from a Canadian survey on 
whether patients with disabling arthritis in the hip or knee were willing to consider surgical 
interventions in a survey format (Hawker, Wright, Badley, & Coyte, 2004). But the base 
probability only applies to 1995 and increases over time.  The probability of moving from OA to 
TKA is larger once the trend and relative risks are applied.  Further details are available in the 
Appendix F.     
Table IV-4 Calibrated TKA Uptake Parameters 
Name Value 
Base Uptake (P(TKA | OA) each year) 0.030 
Trend – Under 45 or 65 years and older 0.090 
Trend – 45-64 years old 0.115 
Relative Risk – Female 0.750 
Relative Risk – Under 45 0.090 
Relative Risk – 65-84 years old 1.100 
Relative Risk – 85 years and older 0.070 
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Trend Prediction 
The future demand for the twenty-year period from 2015 to 2035 was predicted along 
with the budget impact for the TKA procedure being offered in current patterns with no regard 
for obesity restrictions.  To do this, the model was run from 1995-2035 for 250,000 agents.  The 
output was converted in the same manner as with the calibration to make results applicable to the 
entire US population according to relative weight in the population.  The number of discharges 
and complications as well as costs and QALYs were recorded.  Costs were assessed in 2015 
USD.   
Considering all TKAs, primary and revisions, the number of procedures increases by 
about 80% from just under a million to nearly 2 million in the 20 years (Figure IV-2).  Just 
considering primary surgeries this is almost 50% growth from just under 750,000 to almost 1.1 
million procedures.  In part, this reflects the obesity in the population, but as seen by looking at 
the population divided into obesity classes all groups see a rising trend and obesity alone cannot 
explain this growth (Figure IV-3).  The heavier groups are increasing at a slower rate than the 
Class I obesity group and the nonobese.  One retrospective study on the role of obesity in TKA 
found that in 2005, the share of TKA patients who were obese was 52.1% (Fehring, Odum, 
Griffin, Mason, & McCoy, 2007).  In this model, the share of obese patients in the same year 
was slightly lower at 49.2%.  That study found a sharp rise from 30.4% in 1990 which is outside 
the scope of this model.   
  
106 
Figure IV-2 Total Surgeries Predicted by Year 
 
Figure IV-3 Total Surgeries Predicted by Year and Obesity Class 
 
These trend predictions are in line with the findings from other models.  A linear 
regression model predicted growth of similar magnitude and a 2030 estimate of 1.28 million 
primary TKA, a slightly higher figure than that predicted here (Sloan, Premkumar, & Sheth, 
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2018).  These are both much lower than another projection undertaken in 2007 which overshot 
2010 and 2015 estimates substantially and estimated 678% growth between 2005 and 2030 
(Kurtz S. , Ong, Lau, Mowat, & Halpern, 2007).  There was a large uptick in volume in the years 
just prior to that study that has since settled down which likely explains the discrepancy from the 
earlier estimate.   
These discharges translate to a substantial budget impact for the healthcare system.  Over 
the two decades under consideration, the estimated burden for the US population is nearly 2 
trillion dollars.  Of this, nearly $50 billion is spent on complications.  Of the $1.2 trillion spent 
on surgery, primary surgery accounted for almost $700 million or 48.6%, revision surgeries cost 
over $600 million or 45.8%, and deep infection related surgeries about $75 million for just 5.6% 
of the total.  Even with this number of discharges, the cost of treating the OA in the population is 
almost half a billion dollars.   
Obesity Restrictions 
The suggestion that TKA be withheld in obese patients is generally based on financial 
considerations when put in use as in the NHS.  In addition, there is evidence of higher 
complication rates and poorer outcomes.  There is however no clear answer to the budget impact 
of implementing such restrictions.  Obese patients still exist and still require medical treatment 
for OA.  To understand the budget impact of such guidelines, the model was run withholding 
treatment from obese patients in several severity groups.  First, only morbidly obese were denied 
surgical intervention.  Next, patients with a BMI greater than 35 (Class II and III) and finally, all 
obese patients (BMI ≥ 30, Class I -III) were barred from receiving a primary TKA.  Patients who 
received a primary either when in a lower weight class or before the restrictions were 
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implemented in 2015 were allowed to receive revision procedures under these hypothetical 
guidelines.   
There are several ways to consider the effectiveness of the guidelines.  The simplest is 
number of procedures averted from baseline.  This basic measure can help with planning demand 
for surgical time and workforce planning, but it cannot suggest whether it is the best financial 
choice.  Another is to consider the budget impact in isolation.  This number accounts for the fact 
that those denied surgery still must live with OA and thus incur lifelong costs for pain and 
treatment associated with that disease burden.  Again, this is not the full picture as even 
increased costs may be offset by quality of life concerns, so a cost-effectiveness approach is 
warranted as well.   
The number of averted cases is large.  Even including revisions, the total number of 
surgeries falls and nearly flattens in the most restrictive scenario (Figure IV-4).  It drops to zero 
when only considering primary surgeries (not shown).  Over the course of the two decades after 
2015, just restricting access to the morbidly obese averts 10% of primary surgeries, but an even 
greater share of deep infection revisions is averted (Table IV-5).  This is increased to 50% if all 
obese patients are barred from surgery.  Even though obese people are not half the population 
they make up a large share of the TKA surgical pool and many cases can be averted by 
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restricting access.  This is especially true in the expensive Deep Infection Revision category of 
surgery.   
Figure IV-4 Total Surgeries Predicted by Year and Guideline Scenario 
 
Table IV-5 Averted Surgeries (in Thousands) 
Scenario 
Total 
Surgery Primary Revision 
Deep 
Revision 
Baseline 32471 20212 11689 570 
Class III Primary Barred 29504 18136 10922 446 
Averted 2967 2077 767 123 
Percent Averted 9% 10% 7% 22% 
Class II and III Primary 
Barred 25942 15786 9797 359 
Averted 6529 4427 1892 210 
Percent Averted 20% 22% 16% 37% 
Obese Primary Barred 17696 10079 7371 246 
Averted 14775 10134 4318 323 
Percent Averted 46% 50% 37% 57% 
 
The budget impact can be considerable in scale at first glance, but the tradeoffs are stark 
(Table IV-6).  Only barring the heaviest patients saves 10% of surgical costs but saves only 4.2% 
in terms of total costs which include the costs of surgery, complications, and OA treatment as 
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well as the postoperative costs (which in successful cases are minimal).  This does include a 
large decrease in complication costs owing to the high rates of complication in this population, 
but costs of general OA treatment increase to offset most of these savings.  In the most extreme 
restriction, the cost savings overall near $400 million (a 16% savings).  This comes at the 
expense of nearly doubling the cost associated with OA but nearly halves the surgical and 
complication costs.  It is possible to drastically decrease the budget impact of TKA surgeries 
directly, but the indirect total cost consequences of treating OA limit the overall budget impact.   
Table IV-6 Averted Costs (in Billions) 
Scenario Total 
Costs 
Surgical 
Costs 
Complication 
Cost OA Cost 
Baseline $2223.501 $1234.004 $46.547 $461.292 
Class III Primary Barred $2129.865 $1115.633 $36.230 $542.931 
Cost Difference $93.636 $118.371 $10.316 -$81.639 
Percent Saved 4% 10% 22% -18% 
Class II and III Primary Barred $2049.454 $981.226 $29.943 $648.195 
Cost Difference $174.047 $252.778 $16.603 -$186.903 
Percent Saved 8% 20% 36% -41% 
Obese Primary Barred $1860.130 $684.793 $19.642 $856.662 
Cost Difference $363.372 $549.211 $26.904 -$395.371 
Percent Saved 16% 45% 58% -86% 
*Undiscounted 2015 USD 
 
One way to put these costs into perspective is to use a cost-effectiveness framework.  The 
costs are considered along with the health benefits of that policy.  Looking first at the health 
benefits, many agents spend much more time living with OA when restrictions are in place, as is 
to be expected when reducing access to surgical intervention.  Class III Barred, as compared to 
the Baseline with no restrictions, sees 18% more QALYs from OA, an undesirable health state.  
When surgical access is limited, the life years spent with debilitating arthritis rises.  In the most 
restrictive guideline where no obese patients are allowed primary TKA that number is 86%.  The 
health decrements faced from surgeries and complications do fall in these restrictive 
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environments.  In the scenario barring only the morbidly obese, surgical decrements decrease by 
9% and complication decrements by 24%.  The most restrictive scenario is more dramatic with 
46% and 60% respectively.  These health decrements, though, are fleeting, a onetime burden to, 
hopefully, live a fuller life without the limitations of OA.  These two competing pressures, longer 
time spent with a debilitating disease and less exposure to surgical risk and hassle, balance out to 
basically zero or model noise.  Surgical burden falls, but the long-term burden of unrelieved OA 
rises dramatically.  When considering the overall population, overall health may not change with 
reduced access to surgery for some groups, but the type of care and resource mix required does 
change.    
The ICER balances the cost difference against the health benefit difference.  Discounted 
figures are used to account for the time at which these costs and benefits occur.   While there is 
no clear standard in the United States, a figure under $50,000 per QALY gained is considered 
money well spent and even $100,000 may be worthwhile to pursue.  ICERs were computed for 
the analysis of these guideline proposals.   
For the overall population, the guidelines show a cost savings but a loss in health benefit 
across all three restrictions (Table IV-7).  The values differ from the values shown above due to 
discounting.  The surgical values are a one-time event, but the OA costs and QALYs are ongoing 
into the future so the benefits are valued less in this analysis.  This analysis can be thought of as 
a series of hypothetical restrictions being in place and then being lifted.  The current baseline is 
then an expansion of care to allow obese patients of various classes access to TKA once again.  
Under the standards of the United States, “lifting” these restrictions on TKA for obese groups of 
any severity are generally considered cost-effective.  For instance, if Class III primary TKA went 
from unavailable to available costs and QALYs would change at a rate of about $60,000/QALY.      
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Table IV-7 Guideline ICERs 
TKA Status by Obesity  Cost QALY ICER  
Relative to Baseline       
Overall       
Class III Primary Barred       
Baseline  $   1,645,345,069,196  
  
2,716,748,706    
Restricted  $   1,576,843,381,318  
  
2,715,592,594   $ 59,252  
Class II and III Primary Barred       
Baseline  $   1,645,345,069,196  
  
2,716,748,706    
Restricted  $   1,520,172,760,400  
  
2,714,012,307   $ 45,743  
Obese Primary Barred       
Baseline  $   1,645,345,069,196  
  
2,716,748,706    
Restricted  $   1,382,837,832,573  
  
2,712,601,442   $   3,296  
*Discounted at 3%  
 
In comparison to the compartmental model done in Chapter III, the figure for Class III 
Primary Barred is of most interest.  In that analysis TKA was compared to no TKA by obesity 
classification.  This is not exactly analogous in that this analysis allows for revisions for those 
who had surgery when not subject to the restriction, but it is a similar situation for Class III 
obese patients.  The mixed age cohort here also allows for much longer life expectancy than the 
74-year-olds examined in the compartmental model so costs and benefits can both accrue for 
longer periods.  The compartmental model found an ICER of $82,635 for Class III TKA versus 
no TKA.  In this analysis, a similar value of $59,252 was found in the overall population for 
barring Class III primary surgeries.  These are both above the most conservative threshold but 
well under the higher $100,000/QALY.  There is agreement that even in the most obese patients, 
TKA is cost-effective. 
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Obesity Trend 
There is much discussion in the literature about either limiting access for these groups or 
intervening to combat obesity before surgical options are offered.  It would then be expected that 
modifying the obesity rate in the population would alter the volume of TKAs observed and the 
costs associated with TKA.  This model considers obesity to be an increasing trend in the 
population to continue as it has since 1995.  The currently observed pattern may change in the 
future due to outside factors including successful public health interventions dampening the trend 
towards obesity and the possibility that the drivers of the obesity epidemic have not yet reached 
their peak influence.  Obesity is a major driver in healthcare costs generally and as such is a 
focus of many prevention programs.  To see what influence such programs may have on TKA 
usage specifically, the trend for obesity after 2015 is manipulated.  In the earlier prediction and 
guideline scenarios, the trend towards heavier population was considered to be growing at a 
stable rate.  A proportion of the population would increase their obesity level each year.  This 
analysis tests what effect a 50% decrease to a 50% increase in that rate has on the budget impact 
of TKA.  It does not change the existing prevalence, those who are already obese will not lower 
their BMI but will be less likely to advance into a heavier class.  This analysis gives insights into 
how obesity prevention strategies may affect outcomes for this specific procedure.   
Discharges for TKA do not show much change in this analysis (Figure IV-5).  The 
numbers also suggest that the noise in the stochastic process is driving the minimal difference 
more than any obesity trend modifications.   
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Figure IV-5 Total Surgeries Predicted by Year and Obesity Trend 
 
The budgetary impact is also minimal.  No practically significant difference is seen in the 
expected total costs at either extreme trend modification (Figure IV-6).  Reducing obesity by half 
does not make a difference in this key element suggests that the obesity trend is not a place to 
focus immediate energy to modify the costs and surgical burden related to TKA.   
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Figure IV-6 Costs in Billions by Obesity Trend 
 
As a whole, there is not much difference made in TKA even at extreme and unlikely 
changes in obesity patterns.  While this, at first, seems a surprising result given the known health 
burden of obesity and the increased complication rates in TKA, a consideration of the disease 
course makes it less so.  The medical history leading up to TKA is not an instant process.  After 
patients become obese or increase their obesity level (a slow process), patients must then develop 
OA and then sufficiently damage the knee joint before surgical intervention is pursued.  None of 
this happens instantaneously.  While obesity increases the risk of developing OA, age is also a 
major factor in developing OA.  This does not change existing obesity, OA (even that caused by 
obesity), or the aging of the population.  Because these rate changes are slow and long-term, we 
do not see a discernable impact over 20 years. 
Looking at the number of agents with OA across the same time period suggests that this 
is predictable (Figure IV-7).  Those living with OA, the candidate pool for TKA, is virtually 
unchanged by the obesity trend modifications.  The decline in number of agents with OA is due 
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to the closed cohort model design and not a decline in OA prevalence.  It takes time to develop 
OA and while the benefits of reducing obesity burden may bear fruit in the TKA domain in later 
years, the 20 years under study here are not enough to accrue any benefit from such reduction or 
conversely suffer if obesity burden rises dramatically.  While modifying the trend towards 
obesity may have immediate impacts on other disease processes where losing weight yields 
immediate health benefits, TKA and the long progression of OA does not work in the same way.  
Nor should it really be expected to do so.  Curbing the obesity epidemic will not be a magic 
wand to lower the TKA burden on the US health system in the near future.     
Figure IV-7 Agents Living with OA by Year and Obesity Trend 
 
Uptake of TKA Procedures 
TKA uptake is dependent on many things that may be subject to change.  These include 
orthopedic workforce size, orthopedic techniques, implant quality, surgical recovery on the part 
of the medical intervention itself, but also patient perception of pain and quality of life with and 
without surgery, the sense of desirability of TKA as a treatment option, and many others on the 
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part of the patient.  Many things could influence this parameter that are unknowable in the 
present like a new everlasting implant that makes surgery more desirable to younger or heavier 
patients or conversely a public scandal about medical devices such as implants causing some 
long-term consequences that causes patients to stop seeking surgical intervention.  The newly 
available option for outpatient TKA as a billable procedure may increase demand by making the 
surgery seem less onerous to patients as well, or it could drive down surgeon availability because 
of reimbursement patterns.  Regardless of the reasons, surgical uptake may change in the future.  
Like the obesity design above, surgical uptake is tested at a 50% decrease to a 50% increase to 
understand what might happen in those unknown future situations.  This is parameterized as a 
change to the rate at which OA patients get TKA.  
Predicted discharges for TKA follow an interesting pattern.  In 2015, there is a dramatic 
shift for both demand changes, but as time advances both return towards the baseline values.  
This suggests there is some sort of equilibrium in the population for demand (Figure IV-8).  
Again, the OA in the model population is suggestive of the reason for this pattern (Figure IV-9).  
This can be thought of in the framework of a susceptible – infected model.  The OA group is the 
susceptible population and in the increased uptake scenario it initially exhausts more quickly 
than in baseline, but over time the susceptible pool recovers as new people develop OA.  The 
opposite occurs in the decreased uptake scenario.  At first, the susceptible group is much larger, 
but over time they are eventually ‘infected’ with TKA as well and the pool starts to decrease 
towards the same levels seen in the baseline scenario.  The population is larger, so despite the 
lower rate, a similar level of TKA discharges per year eventually emerges.   
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Figure IV-8 Number of Total Surgeries Predicted by Year and Uptake Trend 
 
Figure IV-9 Agents Living with OA by Year and Uptake Trend 
 
Looking at the number of discharges, the impact of the early trajectory changes is more 
apparent.  The impact is slight in comparison.  Halving the uptake of TKA results in about 12% 
fewer discharges total and barely changes deep revision rates (Table IV-8).  Increasing the 
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uptake by half on the other hand increases discharges by about 8% overall.  In this case deep 
revision also moves a similar amount.   Overall, it takes a great deal to change the number of 
procedures performed each year in the long-term.   
Table IV-8 Averted Surgeries by Uptake Trend (in Thousands) 
Scenario 
Total 
Surgery Primary Revision 
Deep 
Revision 
Baseline 32471 20212 11689 570 
Uptake Trend 50% 28673 17903 10217 553 
Averted 3798 2310 1472 17 
Percent Averted 12% 11% 13% 3% 
Uptake Trend 150% 34966 21572 12781 613 
Averted -2495 -1360 -1092 -43 
Percent Averted -8% -7% -9% -8% 
 
Despite the vastly different discharge trajectories, the total budget impact is small as 
expected seeing the averted discharges.  It is more interesting to see how that budget is allocated 
as the surgical and OA costs are quite different (Figure IV-10).  There are meaningful differences 
in how resources should be allocated if the uptake patterns change even if the overall budget is 
not impacted.  As with the tradeoffs in the guideline scenarios, the number of discharges averted 
does not offset the increased burden of living with OA to a great extent.   
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Figure IV-10 Costs in Billions by Uptake Trend 
 
Discussion 
TKA is already a large cost center in health care system.  It is only expected to rise given 
current patterns.  These results are similar to other studies showing increases in the number of 
TKA procedures performed annually in the United States.  The rapid growth in demand for TKA 
and its large economic impact suggest that further study is warranted.  The large share of obese 
patients and the higher complication rates experienced in those groups suggest the guideline 
restrictions imposed in NHS and proposed for the US may be worthy of additional study.  These 
trillions of dollars of budget impact are a large drain on resources that could possibly be spent 
elsewhere if obese patients were denied surgery or obesity patterns changed in theory.  However, 
the budget impact is closer to cost neutral when the resulting increase in OA is accounted for.  
Ways to shift down uptake are also minimally impactive on the overall budget and lead more to a 
reallocation of dollars rather than a cost savings.   
$
$500
$1000
$1500
$2000
$2500
Total Costs Surgical Costs Complication Costs OA Costs
Cost Comparisons by Type 
Baseline Uptake Trend 50% Uptake Trend 150%
  
121 
This is not to say these are not ideas worth pursuing, but not from the perspective of the 
overall health budget.  This may change in a longer time frame, however.  The effects of an 
obesity intervention may be more impactful if the timeline was expanded beyond 20 years.  
There may also be lessons in the steady state that is seen in the uptake changes.  OA is a process 
and the population is still aging.  Short term budget planning may require different approaches 
than longer term planning.  Workforce planning may be a challenge given the lengthy process of 
medical training and the conflicting needs of the short and long term.  In the short term, reducing 
TKA uptake would need fewer orthopedic surgeons.  Within the space of a decade the volume 
trends back up and there would be a problematic shortage of trained surgeons.  The budget 
projections suggest that both short- and long-range perspectives need to be considered in terms 
of the resource allocation before any policy implementation.   
There are further workforce issues to consider.  The obesity restrictions and the uptake 
increase do reduce the surgical burden, but they also increase the OA burden as a result.  These 
are different resources and do save operating theaters for other purposes and suggest that training 
in different specialties could be pursued.  Other shared hospital resources such as surgical nurses 
or office space could also be impacted.  This reduction in TKA demand for surgical resources 
may free these valuable resources up for other departments with different impacts on population 
health.   
Guidelines restricting access to obese patients may be a strategy that would substantially 
reduce the volume of TKA procedures.  There is however no clear rationale to do so.  The total 
budget is virtually unchanged and the cost-effectiveness is within generally reasonable American 
standards.  The ethical questions raised in the UK about denying access are not easily set aside 
by the results of this analysis.  This calculus may be different in other healthcare systems if wait 
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times and constrained resources are considered.  The complication rate differences observed are 
important to consider, but do not alone change the efficacy of the procedure in obese patients.   
Future Research  
This analysis did not consider crowding out of healthy patients by obese patients.  In 
reality, there are a limited number of surgeons and operative time available that could make 
prioritizing rather than banning certain groups a different calculus.  A networked analysis 
incorporating the constraints on the system would be beneficial in addressing this question.  Wait 
times in other healthcare systems in particular would benefit from such an addition to the model.  
Reducing wait times for nonobese patients may be enough to change the cost-effectiveness of the 
guidelines.   
The obesity parameters are also simple extrapolations.  In this model implementation, 
weight does not fluctuate in individual patients.  Nor does OA develop more in the heaviest 
patients.  More weight is not more damaging to knees, artificial or otherwise, according to this 
model.  Although there is some evidence that more weight may be damaging to knees we do not 
have sufficient levels of detail on the progression of OA and obesity or the detriment of knee 
joint mechanics under extreme weight for precisely parameterizing this model so these 
simplifications were used (Cicuttini , Baker, & Spector, 1996), (Landsmeer, et al., 2018).  Better, 
more detailed parameters would fine tune these estimates and the benefits and costs of the 
heaviest patients could be explored more deeply.  Before any restrictions are imposed a better 
understanding of the effect of specific levels of obesity in specific outcomes and disease 
progression is warranted. 
The model also makes use of a generic TKA process that does not vary for patient 
characteristics.  The scope of the model was limited to a generic total replacement without regard 
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for surgical details or provider volume.  Different surgical approaches or implant types may be 
more or less suitable for obese patients and that is not considered here.  Hospital and surgeon 
volume are known to impact outcomes.  Another simplification in the model is that revision rates 
are not age dependent.  This may introduce systematic error into the total surgery estimates in 
either direction.  If heavier patients are also younger this could lead to even higher revision 
burden than predicted here.  If instead heavier patients are forced to wait longer for surgery in 
attempts to lose weight before intervention, then the revision burden may be inflated because the 
heavier patients are actually older and less likely to live long enough to require revision.  
Introducing these details into the surgical process could provide important nuance to the model 
results.   
This analysis does not incorporate the introduction of bundled payments or the new rules 
allowing the procedure to be done on an outpatient basis.  Both changes could dramatically 
change the availability of surgeons in either direction.  The bundled payment may discourage use 
of TKA by being priced too low and becoming unprofitable for hospitals or conversely may 
create financial incentives to focus on the procedure.  It could encourage providers to focus more 
on lower risk, lower weight patients.  The outpatient change could drive demand by patients up 
by appearing as a more minor procedure to fix their knee pain or could cause surgeons to limit 
surgery as an option to only the healthiest patients.  One estimate suggests that an outpatient 
TKA will be reimbursed at a rate 18% less than an inpatient procedure (Rovinsky, Looby, & 
Zacchigna, 2018).  This could tend to lower surgeon participation or organization promotion of 
TKA as a profit center by reducing profitability.  The lower margins could cause only the 
healthiest patients to be offered TKA to minimize risk so that costs remain lower than the lesser 
reimbursement rate.  A best practices group estimates that almost half of the current 
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uncomplicated cases done in hospital could potentially be eligible for outpatient surgery 
(Fontana, Members Ask: How many Medicare TKA cases could shift outpatient?, 2017).  The 
obese, among other chronic conditions and advanced age, were excluded from their analysis.  
With so many cases moved out of the inpatient setting, obese patients may be welcomed by 
hospitals trying to maintain a profit center in orthopedics.  Alternatively, with that much of the 
volume moved to an outpatient setting, the number of joint replacement surgeons working out of 
a hospital may reduce dramatically leaving no surgical capacity for obese patients.  These 
changes in payment structure are indirectly considered in the uptake analysis, but future research 
should directly include these changes.   
Overall, TKA procedures are expected to increase dramatically in the next 20 years.  
Although obesity appears to be driving this increase, changes in the rates of obesity growth over 
time may not be sufficient to see a noticeable change in the number of TKA procedures.  Of all 
the policies evaluated, a strict prohibition on TKAs for obese individuals was the only policy that 
substantially altered the volume of TKA procedures performed, but this may not be an ethical or 
cost-effective policy choice. 
Future research may evaluate the impact of other policies including different impacts and 
effects over a longer time horizon. 
Clinical Applications 
Restrictions on access to TKA for obese patients would function more like a budget 
reallocation than overall cost savings.  The largest lesson from this model is that OA is also a 
large part of the story of TKA.  Rheumatology and primary care providers who treat and refer 
patients for surgery should work together with orthopedic surgeons to develop an idea of what 
makes a good candidate.  Rather than working in isolation, these groups of doctors should 
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collectively consider risk factors as discussed in Chapter III before scarce resources are spent in 
referrals unlikely to be good candidates.   
Methodological Advances 
This is the first study to make use of an agent-based model to understand the budget 
impacts of OA and TKA in the population level.  The calibration required to ensure the volume 
predictions followed existing conditions made use of a novel combination of techniques.  The 
use of logarithmic regressions on the stochastic model results allowed for better calibration with 
fewer costly stochastic simulation runs.  The choice to use relationships of confidence intervals 
rather than a traditional mean squared error approach to the objective function also allowed a 
more holistic choice with regards to the trend in the data.  
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Conclusion 
 
The goal of this dissertation was to apply operations research and decision science 
techniques to the policy conversation around obesity and TKA.  Currently, the conversation 
centers on possibly increased complication rates in obese populations and possible 
implementation of guidelines restricting access to surgery in certain groups.  The large volume of 
TKAs and the growing share of obese patients make this an important topic in terms of 
individual patient outcomes and as a large item in the national healthcare budget.  These studies 
affirm that obesity does matter, but not always in the anticipated manner.   
The general consensus is, that by American standards, TKA is a cost-effective procedure 
is repeated and expanded to include even the morbidly obese.   Being a good value for money 
does not necessarily translate to inexpensive.  The budget impact is large and expected to rise.  
Better understanding of what does and does not drive the process and costs can inform policy 
makers as they attempt to plan, budget, and influence the future volume of this popular 
procedure.   
The meta-analysis in Chapter II helped reduce the conflicting data relating to 
complication rates in obese populations.  The results suggest that obesity does increase 
complication rates for important individual complications.  It does not find a dose-response 
relationship which suggests that other factors besides obesity itself are driving at least some of 
the observed difference.  Postoperative care or informal preoperative criteria may be creating 
differences in the complication rates not readily apparent in the existing studies.  The seeming 
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lack of consensus in the current literature is less of an issue than it appears when looking at 
individual studies.  Taken together, there is much more agreement at least in those areas where 
the same outcomes were considered.  An effort towards a standard set of complications and a 
more detailed approach to obesity definitions is still needed to fully understand the role of 
obesity in outcomes of TKA.   
The CEA in Chapter III provides a systematic way to consider whether TKA should be 
offered to patients with various levels of obesity.  Guidelines currently implemented in the UK 
are not based on a rigorous calculation of benefit, but purely a cost-savings experiment based on 
the notion that obese patients benefit less from surgery than others.  This analysis demonstrated 
that even the heaviest patients still meet US standards of cost-effectiveness.  The sensitivity 
analyses also point to several key areas for possible policy levers.  Failure and complication rates 
mattered greatly and are both potentially modifiable with innovation in medical devices, surgical 
techniques, postoperative instructions, or other policy changes.  The results also suggest that the 
concerns around the morbidly obese are not without merit.  It is quite difficult to create a 
scenario that nonobese patients are not cost-effective, but simple to create one that is wildly 
expensive for Class III patients.   
Chapter IV explicitly examined several potential policy levers and at the population level.  
The predicted volume of TKA procedures is expected to grow, but obesity is only part of that 
story.  Obese patients do continue to be a growing share of TKA patients, but the volume is 
trending upwards independent of that change in patient demographics.  Guidelines restricting 
access to TKA were explicitly modeled and, similar to the CEA results, the case for restricting 
access is not clear cut.  Restricting access to TKA would have a noticeable impact on reducing 
overall volumes of TKA procedures.  However, large numbers of people have OA of the knee 
  
128 
regardless of whether TKA is an option to alleviate pain and immobility.  Controlling the volume 
of TKA does not control the budget impact of OA.  The guideline experiments demonstrate the 
need for tradeoffs in healthcare decision making.  Policy makers need to plan workforce sizes 
and training priorities as well as budgetary concerns.  The impact of reducing obesity in the 
population through broader public health initiatives is minimal in this specific domain, at least 
over the next 20 years.  The damage to knees is a long-term process and will not be reversed in 
the short term.  The ability to bend the demand for the procedure appears to be a temporary 
influence.  The levels of OA in the population are much more powerful than policies or events 
that influence desirability of TKA.  Obesity plays a role in the development of OA, so any 
actions need to be focused upstream on the development of the underlying disease rather than 
TKA usage itself.   
These results also give some clinical insights.  First, risk factors for deep infection and 
failure besides obesity should be strong markers against offering TKA in obese populations.  
Second, the suspicion that quality of life improvement will be less than average due to 
temperament or lifestyle of the patient should also give pause to surgeons considering obese 
patients for surgery.  Third, the limited resources of the orthopedic staff need to be considered in 
light of rheumatology and primary care burdens of OA and these departments should discuss 
who make good surgical candidates before not after referrals occur to better use everyone’s time.   
Methodologically, this dissertation expanded the knowledge base around obesity and 
TKA by applying existing techniques to the new policy area and by also by using novel 
techniques when needed to better use models to answer these policy questions.   
Two broad themes are found in these studies.  The current data on obesity and TKA 
outcomes is limited.  Better information can change policy recommendations as seen in the CEA 
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and should be easily obtainable if a consensus is reached on what outcomes matter.  The sheer 
volume of TKA procedures make any investment in obtaining more precise estimates of the 
impact of obesity on TKA outcomes worth pursuing.  The other theme is that an application of 
decision science techniques to this area can add an important amount of fairness into this 
conversation.  As seen in the UK, the idea of limiting care can elicit pushback from the public 
and from providers, an effect more pronounced in the American setting where rationing is not a 
welcome part of any health care conversation.  Adding the charged topic of obesity to the mix 
does not calm these concerns.  The models in Chapter III and IV show that while TKA is a 
generally a good value for money it is less so for the heaviest patients while also highlighting the 
tradeoffs in different treatment decisions and potential modifiable factors, short of restricting 
access to obese patients, that can make an impact on this large cost center in the American 
healthcare landscape.  
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Literature Search Details 
 
 
After the 26 papers were selected for inclusion, the data was extracted in a three-phase 
process.  As a first step, I read all papers and developed an Excel workbook to record the various 
reporting styles in the studies.  Generally, each row was a single study and columns were 
arranged in sets according to obesity classification.  Obesity classifications were as specific as 
the papers reported.  They include the WHO classifications and thresholds such as BMI ≥ 35.  
Each set included any of the reported figures.  For survival rates, this included all postoperative 
years up to the longest study of 18 years.  The complication rates recorded odds ratios, values 
from contingency tables, and confidence intervals.   
In the second phase, two master’s students served as reviewers.  The first reviewer did 11 
papers, index numbers from 103-238 in the Table A-1.  Table A-1 is also available in the Study 
Quality tab of the workbook MetaAnalysisExclusionAndDataFinal included in the 
supplementary materials available on the Drive for easier viewing.  The second reviewer did the 
remaining 15 papers after the first graduated.  There was no overlap between the two reviewers.  
Each was given a basic description of the project and the outcomes under consideration.  The 
variety of outcome reporting styles was explained as was the graphing tool for extracting values 
from survival curve graphs.  The instruction document attempted to balance detailed instructions 
with wide latitude to use own judgement to preserve the independence of the second review.  
The instructions also asked for recording of page or table number to easily find the source within 
the paper.   
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Considering the two student reviewers as one, agreement was 29.9%.  For the first 
reviewer, it was 33.9% and the second saw 25%.  This low rate of agreement can be explained 
partially by the very loose definitions in the grouped complications.  Excluding those from the 
calculation sees overall agreement rise to 35.7% and the two reviewers to 40.6% and 29.2% 
respectively.   
The third phase involved David Hutton as arbiter between differing results both in terms 
of finding any number at all and in disagreement of specific values in the same paper.  He and I 
walked through each of the papers and value.  Prof. Hutton then made the final decision on 
whether to include a value or not.  For instance, the first reviewer included many values for 
survival of revision operations.  Yet all 7 of the papers he found were only about the revision of 
primary surgeries and they were not included in the analysis.  Other sources of disagreement 
related to definition of complications or groupings in the primary papers.  For instance, some 
papers discussed pulmonary embolism and deep vein thrombosis separately but together they are 
venous thromboembolism so with some simple addition can be made a part of the analysis.  
There were also several that were simply overlooking a table not mentioned inline or vice versa 
on my part that the reviewers found.   
After this process, consensus was achieved on which values to include and that all 
possible data was extracted.  From this base, the analysis continued as described above.   
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Table A-1 Study Quality Analysis 
 
Chart report 
only is yellow.  
In person 
measure is 
green.
Must define 
type of 
TKR/approach 
for green.  
Same or mostly 
same implant 
process for 
green.  
Index
Sample - 
Inclusion 
Criteria 
Defined
Sample - 
Sample 
Selection 
Explained
Sample - 
Adequate 
Description of 
diagnostic 
criteria
Sample - Cinical 
and 
Demographics 
Fully Described
Sample - 
Representative
Sample - 
Assembled at a 
common point 
in disease
F/U - 
Sufficiently 
Long
Outcome- 
Objective
Outcome - 
Unbiased
Outcome - 
Fully defined
Outcome - 
Appropriate
Outcome- 
Known for high 
share
Prognostic Var - 
Fully defined
Prognostic Var - 
Precisely 
Measured
Prognostic Var - 
Avail for high 
share
Ax- Good 
procedures
Treatment 
subsequent to 
inclusion - fully 
described
Treatment sub - 
Treatment 
standardized 
or randomized
32 good good good okay okay good good good good good good good good okay good good okay okay
37 good good good good good good good good good okay good good good good good good okay okay
38 good okay good good good good good good good good okay good good okay good okay okay okay
46 good good good okay okay good good good good good good good good okay good good okay okay
59 good good good good good good good good good good okay good good good good good okay okay
61 good good good good good good good good good good good good good okay good good okay okay
73 good good good good okay good okay good good good good good good good good good okay okay
76 good good good okay okay good good good good good okay good good okay good good good good
78 good good okay okay okay okay okay good okay good good okay good good good good okay okay
81 good good good good good good good good good okay good good okay okay good good okay okay
100 good good good okay okay good okay good good good okay good good good good good okay okay
103 good good good okay okay good okay good good good good good good good good good good good
113 good good good okay okay good okay good good good good good good good good good good good
117 OKAY good good okay okay good okay good good good good good good good good good okay okay
124 good good good good okay good good good good good good okay good okay good good good good
126 good good good okay okay good good good good good good okay good good good good good okay
172 good good good good okay good okay good good good good good good good good good good good
174 good good good good okay good good good good good good good good okay good good good good
195 good good good okay okay good good good good good good good good good good good good good
206 good good good okay okay good good good good good good good good good good good good good
224 good good good okay okay good okay good good good good good good okay good good good good
238 good good good okay okay good okay good good good good good good good good good okay okay
253 good good good okay okay good okay good good good good good good good good good good okay
L1 good good good okay okay good good good good good good good good okay good good good okay
L3 good good good okay okay good good good good good good good good okay good good okay okay
L5 good good good okay good good good good good good good good good okay good good okay okay
Green = Good, Yellow = Fair, Red = Bad
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Table A-2 Number of Studies and Knees by Year and Obesity Class 
Number of Knees (Number of Studies) 
Year BMI < 30 BMI > 30 BMI 30-35 BMI > 40 BMI > 35 
1 561  479 187 684 187 
5 6 3 3 3 
2 561 479 187 684 187 
5 6 3 3 3 
3 561 479 187 684 187 
5 6 3 3 3 
4 561 479 187 684 187 
5 6 3 3 3 
5 602 479 187 684 187 
6 6 3 3 3 
6 561 479 187 684 187 
5 6 3 3 3 
7 269 269 187 602 187 
3 5 3 2 3 
8 269 269 187 602 187 
3 5 3 2 3 
9 269 269 187 602 187 
3 5 3 2 3 
10 269 269 325 602 187 
3 5 4 2 3 
11 32 32 0 0 0 
1 1 0 0 0 
12 32 32 0 0 0 
1 1 0 0 0 
13 32 32 0 0 0 
1 1 0 0 0 
14 32 32 0 0 0 
1 1 0 0 0 
15 32 32 0 0 0 
1 1 0 0 0 
16 32 32 0 0 0 
1 1 0 0 0 
17 32 32 0 0 0 
1 1 0 0 0 
18 32 32 0 0 0 
1 1 0 0 0 
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Full Sensitivity Analysis Results 
 
The full univariate sensitivity analysis results for all 248 parameters are shown below.  
The four obesity groups (Table B-2 – 4) form the basis of the weighted average shown as overall 
in Table B-1.  Red values have been artificially inflated to reflect that the value was changed 
from a negative ICER due to dominance.  Yellow cells are highlighted negative values that 
reflect domination.     
Table B-1 Full Univariate Sensitivity Analysis Results for Overall Population 
Overall 
Base  $                                                                                16,272.89  
Parameter Name Low High Min Max Gap 
qalyFull 
 $ 
(44,076.85) 
 $       
5,913.62  
 $ 
150,000.00  
 $       
5,913.62   $ 144,086.38  
transitionRevisionToFull 
 $ 
132,497.56  
 $      
11,154.97  
 $      
11,154.97  
 $ 
132,497.56  
 $   
121,342.59  
transitionTKAtoFull 
 $    
121,413.85  
 $     
10,327.51  
 $     
10,327.51  
 $    
121,413.85  
 $    
111,086.34  
costOATreatment 
 $     
41,103.36  
 $ 
(33,388.07) 
 $ 
(33,388.07) 
 $     
41,103.36  
 $    
74,491.43  
complicationDeepInfectionLess Obese 
 $      
14,221.18  
 $   
58,909.95  
 $      
14,221.18  
 $   
58,909.95   $   44,688.77  
complicationDeepInfection 
 $      
6,084.82  
 $   
46,240.60  
 $      
6,084.82  
 $   
46,240.60  
 $    
40,155.78  
costTKA 
 $      
2,905.72  
 $   
43,007.22  
 $      
2,905.72  
 $   
43,007.22  
 $     
40,101.50  
costRevision 
 $      
4,056.95  
 $   
40,704.76  
 $      
4,056.95  
 $   
40,704.76  
 $    
36,647.81  
qalyOA 
 $    
15,465.50  
 $   
49,058.97  
 $    
15,465.50  
 $   
49,058.97   $   33,593.47  
Age 
 $     
10,512.95  
 $   
23,297.86  
 $     
10,512.95  
 $   
23,297.86  
 $    
12,784.92  
Discount Rate 
 $     
11,889.78  
 $   
23,227.34  
 $     
11,889.78  
 $   
23,227.34  
 $     
11,337.56  
transitionDeepLateToRevision 
 $    
16,272.89  
 $   
27,057.79  
 $    
16,272.89  
 $   
27,057.79  
 $     
10,784.91  
transitionTKAFullToNo10 
 $       
7,615.39  
 $     
18,361.94  
 $       
7,615.39  
 $     
18,361.94  
 $    
10,746.55  
qalyDecRevision 
 $    
15,227.32  
 $    
24,781.57  
 $    
15,227.32  
 $    
24,781.57  
 $      
9,554.25  
costsDeepContinuingWorst 
 $     
13,373.31  
 $   
22,072.03  
 $     
13,373.31  
 $   
22,072.03  
 $      
8,698.72  
qalyDecTKA 
 $    
14,282.08  
 $   
22,220.05  
 $    
14,282.08  
 $   
22,220.05  
 $      
7,937.97  
transitionRevisionFullToNo1 
 $     
16,179.97  
 $    
23,210.63  
 $     
16,179.97  
 $    
23,210.63  
 $      
7,030.66  
transitionTKAFullToNo1 
 $    
15,830.88  
 $   
22,703.27  
 $    
15,830.88  
 $   
22,703.27  
 $      
6,872.40  
complicationDeepInfectionMore Obese 
 $    
14,892.90  
 $    
21,744.65  
 $    
14,892.90  
 $    
21,744.65  
 $       
6,851.76  
transitionTKAFullToNo2 
 $     
15,446.17  
 $    
21,575.27  
 $     
15,446.17  
 $    
21,575.27  
 $        
6,129.10  
transitionRevisionFullToNo2 
 $     
16,177.66  
 $     
21,947.81  
 $     
16,177.66  
 $     
21,947.81  
 $       
5,770.15  
complicationDeepInfectionMorbid Obese 
 $      
14,843.11  
 $      
20,371.11  
 $      
14,843.11  
 $      
20,371.11  
 $      
5,528.00  
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transitionTKAFullToNo3 
 $    
15,385.23  
 $    
20,816.05  
 $    
15,385.23  
 $    
20,816.05  
 $      
5,430.82  
transitionLateFailureToRevision 
 $       
11,350.11  
 $    
16,283.48  
 $       
11,350.11  
 $    
16,283.48  
 $      
4,933.37  
transitionTKAFullToNo4 
 $    
15,496.77  
 $   
20,270.83  
 $    
15,496.77  
 $   
20,270.83  
 $      
4,774.07  
transitionRevisionFullToNo3 
 $     
16,074.18  
 $   
20,786.69  
 $     
16,074.18  
 $   
20,786.69  
 $        
4,712.51  
transitionTKAFullToNo5 
 $    
15,468.93  
 $    
19,636.90  
 $    
15,468.93  
 $    
19,636.90  
 $       
4,167.97  
costsDeepRevision 
 $    
14,920.62  
 $    
18,977.42  
 $    
14,920.62  
 $    
18,977.42  
 $      
4,056.80  
transitionRevisionFullToNo4 
 $    
16,023.82  
 $    
19,864.65  
 $    
16,023.82  
 $    
19,864.65  
 $      
3,840.84  
transitionTKAFullToNo6 
 $    
15,435.97  
 $     
19,043.19  
 $    
15,435.97  
 $     
19,043.19  
 $      
3,607.23  
transitionRevisionFullToNo10 
 $    
14,576.88  
 $     
17,961.36  
 $    
14,576.88  
 $     
17,961.36  
 $      
3,384.48  
costPostOpTKA 
 $     
15,168.38  
 $     
18,481.90  
 $     
15,168.38  
 $     
18,481.90  
 $        
3,313.51  
qalyFailed 
 $     
18,321.45  
 $    
15,039.54  
 $    
15,039.54  
 $     
18,321.45  
 $        
3,281.91  
transitionTKAtoFullNon Obese 
 $     
18,405.13  
 $     
15,155.92  
 $     
15,155.92  
 $     
18,405.13  
 $       
3,249.21  
transitionRevisionFullToNo5 
 $    
16,065.63  
 $      
19,178.16  
 $    
16,065.63  
 $      
19,178.16  
 $        
3,112.53  
transitionTKAFullToNo7 
 $      
15,104.17  
 $     
18,214.78  
 $      
15,104.17  
 $     
18,214.78  
 $        
3,110.62  
transitionRevisionToFullLess Obese 
 $    
14,544.33  
 $     
17,631.55  
 $    
14,544.33  
 $     
17,631.55  
 $      
3,087.22  
costFailure 
 $     
15,371.46  
 $    
18,075.73  
 $     
15,371.46  
 $    
18,075.73  
 $      
2,704.27  
transitionTKAFullToNo8 
 $     
14,810.04  
 $    
17,474.22  
 $     
14,810.04  
 $    
17,474.22  
 $       
2,664.17  
transitionRevisionToFullNon Obese 
 $     
18,097.19  
 $    
15,464.87  
 $    
15,464.87  
 $     
18,097.19  
 $      
2,632.32  
transitionRevisionFullToNo6 
 $    
16,077.69  
 $    
18,582.35  
 $    
16,077.69  
 $    
18,582.35  
 $      
2,504.66  
transitionTKAFullToNo9 
 $     
14,466.12  
 $    
16,743.20  
 $     
14,466.12  
 $    
16,743.20  
 $      
2,277.09  
costDeepInfection 
 $     
15,514.99  
 $    
17,788.67  
 $     
15,514.99  
 $    
17,788.67  
 $      
2,273.68  
transitionDeepEarlyToRevision 
 $    
16,272.89  
 $    
18,497.93  
 $    
16,272.89  
 $    
18,497.93  
 $      
2,225.04  
transitionTKAtoFullLess Obese 
 $    
14,860.36  
 $    
17,045.63  
 $    
14,860.36  
 $    
17,045.63  
 $       
2,185.27  
transitionRevisionFullToNo7 
 $    
16,083.73  
 $     
18,081.44  
 $    
16,083.73  
 $     
18,081.44  
 $       
1,997.70  
complicationWound 
 $       
16,174.11  
 $    
18,000.64  
 $       
16,174.11  
 $    
18,000.64  
 $       
1,826.53  
qalyDeepWorstDecrement 
 $    
17,099.62  
 $     
15,522.41  
 $     
15,522.41  
 $    
17,099.62  
 $       
1,577.22  
transitionRevisionFullToNo8 
 $      
16,116.44  
 $    
17,687.05  
 $      
16,116.44  
 $    
17,687.05  
 $       
1,570.62  
transitionRevisionToFullMore Obese 
 $      
15,413.15  
 $    
16,935.92  
 $      
15,413.15  
 $    
16,935.92  
 $       
1,522.77  
transitionTKAFullToNo10Less Obese 
 $    
15,666.65  
 $     
17,002.12  
 $    
15,666.65  
 $     
17,002.12  
 $       
1,335.47  
transitionRevisionFullToNo9 
 $    
15,995.29  
 $    
17,240.70  
 $    
15,995.29  
 $    
17,240.70  
 $        
1,245.41  
complicationDeepVTE 
 $    
16,267.40  
 $     
17,427.01  
 $    
16,267.40  
 $     
17,427.01  
 $         
1,159.61  
transitionTKAtoFullMore Obese 
 $     
15,553.17  
 $    
16,663.28  
 $     
15,553.17  
 $    
16,663.28  
 $          
1,110.12  
transitionRevisionToFullMorbid Obese 
 $     
15,649.01  
 $    
16,746.48  
 $     
15,649.01  
 $    
16,746.48  
 $       
1,097.47  
transitionTKAtoFullMorbid Obese 
 $    
15,708.25  
 $    
16,578.49  
 $    
15,708.25  
 $    
16,578.49   $         870.24  
complicationVTE 
 $    
15,994.82  
 $      
16,813.19  
 $    
15,994.82  
 $      
16,813.19  
 $          
818.36  
complicationDeepSubsequentDeepLess Obese 
 $     
16,228.10  
 $     
17,044.61  
 $     
16,228.10  
 $     
17,044.61  
 $           
816.51  
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transitionTKAFullToNo10More Obese 
 $     
15,971.33  
 $     
16,634.10  
 $     
15,971.33  
 $     
16,634.10   $         662.77  
costsDeepSubsequentDeep 
 $      
16,112.93  
 $     
16,592.81  
 $      
16,112.93  
 $     
16,592.81   $         479.88  
transitionTKAFullToNo10Morbid Obese 
 $    
16,058.82  
 $     
16,531.98  
 $    
16,058.82  
 $     
16,531.98  
 $          
473.17  
tranistionEarlyFailureToRevision 
 $     
16,718.67  
 $    
16,272.89  
 $    
16,272.89  
 $     
16,718.67   $         445.78  
transitionTKAFullToNo9Less Obese 
 $      
16,114.45  
 $    
16,528.02  
 $      
16,114.45  
 $    
16,528.02  
 $          
413.57  
costVTE 
 $     
16,135.29  
 $    
16,548.07  
 $     
16,135.29  
 $    
16,548.07  
 $          
412.78  
transitionDeepBestToFail1 
 $     
16,028.01  
 $    
16,404.46  
 $     
16,028.01  
 $    
16,404.46   $         376.45  
transitionRevisionFullToNo10Less Obese 
 $     
16,107.04  
 $     
16,471.08  
 $     
16,107.04  
 $     
16,471.08   $         364.05  
complicationDeepSubsequentDeepMorbid 
Obese 
 $      
16,180.81  
 $     
16,541.89  
 $      
16,180.81  
 $     
16,541.89  
 $          
361.08  
qalyDecDeepInfection 
 $     
16,213.60  
 $    
16,563.08  
 $     
16,213.60  
 $    
16,563.08   $         349.48  
qalyDeepRevisionDecrement 
 $     
16,216.08  
 $     
16,563.01  
 $     
16,216.08  
 $     
16,563.01   $         346.93  
transitionTKAFullToNo8Less Obese 
 $     
16,142.89  
 $      
16,482.11  
 $     
16,142.89  
 $      
16,482.11   $         339.23  
complicationWoundLess Obese 
 $    
16,233.78  
 $     
16,517.27  
 $    
16,233.78  
 $     
16,517.27   $         283.49  
transitionDeepRevisionToBest 
 $    
16,423.32  
 $     
16,140.67  
 $     
16,140.67  
 $    
16,423.32   $         282.65  
transitionTKAFullToNo7Less Obese 
 $     
16,167.50  
 $    
16,442.42  
 $     
16,167.50  
 $    
16,442.42   $         274.92  
complicationDeepSubsequentDeepMore Obese 
 $    
16,220.78  
 $    
16,479.07  
 $    
16,220.78  
 $    
16,479.07   $         258.28  
complicationVTEMorbid Obese 
 $    
16,237.28  
 $     
16,462.19  
 $    
16,237.28  
 $     
16,462.19  
 $          
224.91  
transitionTKAFullToNo3Less Obese 
 $     
16,188.28  
 $    
16,408.95  
 $     
16,188.28  
 $    
16,408.95   $         220.67  
transitionTKAFullToNo2Less Obese 
 $     
16,193.28  
 $    
16,400.89  
 $     
16,193.28  
 $    
16,400.89   $         207.60  
costRevisionLess Obese 
 $    
16,204.03  
 $     
16,410.60  
 $    
16,204.03  
 $     
16,410.60   $         206.57  
transitionTKAFullToNo9More Obese 
 $     
16,193.87  
 $    
16,399.93  
 $     
16,193.87  
 $    
16,399.93   $         206.06  
transitionTKAFullToNo6Less Obese 
 $     
16,196.44  
 $    
16,395.80  
 $     
16,196.44  
 $    
16,395.80  
 $          
199.36  
transitionTKAFullToNo5Less Obese 
 $     
16,198.30  
 $    
16,392.80  
 $     
16,198.30  
 $    
16,392.80  
 $          
194.50  
transitionTKAFullToNo4Less Obese 
 $     
16,199.90  
 $    
16,390.22  
 $     
16,199.90  
 $    
16,390.22  
 $          
190.32  
transitionRevisionFullToNo10More Obese 
 $      
16,191.97  
 $    
16,369.45  
 $      
16,191.97  
 $    
16,369.45  
 $          
177.48  
transitionTKAFullToNo8More Obese 
 $    
16,207.97  
 $    
16,377.24  
 $    
16,207.97  
 $    
16,377.24  
 $          
169.27  
costTKALess Obese 
 $     
16,221.75  
 $     
16,375.16  
 $     
16,221.75  
 $     
16,375.16  
 $           
153.41  
transitionTKAFullToNo9Morbid Obese 
 $      
16,214.16  
 $    
16,367.27  
 $      
16,214.16  
 $    
16,367.27  
 $            
153.11  
complicationDeepSubsequentDeep 
 $      
16,198.61  
 $     
16,347.19  
 $      
16,198.61  
 $     
16,347.19  
 $          
148.58  
costWound 
 $     
16,224.18  
 $    
16,370.29  
 $     
16,224.18  
 $    
16,370.29  
 $           
146.10  
transitionTKAFullToNo7More Obese 
 $     
16,220.19  
 $    
16,357.57  
 $     
16,220.19  
 $    
16,357.57  
 $          
137.38  
transitionTKAFullToNo8Morbid Obese 
 $    
16,224.29  
 $    
16,350.98  
 $    
16,224.29  
 $    
16,350.98  
 $          
126.70  
qalyDeepBestCase 
 $    
16,335.90  
 $     
16,210.35  
 $     
16,210.35  
 $    
16,335.90  
 $          
125.55  
transitionDeepBestToFail2 
 $    
16,206.09  
 $    
16,327.82  
 $    
16,206.09  
 $    
16,327.82  
 $           
121.72  
transitionRevisionFullToNo10Morbid Obese 
 $     
16,219.50  
 $    
16,337.00  
 $     
16,219.50  
 $    
16,337.00  
 $            
117.51  
transitionTKAFullToNo1Less Obese 
 $    
16,230.09  
 $     
16,341.66  
 $    
16,230.09  
 $     
16,341.66  
 $            
111.57  
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transitionTKAFullToNo3More Obese 
 $    
16,230.36  
 $     
16,341.22  
 $    
16,230.36  
 $     
16,341.22  
 $           
110.86  
transitionTKAFullToNo2More Obese 
 $    
16,232.83  
 $    
16,337.25  
 $    
16,232.83  
 $    
16,337.25  
 $          
104.43  
transitionTKAFullToNo7Morbid Obese 
 $     
16,233.18  
 $    
16,336.68  
 $     
16,233.18  
 $    
16,336.68  
 $           
103.51  
costRevisionMorbid Obese 
 $     
16,231.83  
 $    
16,334.46  
 $     
16,231.83  
 $    
16,334.46  
 $          
102.63  
transitionTKAFullToNo6More Obese 
 $     
16,234.61  
 $    
16,334.38  
 $     
16,234.61  
 $    
16,334.38  
 $            
99.76  
transitionTKAFullToNo5More Obese 
 $    
16,235.50  
 $    
16,332.96  
 $    
16,235.50  
 $    
16,332.96  
 $            
97.46  
costRevisionMore Obese 
 $    
16,240.76  
 $     
16,337.14  
 $    
16,240.76  
 $     
16,337.14  
 $            
96.39  
transitionTKAFullToNo4More Obese 
 $    
16,236.25  
 $     
16,331.74  
 $    
16,236.25  
 $     
16,331.74  
 $            
95.49  
transitionTKAFullToNo3Morbid Obese 
 $    
16,240.20  
 $    
16,325.39  
 $    
16,240.20  
 $    
16,325.39  
 $             
85.18  
transitionRevisionFullToNo9Less Obese 
 $     
16,239.81  
 $    
16,323.28  
 $     
16,239.81  
 $    
16,323.28  
 $            
83.47  
costTKAMorbid Obese 
 $    
16,239.67  
 $    
16,322.70  
 $    
16,239.67  
 $    
16,322.70  
 $            
83.03  
transitionTKAFullToNo2Morbid Obese 
 $     
16,241.98  
 $    
16,322.53  
 $     
16,241.98  
 $    
16,322.53  
 $            
80.55  
transitionRevisionFullToNo4Less Obese 
 $    
16,242.04  
 $    
16,320.04  
 $    
16,242.04  
 $    
16,320.04  
 $            
78.00  
transitionTKAFullToNo6Morbid Obese 
 $    
16,243.88  
 $     
16,319.48  
 $    
16,243.88  
 $     
16,319.48  
 $            
75.60  
transitionTKAFullToNo5Morbid Obese 
 $    
16,244.40  
 $     
16,318.64  
 $    
16,244.40  
 $     
16,318.64  
 $            
74.24  
transitionTKAFullToNo4Morbid Obese 
 $    
16,244.85  
 $     
16,317.92  
 $    
16,244.85  
 $     
16,317.92  
 $            
73.07  
qalyDeepSubsequentDeepDecrement 
 $    
16,260.33  
 $    
16,333.28  
 $    
16,260.33  
 $    
16,333.28  
 $            
72.95  
costTKAMore Obese 
 $    
16,248.64  
 $     
16,321.39  
 $    
16,248.64  
 $     
16,321.39  
 $            
72.75  
transitionRevisionFullToNo5Less Obese 
 $    
16,247.40  
 $      
16,311.79  
 $    
16,247.40  
 $      
16,311.79  
 $            
64.39  
transitionRevisionFullToNo3Less Obese 
 $     
16,248.21  
 $     
16,310.56  
 $     
16,248.21  
 $     
16,310.56  
 $            
62.35  
transitionRevisionFullToNo6Less Obese 
 $    
16,249.04  
 $    
16,309.24  
 $    
16,249.04  
 $    
16,309.24  
 $            
60.20  
transitionRevisionFullToNo7Less Obese 
 $    
16,249.97  
 $    
16,307.80  
 $    
16,249.97  
 $    
16,307.80  
 $            
57.84  
transitionTKAFullToNo1More Obese 
 $     
16,251.32  
 $    
16,307.52  
 $     
16,251.32  
 $    
16,307.52  
 $             
56.19  
costsDeepContinuingBest 
 $     
16,254.51  
 $    
16,309.63  
 $     
16,254.51  
 $    
16,309.63  
 $             
55.12  
transitionDeepBestToFail3 
 $    
16,246.92  
 $     
16,297.61  
 $    
16,246.92  
 $     
16,297.61  
 $            
50.69  
transitionRevisionFullToNo8Less Obese 
 $     
16,254.14  
 $      
16,301.41  
 $     
16,254.14  
 $      
16,301.41  
 $            
47.26  
transitionTKAFullToNo1Morbid Obese 
 $     
16,256.19  
 $    
16,299.69  
 $     
16,256.19  
 $    
16,299.69  
 $            
43.50  
transitionRevisionFullToNo9More Obese 
 $    
16,256.74  
 $    
16,297.48  
 $    
16,256.74  
 $    
16,297.48  
 $            
40.74  
transitionRevisionFullToNo4More Obese 
 $    
16,257.79  
 $    
16,295.95  
 $    
16,257.79  
 $    
16,295.95  
 $             
38.16  
qalyDecObesity 
 $    
16,289.97  
 $     
16,256.18  
 $     
16,256.18  
 $    
16,289.97  
 $            
33.80  
transitionRevisionFullToNo5More Obese 
 $    
16,260.42  
 $     
16,291.90  
 $    
16,260.42  
 $     
16,291.90  
 $             
31.49  
transitionRevisionFullToNo3More Obese 
 $    
16,260.80  
 $     
16,291.32  
 $    
16,260.80  
 $     
16,291.32  
 $            
30.52  
complicationDeepWound 
 $     
16,271.24  
 $     
16,301.69  
 $     
16,271.24  
 $     
16,301.69  
 $            
30.45  
transitionRevisionFullToNo2Less Obese 
 $     
16,261.05  
 $    
16,290.89  
 $     
16,261.05  
 $    
16,290.89  
 $            
29.83  
transitionRevisionFullToNo6More Obese 
 $     
16,261.23  
 $    
16,290.65  
 $     
16,261.23  
 $    
16,290.65  
 $            
29.42  
transitionRevisionFullToNo1Less Obese 
 $     
16,261.30  
 $     
16,290.51  
 $     
16,261.30  
 $     
16,290.51  
 $             
29.21  
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transitionRevisionFullToNo7More Obese 
 $     
16,261.69  
 $    
16,289.94  
 $     
16,261.69  
 $    
16,289.94  
 $            
28.26  
transitionRevisionFullToNo9Morbid Obese 
 $     
16,261.87  
 $    
16,289.65  
 $     
16,261.87  
 $    
16,289.65  
 $            
27.78  
transitionRevisionFullToNo4Morbid Obese 
 $    
16,262.29  
 $    
16,289.07  
 $    
16,262.29  
 $    
16,289.07  
 $            
26.79  
costsDeepRevisionMorbid Obese 
 $    
16,262.48  
 $    
16,288.50  
 $    
16,262.48  
 $    
16,288.50  
 $            
26.02  
transitionDeepRevisionToBestNon Obese 
 $    
16,289.03  
 $     
16,264.21  
 $     
16,264.21  
 $    
16,289.03  
 $            
24.82  
qalyDecVTE 
 $    
16,269.96  
 $    
16,293.63  
 $    
16,269.96  
 $    
16,293.63  
 $            
23.67  
transitionRevisionFullToNo8More Obese 
 $    
16,263.73  
 $     
16,286.81  
 $    
16,263.73  
 $     
16,286.81  
 $            
23.08  
transitionDeepBestToFail4 
 $     
16,261.45  
 $     
16,284.19  
 $     
16,261.45  
 $     
16,284.19  
 $            
22.74  
transitionDeepBestToFail1Less Obese 
 $    
16,256.43  
 $    
16,278.86  
 $    
16,256.43  
 $    
16,278.86  
 $            
22.43  
transitionRevisionFullToNo5Morbid Obese 
 $     
16,264.17  
 $     
16,286.17  
 $     
16,264.17  
 $     
16,286.17  
 $            
22.00  
transitionDeepBestToFail1Morbid Obese 
 $    
16,257.09  
 $    
16,278.63  
 $    
16,257.09  
 $    
16,278.63  
 $             
21.54  
transitionRevisionFullToNo3Morbid Obese 
 $    
16,264.36  
 $    
16,285.89  
 $    
16,264.36  
 $    
16,285.89  
 $             
21.53  
transitionRevisionFullToNo6Morbid Obese 
 $    
16,264.78  
 $    
16,285.23  
 $    
16,264.78  
 $    
16,285.23  
 $            
20.45  
transitionRevisionFullToNo7Morbid Obese 
 $     
16,265.15  
 $    
16,284.67  
 $     
16,265.15  
 $    
16,284.67  
 $             
19.52  
complicationWoundMorbid Obese 
 $    
16,268.42  
 $    
16,287.29  
 $    
16,268.42  
 $    
16,287.29  
 $             
18.87  
transitionDeepBestToFail1More Obese 
 $    
16,259.20  
 $    
16,277.86  
 $    
16,259.20  
 $    
16,277.86  
 $             
18.66  
complicationVTELess Obese 
 $    
16,264.96  
 $    
16,282.07  
 $    
16,264.96  
 $    
16,282.07  
 $               
17.11  
tranistionToDeathMorbid Obese 
 $     
16,281.40  
 $    
16,264.42  
 $    
16,264.42  
 $     
16,281.40  
 $             
16.98  
complicationWoundMore Obese 
 $    
16,267.33  
 $    
16,284.02  
 $    
16,267.33  
 $    
16,284.02  
 $             
16.69  
costsDeepRevisionLess Obese 
 $    
16,267.47  
 $     
16,283.71  
 $    
16,267.47  
 $     
16,283.71  
 $             
16.23  
transitionRevisionFullToNo8Morbid Obese 
 $    
16,266.60  
 $    
16,282.45  
 $    
16,266.60  
 $    
16,282.45  
 $             
15.85  
qalyDecWound 
 $      
16,271.51  
 $    
16,287.27  
 $      
16,271.51  
 $    
16,287.27  
 $             
15.76  
transitionRevisionFullToNo2More Obese 
 $    
16,267.09  
 $     
16,281.70  
 $    
16,267.09  
 $     
16,281.70  
 $              
14.61  
transitionRevisionFullToNo1More Obese 
 $     
16,267.21  
 $     
16,281.52  
 $     
16,267.21  
 $     
16,281.52  
 $              
14.31  
costsDeepRevisionMore Obese 
 $    
16,268.39  
 $     
16,281.88  
 $    
16,268.39  
 $     
16,281.88  
 $             
13.49  
transitionDeepBestToFail5 
 $    
16,267.70  
 $    
16,278.06  
 $    
16,267.70  
 $    
16,278.06  
 $             
10.35  
transitionRevisionFullToNo2Morbid Obese 
 $    
16,268.78  
 $     
16,279.13  
 $    
16,268.78  
 $     
16,279.13  
 $             
10.35  
transitionRevisionFullToNo1Morbid Obese 
 $    
16,268.85  
 $    
16,279.03  
 $    
16,268.85  
 $    
16,279.03  
 $              
10.18  
complicationDeepVTEMorbid Obese 
 $     
16,271.29  
 $     
16,281.38  
 $     
16,271.29  
 $     
16,281.38  
 $              
10.10  
costsDeepVTE 
 $     
16,270.17  
 $     
16,278.31  
 $     
16,270.17  
 $     
16,278.31  
 $               
8.14  
transitionDeepBestToFail6 
 $    
16,270.53  
 $    
16,275.24  
 $    
16,270.53  
 $    
16,275.24  
 $               
4.71  
tranistionToDeathMore Obese 
 $    
16,275.22  
 $    
16,270.58  
 $    
16,270.58  
 $    
16,275.22  
 $              
4.64  
transitionDeepRevisionToBestLess Obese 
 $    
16,270.00  
 $    
16,274.44  
 $    
16,270.00  
 $    
16,274.44  
 $              
4.44  
transitionDeepRevisionToBestMorbid Obese 
 $      
16,270.11  
 $    
16,274.38  
 $      
16,270.11  
 $    
16,274.38  
 $              
4.27  
complicationDeepWoundLess Obese 
 $     
16,272.31  
 $    
16,276.47  
 $     
16,272.31  
 $    
16,276.47  
 $               
4.16  
transitionDeepRevisionToBestMore Obese 
 $    
16,270.48  
 $     
16,274.18  
 $    
16,270.48  
 $     
16,274.18  
 $              
3.70  
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complicationVTEMore Obese 
 $     
16,271.44  
 $    
16,274.38  
 $     
16,271.44  
 $    
16,274.38  
 $              
2.94  
costsDeepWound 
 $    
16,272.07  
 $     
16,274.51  
 $    
16,272.07  
 $     
16,274.51  
 $              
2.44  
transitionDeepBestToFail2Less Obese 
 $      
16,271.16  
 $     
16,273.51  
 $      
16,271.16  
 $     
16,273.51  
 $              
2.35  
transitionDeepBestToFail2Morbid Obese 
 $     
16,271.23  
 $    
16,273.49  
 $     
16,271.23  
 $    
16,273.49  
 $              
2.25  
transitionDeepBestToFail7 
 $     
16,271.82  
 $    
16,273.95  
 $     
16,271.82  
 $    
16,273.95  
 $               
2.14  
transitionDeepBestToFail2More Obese 
 $     
16,271.45  
 $     
16,273.41  
 $     
16,271.45  
 $     
16,273.41  
 $               
1.95  
tranistionToDeathLess Obese 
 $    
16,272.00  
 $    
16,273.79  
 $    
16,272.00  
 $    
16,273.79  
 $               
1.79  
transitionDeepBestToFail8 
 $    
16,272.40  
 $    
16,273.37  
 $    
16,272.40  
 $    
16,273.37  
 $              
0.96  
complicationDeepWoundMorbid Obese 
 $    
16,272.69  
 $    
16,273.53  
 $    
16,272.69  
 $    
16,273.53  
 $              
0.85  
transitionDeepBestToFail10 
 $    
16,272.30  
 $    
16,272.98  
 $    
16,272.30  
 $    
16,272.98  
 $              
0.68  
qalyDeepVTEDecrement 
 $    
16,272.83  
 $    
16,273.29  
 $    
16,272.83  
 $    
16,273.29  
 $              
0.47  
complicationDeepWoundMore Obese 
 $    
16,272.74  
 $     
16,273.17  
 $    
16,272.74  
 $     
16,273.17  
 $              
0.43  
transitionDeepBestToFail9 
 $    
16,272.67  
 $     
16,273.10  
 $    
16,272.67  
 $     
16,273.10  
 $              
0.43  
qalyDeepWoundDecrement 
 $    
16,272.86  
 $     
16,273.13  
 $    
16,272.86  
 $     
16,273.13  
 $              
0.26  
complicationDeepVTELess Obese 
 $    
16,272.77  
 $    
16,273.02  
 $    
16,272.77  
 $    
16,273.02  
 $              
0.25  
transitionDeepBestToFail3Less Obese 
 $     
16,272.71  
 $    
16,272.95  
 $     
16,272.71  
 $    
16,272.95  
 $              
0.25  
transitionDeepBestToFail3Morbid Obese 
 $     
16,272.71  
 $    
16,272.95  
 $     
16,272.71  
 $    
16,272.95  
 $              
0.23  
transitionDeepBestToFail3More Obese 
 $    
16,272.74  
 $    
16,272.94  
 $    
16,272.74  
 $    
16,272.94  
 $              
0.20  
complicationDeepVTEMore Obese 
 $    
16,272.85  
 $    
16,272.92  
 $    
16,272.85  
 $    
16,272.92  
 $              
0.08  
transitionDeepBestToFail4Less Obese 
 $    
16,272.87  
 $    
16,272.89  
 $    
16,272.87  
 $    
16,272.89  
 $              
0.03  
transitionDeepBestToFail4Morbid Obese 
 $    
16,272.87  
 $    
16,272.89  
 $    
16,272.87  
 $    
16,272.89  
 $              
0.02  
transitionDeepBestToFail4More Obese 
 $    
16,272.87  
 $    
16,272.89  
 $    
16,272.87  
 $    
16,272.89  
 $              
0.02  
transitionDeepBestToFail5Less Obese 
 $    
16,272.88  
 $    
16,272.89  
 $    
16,272.88  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail5Morbid Obese 
 $    
16,272.88  
 $    
16,272.89  
 $    
16,272.88  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail5More Obese 
 $    
16,272.88  
 $    
16,272.89  
 $    
16,272.88  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail6Less Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail6Morbid Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail6More Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail7Less Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail7Morbid Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail7More Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail8Less Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail8Morbid Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail8More Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail9Less Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail9Morbid Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
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transitionDeepBestToFail9More Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail10Less Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail10Morbid Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionDeepBestToFail10More Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $              
0.00  
transitionOAtoTKA 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionTKAFullToNo1Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionTKAFullToNo2Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionTKAFullToNo3Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionTKAFullToNo4Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionTKAFullToNo5Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionTKAFullToNo6Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionTKAFullToNo7Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionTKAFullToNo8Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionTKAFullToNo9Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionTKAFullToNo10Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionRevisionFullToNo1Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionRevisionFullToNo2Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionRevisionFullToNo3Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionRevisionFullToNo4Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionRevisionFullToNo5Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionRevisionFullToNo6Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionRevisionFullToNo7Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionRevisionFullToNo8Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionRevisionFullToNo9Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionRevisionFullToNo10Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
tranistionToDeath 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
tranistionToDeathNon Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
complicationVTENon Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
complicationWoundNon Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
complicationDeepInfectionNon Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
costTKANon Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
costRevisionNon Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
complicationDeepVTENon Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
complicationDeepWoundNon Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
complicationDeepSubsequentDeepNon Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionDeepBestToFail1Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
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transitionDeepBestToFail2Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionDeepBestToFail3Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionDeepBestToFail4Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionDeepBestToFail5Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionDeepBestToFail6Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionDeepBestToFail7Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionDeepBestToFail8Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionDeepBestToFail9Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
transitionDeepBestToFail10Non Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
costsDeepRevisionNon Obese 
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89  
 $    
16,272.89   $                   -    
 
Table B-2 Full Univariate Sensitivity Analysis Results for Nonobese Population 
Nonobese 
Base  $                                                                              4,932.35  
Parameter Name Low High Min Max Gap 
qalyFull 
 $ 
(17,349.50) 
 $      
1,866.09  
 $ 
100,000.00  
 $     
1,866.09  
 $    
98,133.91  
transitionTKAtoFull  $ 78,887.45  
 $        
855.73  
 $         
855.73   $ 78,887.45  
 $   
78,031.72  
costOATreatment  $ 27,784.77  
 $ 
(40,772.51) 
 $ 
(40,772.51)  $ 27,784.77   $ 68,557.29  
transitionRevisionToFull  $ 66,968.36  
 $      
2,247.12  
 $       
2,247.12   $ 66,968.36  
 $   
64,721.24  
costTKA  $ (7,151.78) 
 $   
29,100.60   $ (7,151.78) 
 $   
29,100.60   $ 36,252.38  
costRevision  $ (3,372.68) 
 $   
21,542.40   $ (3,372.68) 
 $   
21,542.40  
 $   
24,915.08  
complicationDeepInfection  $ (853.20)  $ 20,438.97   $ (853.20)  $ 20,438.97  
 $    
21,292.17  
transitionLateFailureToRevision  $ (433.82) 
 $       
5,156.17  
 $ 
(10,000.00) 
 $      
5,156.17  
 $     
15,156.17  
Age  $ (648.55) 
 $     
11,174.35   $ (648.55) 
 $     
11,174.35  
 $    
11,822.89  
Discount Rate 
 $      
1,084.80  
 $   
10,932.80  
 $       
1,084.80  
 $   
10,932.80  
 $    
9,847.99  
transitionTKAFullToNo10  $ (1,348.06) 
 $     
6,546.84   $ (1,348.06) 
 $    
6,546.84  
 $    
7,894.90  
qalyOA 
 $     
4,778.35  
 $   
12,650.90  
 $      
4,778.35  
 $   
12,650.90  
 $    
7,872.55  
costsDeepContinuingWorst 
 $      
3,184.54  
 $     
8,427.96  
 $       
3,184.54  
 $    
8,427.96  
 $    
5,243.42  
transitionDeepLateToRevision 
 $     
4,932.35  
 $     
9,769.29  
 $      
4,932.35  
 $    
9,769.29  
 $    
4,836.95  
transitionTKAFullToNo1 
 $     
4,658.75  
 $     
8,850.04  
 $      
4,658.75  
 $    
8,850.04  
 $      
4,191.29  
transitionTKAtoFullNon Obese 
 $      
7,680.10  
 $     
3,508.30  
 $      
3,508.30  
 $     
7,680.10  
 $      
4,171.79  
transitionTKAFullToNo2 
 $       
4,414.91  
 $     
8,205.43  
 $        
4,414.91  
 $    
8,205.43  
 $     
3,790.51  
transitionTKAFullToNo3 
 $     
4,369.63  
 $     
7,778.29  
 $      
4,369.63  
 $    
7,778.29  
 $    
3,408.66  
transitionRevisionToFullNon Obese 
 $     
7,276.80  
 $     
3,903.04  
 $      
3,903.04  
 $    
7,276.80  
 $    
3,373.75  
costPostOpTKA 
 $     
3,890.67  
 $      
7,015.69  
 $      
3,890.67  
 $     
7,015.69  
 $     
3,125.02  
transitionTKAFullToNo4 
 $      
4,433.15  
 $     
7,477.94  
 $       
4,433.15  
 $    
7,477.94  
 $    
3,044.79  
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transitionRevisionFullToNo1 
 $     
4,890.03  
 $      
7,831.46  
 $      
4,890.03  
 $     
7,831.46  
 $     
2,941.43  
transitionTKAFullToNo5 
 $     
4,407.25  
 $       
7,110.95  
 $      
4,407.25  
 $      
7,110.95  
 $    
2,703.70  
transitionRevisionFullToNo2 
 $     
4,888.64  
 $     
7,365.59  
 $      
4,888.64  
 $    
7,365.59  
 $    
2,476.95  
transitionTKAFullToNo6 
 $     
4,376.40  
 $     
6,759.69  
 $      
4,376.40  
 $    
6,759.69  
 $    
2,383.29  
costsDeepRevision 
 $      
4,146.00  
 $     
6,505.04  
 $       
4,146.00  
 $    
6,505.04  
 $    
2,359.04  
qalyDecTKA 
 $     
4,373.39  
 $     
6,536.43  
 $      
4,373.39  
 $    
6,536.43  
 $     
2,163.04  
costFailure 
 $      
4,221.33  
 $     
6,354.38  
 $       
4,221.33  
 $    
6,354.38  
 $     
2,133.06  
transitionTKAFullToNo7 
 $       
4,143.14  
 $     
6,236.07  
 $        
4,143.14  
 $    
6,236.07  
 $    
2,092.93  
transitionRevisionFullToNo3 
 $     
4,840.39  
 $      
6,912.54  
 $      
4,840.39  
 $     
6,912.54  
 $     
2,072.15  
transitionRevisionFullToNo10 
 $     
4,070.67  
 $     
5,925.78  
 $      
4,070.67  
 $    
5,925.78  
 $       
1,855.11  
transitionTKAFullToNo8 
 $     
3,927.38  
 $     
5,753.76  
 $      
3,927.38  
 $    
5,753.76  
 $     
1,826.38  
qalyDecRevision 
 $     
4,708.09  
 $     
6,474.42  
 $      
4,708.09  
 $    
6,474.42  
 $     
1,766.33  
transitionRevisionFullToNo4 
 $       
4,816.01  
 $      
6,542.12  
 $        
4,816.01  
 $     
6,542.12  
 $       
1,726.11  
transitionTKAFullToNo9 
 $      
3,671.08  
 $     
5,259.40  
 $       
3,671.08  
 $    
5,259.40  
 $     
1,588.32  
transitionRevisionFullToNo5 
 $     
4,834.42  
 $       
6,263.11  
 $      
4,834.42  
 $      
6,263.11  
 $     
1,428.68  
costDeepInfection 
 $     
4,478.79  
 $     
5,839.46  
 $      
4,478.79  
 $    
5,839.46  
 $     
1,360.67  
transitionRevisionFullToNo6 
 $     
4,838.93  
 $      
6,012.69  
 $      
4,838.93  
 $     
6,012.69  
 $      
1,173.76  
transitionRevisionFullToNo7 
 $     
4,840.47  
 $     
5,796.66  
 $      
4,840.47  
 $    
5,796.66  
 $         
956.19  
complicationWound 
 $      
4,884.01  
 $      
5,777.13  
 $       
4,884.01  
 $     
5,777.13  
 $          
893.11  
transitionDeepEarlyToRevision 
 $     
4,932.35  
 $     
5,768.37  
 $      
4,932.35  
 $    
5,768.37  
 $        
836.03  
transitionRevisionFullToNo8 
 $      
4,854.91  
 $     
5,624.62  
 $       
4,854.91  
 $    
5,624.62  
 $         
769.71  
qalyFailed 
 $     
5,343.36  
 $     
4,668.94  
 $      
4,668.94  
 $    
5,343.36  
 $        
674.42  
transitionRevisionFullToNo9 
 $     
4,792.98  
 $      
5,414.55  
 $      
4,792.98  
 $     
5,414.55  
 $         
621.56  
complicationVTE 
 $      
4,751.36  
 $     
5,283.94  
 $       
4,751.36  
 $    
5,283.94  
 $        
532.58  
complicationDeepVTE 
 $      
4,930.31  
 $     
5,359.36  
 $       
4,930.31  
 $    
5,359.36  
 $        
429.05  
transitionDeepBestToFail1 
 $      
4,778.41  
 $     
5,086.49  
 $       
4,778.41  
 $    
5,086.49  
 $        
308.08  
transitionDeepRevisionToBest 
 $     
5,090.46  
 $     
4,797.28  
 $      
4,797.28  
 $    
5,090.46  
 $         
293.18  
qalyDeepWorstDecrement 
 $     
5,079.25  
 $     
4,793.70  
 $      
4,793.70  
 $    
5,079.25  
 $        
285.54  
costVTE 
 $      
4,842.14  
 $       
5,112.77  
 $       
4,842.14  
 $      
5,112.77  
 $        
270.63  
tranistionEarlyFailureToRevision 
 $      
5,104.08  
 $     
4,932.35  
 $      
4,932.35  
 $     
5,104.08  
 $          
171.73  
costsDeepSubsequentDeep 
 $      
4,881.45  
 $      
5,034.13  
 $       
4,881.45  
 $     
5,034.13  
 $         
152.68  
transitionDeepBestToFail2 
 $      
4,861.03  
 $      
5,003.71  
 $       
4,861.03  
 $     
5,003.71  
 $         
142.68  
costWound 
 $     
4,908.28  
 $     
4,980.47  
 $      
4,908.28  
 $    
4,980.47  
 $           
72.19  
costsDeepContinuingBest 
 $     
4,909.75  
 $     
4,977.53  
 $      
4,909.75  
 $    
4,977.53  
 $          
67.78  
transitionDeepBestToFail3 
 $     
4,899.42  
 $     
4,965.28  
 $      
4,899.42  
 $    
4,965.28  
 $          
65.86  
qalyDecDeepInfection 
 $      
4,921.58  
 $      
4,984.61  
 $       
4,921.58  
 $     
4,984.61  
 $          
63.03  
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qalyDeepRevisionDecrement 
 $     
4,922.03  
 $     
4,984.60  
 $      
4,922.03  
 $    
4,984.60  
 $          
62.57  
complicationDeepSubsequentDeep 
 $     
4,909.33  
 $     
4,955.36  
 $      
4,909.33  
 $    
4,955.36  
 $          
46.03  
qalyDeepBestCase 
 $      
4,948.71  
 $      
4,916.09  
 $       
4,916.09  
 $     
4,948.71  
 $          
32.62  
transitionDeepRevisionToBestNon Obese 
 $     
4,952.93  
 $      
4,921.28  
 $       
4,921.28  
 $    
4,952.93  
 $           
31.65  
transitionDeepBestToFail4 
 $      
4,917.20  
 $     
4,947.49  
 $       
4,917.20  
 $    
4,947.49  
 $          
30.28  
transitionDeepBestToFail5 
 $      
4,925.41  
 $     
4,939.28  
 $       
4,925.41  
 $    
4,939.28  
 $           
13.87  
complicationDeepWound 
 $      
4,931.80  
 $      
4,941.82  
 $       
4,931.80  
 $     
4,941.82  
 $            
10.01  
qalyDeepSubsequentDeepDecrement 
 $       
4,931.13  
 $      
4,938.16  
 $        
4,931.13  
 $     
4,938.16  
 $             
7.02  
transitionDeepBestToFail6 
 $      
4,929.19  
 $      
4,935.51  
 $       
4,929.19  
 $     
4,935.51  
 $             
6.32  
qalyDecVTE 
 $      
4,931.76  
 $     
4,936.47  
 $       
4,931.76  
 $    
4,936.47  
 $             
4.70  
costsDeepVTE 
 $      
4,931.33  
 $     
4,934.37  
 $       
4,931.33  
 $    
4,934.37  
 $             
3.04  
transitionDeepBestToFail7 
 $      
4,930.91  
 $     
4,933.78  
 $       
4,930.91  
 $    
4,933.78  
 $             
2.87  
qalyDecWound 
 $      
4,932.14  
 $     
4,934.50  
 $       
4,932.14  
 $    
4,934.50  
 $             
2.36  
transitionDeepBestToFail8 
 $      
4,931.70  
 $     
4,932.99  
 $       
4,931.70  
 $    
4,932.99  
 $              
1.29  
transitionDeepBestToFail10 
 $      
4,931.57  
 $     
4,932.47  
 $       
4,931.57  
 $    
4,932.47  
 $              
0.91  
costsDeepWound 
 $     
4,932.08  
 $     
4,932.89  
 $      
4,932.08  
 $    
4,932.89  
 $              
0.81  
transitionDeepBestToFail9 
 $     
4,932.06  
 $     
4,932.64  
 $      
4,932.06  
 $    
4,932.64  
 $             
0.58  
qalyDeepVTEDecrement 
 $     
4,932.34  
 $     
4,932.39  
 $      
4,932.34  
 $    
4,932.39  
 $             
0.05  
qalyDeepWoundDecrement 
 $     
4,932.34  
 $     
4,932.37  
 $      
4,932.34  
 $    
4,932.37  
 $             
0.03  
transitionOAtoTKA 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAtoFullLess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAtoFullMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAtoFullMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo1Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo1Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo1More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo1Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo2Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo2Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo2More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo2Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo3Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo3Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo3More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo3Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo4Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
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transitionTKAFullToNo4Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo4More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo4Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo5Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo5Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo5More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo5Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo6Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo6Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo6More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo6Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo7Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo7Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo7More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo7Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo8Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo8Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo8More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo8Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo9Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo9Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo9More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo9Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo10Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo10Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo10More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionTKAFullToNo10Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionToFullLess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionToFullMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionToFullMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo1Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo1Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo1More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo1Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo2Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo2Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
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transitionRevisionFullToNo2More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo2Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo3Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo3Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo3More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo3Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo4Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo4Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo4More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo4Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo5Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo5Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo5More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo5Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo6Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo6Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo6More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo6Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo7Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo7Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo7More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo7Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo8Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo8Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo8More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo8Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo9Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo9Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo9More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo9Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo10Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo10Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo10More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionRevisionFullToNo10Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
tranistionToDeath 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
tranistionToDeathNon Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
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tranistionToDeathLess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
tranistionToDeathMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
tranistionToDeathMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationVTENon Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationVTELess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationVTEMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationVTEMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationWoundNon Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationWoundLess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationWoundMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationWoundMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepInfectionNon Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepInfectionLess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepInfectionMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepInfectionMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costTKANon Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costTKALess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costTKAMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costTKAMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costRevisionNon Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costRevisionLess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costRevisionMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costRevisionMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
qalyDecObesity 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepVTENon Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepVTELess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepVTEMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepVTEMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepWoundNon Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepWoundLess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepWoundMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepWoundMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepSubsequentDeepNon Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepSubsequentDeepLess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepSubsequentDeepMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
complicationDeepSubsequentDeepMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
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transitionDeepRevisionToBestLess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepRevisionToBestMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepRevisionToBestMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail1Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail1Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail1More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail1Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail2Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail2Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail2More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail2Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail3Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail3Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail3More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail3Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail4Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail4Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail4More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail4Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail5Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail5Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail5More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail5Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail6Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail6Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail6More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail6Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail7Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail7Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail7More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail7Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail8Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail8Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail8More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail8Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail9Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
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transitionDeepBestToFail9Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail9More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail9Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail10Non Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail10Less Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail10More Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
transitionDeepBestToFail10Morbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costsDeepRevisionNon Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costsDeepRevisionLess Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costsDeepRevisionMore Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
costsDeepRevisionMorbid Obese 
 $     
4,932.35  
 $     
4,932.35  
 $      
4,932.35  
 $    
4,932.35  
 $                  
-    
 
Table B-3 Full Univariate Sensitivity Analysis Results for Class I Obese Population 
Class I Obesity 
Base  $                                                                                   33,891.07  
Parameter Name Low High Min Max Gap 
qalyFull 
 $ 
(67,282.49) 
 $          
11,591.18  
 $ 
550,000.00  
 $       
11,591.18   $ 538,408.82  
complicationDeepInfectionLess Obese 
 $    
21,258.22   $ (373,698.53) 
 $ 
500,000.00  
 $    
21,258.22  
 $   
478,741.78  
transitionRevisionToFull 
 $ 
453,601.46   $      23,330.37  
 $    
23,330.37  
 $ 
453,601.46  
 $   
430,271.09  
transitionTKAtoFull 
 $   
201,993.13  
 $       
24,351.88  
 $     
24,351.88  
 $   
201,993.13  
 $    
177,641.25  
qalyOA 
 $    
31,929.87  
 $    
129,377.64  
 $     
31,929.87  
 $ 
129,377.64  
 $    
97,447.78  
costOATreatment 
 $     
61,845.91   $ (22,018.60) 
 $ 
(22,018.60) 
 $     
61,845.91  
 $     
83,864.51  
costRevision 
 $    
13,263.46  
 $       
75,146.29  
 $     
13,263.46  
 $    
75,146.29  
 $     
61,882.82  
complicationDeepInfection 
 $   
20,546.95   $      75,606.00  
 $    
20,546.95  
 $   
75,606.00  
 $    
55,059.05  
qalyDecRevision 
 $   
30,399.38  
 $       
79,621.50  
 $    
30,399.38  
 $    
79,621.50  
 $      
49,222.11  
costTKA 
 $     
18,571.87   $      64,529.48  
 $      
18,571.87  
 $   
64,529.48  
 $     
45,957.61  
transitionRevisionToFullLess Obese 
 $    
23,137.09   $      43,403.09  
 $     
23,137.09  
 $   
43,403.09  
 $    
20,266.00  
qalyDecTKA 
 $   
29,284.48   $      48,557.58  
 $    
29,284.48  
 $   
48,557.58  
 $      
19,273.10  
transitionRevisionFullToNo1 
 $    
33,676.71  
 $       
51,458.79  
 $     
33,676.71  
 $    
51,458.79  
 $     
17,782.08  
transitionTKAFullToNo10 
 $   
20,490.38  
 $       
36,869.51  
 $    
20,490.38  
 $    
36,869.51  
 $      
16,379.13  
transitionRevisionFullToNo2 
 $     
33,672.11   $      47,953.55  
 $      
33,672.11  
 $   
47,953.55  
 $      
14,281.44  
transitionTKAtoFullLess Obese 
 $   
25,009.28  
 $       
39,165.54  
 $    
25,009.28  
 $    
39,165.54  
 $      
14,156.27  
transitionDeepLateToRevision 
 $    
33,891.07  
 $       
47,915.03  
 $     
33,891.07  
 $    
47,915.03  
 $     
14,023.95  
Age 
 $   
28,249.08  
 $       
41,722.69  
 $    
28,249.08  
 $    
41,722.69  
 $      
13,473.61  
Discount Rate 
 $    
28,981.32  
 $       
41,965.20  
 $     
28,981.32  
 $    
41,965.20  
 $     
12,983.88  
transitionTKAFullToNo1 
 $   
33,094.28   $      45,837.86  
 $    
33,094.28  
 $   
45,837.86  
 $     
12,743.59  
  
150 
qalyFailed 
 $    
41,765.56   $      29,773.89  
 $    
29,773.89  
 $    
41,765.56  
 $       
11,991.66  
transitionRevisionFullToNo3 
 $   
33,436.03   $      44,862.82  
 $    
33,436.03  
 $   
44,862.82  
 $      
11,426.79  
transitionTKAFullToNo2 
 $    
32,415.29  
 $       
43,607.91  
 $     
32,415.29  
 $    
43,607.91  
 $       
11,192.63  
costsDeepContinuingWorst 
 $    
30,414.40  
 $       
40,844.41  
 $     
30,414.40  
 $    
40,844.41  
 $      
10,430.01  
transitionTKAFullToNo3 
 $   
32,323.52   $      42,096.70  
 $    
32,323.52  
 $   
42,096.70  
 $        
9,773.17  
transitionRevisionFullToNo4 
 $    
33,323.19   $      42,476.05  
 $     
33,323.19  
 $   
42,476.05  
 $        
9,152.86  
transitionTKAFullToNo10Less Obese 
 $   
30,003.54   $      38,786.33  
 $    
30,003.54  
 $   
38,786.33  
 $       
8,782.79  
transitionTKAFullToNo4 
 $   
32,537.37   $      40,998.50  
 $    
32,537.37  
 $   
40,998.50  
 $         
8,461.13  
transitionRevisionFullToNo5 
 $   
33,420.95   $      40,728.03  
 $    
33,420.95  
 $   
40,728.03  
 $       
7,307.08  
transitionTKAFullToNo5 
 $   
32,508.08  
 $       
39,771.20  
 $    
32,508.08  
 $    
39,771.20  
 $        
7,263.12  
transitionRevisionFullToNo10 
 $    
30,187.06   $      37,236.24  
 $     
30,187.06  
 $   
37,236.24  
 $        
7,049.19  
transitionTKAFullToNo6 
 $   
32,473.94   $      38,644.24  
 $    
32,473.94  
 $   
38,644.24  
 $        
6,170.30  
transitionRevisionFullToNo6 
 $     
33,451.01   $      39,246.73  
 $      
33,451.01  
 $   
39,246.73  
 $       
5,795.72  
transitionTKAFullToNo7 
 $    
31,943.88  
 $        
37,161.73  
 $     
31,943.88  
 $     
37,161.73  
 $        
5,217.85  
complicationWound 
 $    
33,616.20  
 $       
38,712.40  
 $     
33,616.20  
 $    
38,712.40  
 $       
5,096.20  
complicationDeepSubsequentDeepLess Obese 
 $    
33,620.01  
 $       
38,604.61  
 $     
33,620.01  
 $    
38,604.61  
 $       
4,984.59  
costsDeepRevision 
 $   
32,270.00  
 $        
37,133.21  
 $    
32,270.00  
 $     
37,133.21  
 $        
4,863.21  
transitionRevisionFullToNo7 
 $    
33,467.81   $      38,024.96  
 $     
33,467.81  
 $   
38,024.96  
 $        
4,557.14  
transitionTKAFullToNo8 
 $    
31,495.80   $      35,875.55  
 $     
31,495.80  
 $   
35,875.55  
 $       
4,379.75  
qalyDeepWorstDecrement 
 $   
35,988.36   $      32,024.77  
 $    
32,024.77  
 $   
35,988.36  
 $       
3,963.58  
costFailure 
 $   
32,584.93   $      36,503.36  
 $    
32,584.93  
 $   
36,503.36  
 $        
3,918.44  
transitionTKAFullToNo9 
 $    
30,981.08   $      34,654.00  
 $     
30,981.08  
 $   
34,654.00  
 $       
3,672.92  
transitionLateFailureToRevision 
 $   
36,584.39   $      32,972.64  
 $    
32,972.64  
 $   
36,584.39  
 $         
3,611.75  
costPostOpTKA 
 $   
32,690.95  
 $       
36,291.32  
 $    
32,690.95  
 $    
36,291.32  
 $       
3,600.37  
transitionRevisionFullToNo8 
 $   
33,544.44   $      37,073.38  
 $    
33,544.44  
 $   
37,073.38  
 $       
3,528.94  
tranistionEarlyFailureToRevision 
 $    
37,260.51  
 $       
33,891.07  
 $     
33,891.07  
 $    
37,260.51  
 $       
3,369.44  
transitionDeepEarlyToRevision 
 $    
33,891.07  
 $       
36,985.31  
 $     
33,891.07  
 $    
36,985.31  
 $       
3,094.23  
transitionRevisionFullToNo9 
 $   
33,280.94   $      36,042.84  
 $    
33,280.94  
 $   
36,042.84  
 $        
2,761.90  
costDeepInfection 
 $   
32,983.29   $      35,706.64  
 $    
32,983.29  
 $   
35,706.64  
 $       
2,723.35  
transitionTKAFullToNo9Less Obese 
 $   
32,859.65   $      35,575.69  
 $    
32,859.65  
 $   
35,575.69  
 $        
2,716.03  
transitionRevisionFullToNo10Less Obese 
 $     
32,811.20  
 $       
35,197.72  
 $      
32,811.20  
 $    
35,197.72  
 $        
2,386.51  
transitionTKAFullToNo8Less Obese 
 $   
33,043.89   $      35,270.52  
 $    
33,043.89  
 $   
35,270.52  
 $       
2,226.63  
transitionTKAFullToNo7Less Obese 
 $   
33,203.65   $      35,007.43  
 $    
33,203.65  
 $   
35,007.43  
 $        
1,803.78  
complicationWoundLess Obese 
 $    
33,660.18  
 $       
35,335.61  
 $     
33,660.18  
 $    
35,335.61  
 $        
1,675.43  
transitionTKAFullToNo3Less Obese 
 $   
33,338.53   $      34,786.40  
 $    
33,338.53  
 $   
34,786.40  
 $        
1,447.87  
transitionTKAFullToNo2Less Obese 
 $    
33,371.07   $      34,733.22  
 $     
33,371.07  
 $   
34,733.22  
 $         
1,362.15  
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transitionTKAFullToNo6Less Obese 
 $    
33,391.87   $      34,699.23  
 $     
33,391.87  
 $   
34,699.23  
 $        
1,307.36  
transitionTKAFullToNo5Less Obese 
 $   
33,403.96   $      34,679.50  
 $    
33,403.96  
 $   
34,679.50  
 $        
1,275.54  
transitionTKAFullToNo4Less Obese 
 $    
33,414.34   $      34,662.58  
 $     
33,414.34  
 $   
34,662.58  
 $        
1,248.25  
costRevisionLess Obese 
 $   
33,490.54  
 $       
34,692.14  
 $    
33,490.54  
 $    
34,692.14  
 $          
1,201.61  
complicationDeepVTE 
 $    
33,886.10   $      34,936.85  
 $     
33,886.10  
 $   
34,936.85  
 $        
1,050.75  
complicationVTE 
 $   
33,552.02   $      34,549.94  
 $    
33,552.02  
 $   
34,549.94  
 $          
997.93  
costTKALess Obese 
 $    
33,593.61   $      34,485.99  
 $     
33,593.61  
 $   
34,485.99  
 $          
892.38  
qalyDecDeepInfection 
 $   
33,743.30  
 $       
34,617.55  
 $    
33,743.30  
 $    
34,617.55  
 $          
874.25  
qalyDeepRevisionDecrement 
 $   
33,749.47  
 $       
34,617.36  
 $    
33,749.47  
 $    
34,617.36  
 $          
867.89  
transitionTKAFullToNo1Less Obese 
 $      
33,611.10   $      34,342.67  
 $       
33,611.10  
 $   
34,342.67  
 $           
731.57  
transitionRevisionFullToNo9Less Obese 
 $   
33,674.80  
 $       
34,221.57  
 $    
33,674.80  
 $    
34,221.57  
 $          
546.77  
transitionRevisionFullToNo4Less Obese 
 $   
33,689.34   $      34,200.28  
 $    
33,689.34  
 $   
34,200.28  
 $           
510.94  
costVTE 
 $    
33,725.18   $      34,222.85  
 $     
33,725.18  
 $   
34,222.85  
 $          
497.66  
transitionRevisionFullToNo5Less Obese 
 $   
33,724.34  
 $       
34,146.08  
 $    
33,724.34  
 $    
34,146.08  
 $           
421.74  
transitionRevisionFullToNo3Less Obese 
 $   
33,729.64  
 $       
34,138.06  
 $    
33,729.64  
 $    
34,138.06  
 $           
408.41  
costWound 
 $   
33,757.54  
 $        
34,158.14  
 $    
33,757.54  
 $     
34,158.14  
 $          
400.60  
costsDeepSubsequentDeep 
 $   
33,757.97  
 $       
34,157.26  
 $    
33,757.97  
 $    
34,157.26  
 $          
399.29  
transitionRevisionFullToNo6Less Obese 
 $     
33,735.11  
 $       
34,129.37  
 $      
33,735.11  
 $    
34,129.37  
 $          
394.26  
transitionRevisionFullToNo7Less Obese 
 $     
33,741.15  
 $        
34,119.94  
 $      
33,741.15  
 $     
34,119.94  
 $          
378.79  
transitionDeepBestToFail1 
 $   
33,599.90  
 $       
33,928.41  
 $    
33,599.90  
 $    
33,928.41  
 $           
328.51  
transitionRevisionFullToNo8Less Obese 
 $   
33,768.44   $      34,077.96  
 $    
33,768.44  
 $   
34,077.96  
 $          
309.52  
qalyDeepBestCase 
 $    
33,998.01   $      33,784.80  
 $    
33,784.80  
 $    
33,998.01  
 $            
213.21  
transitionRevisionFullToNo2Less Obese 
 $    
33,813.64  
 $       
34,009.01  
 $     
33,813.64  
 $    
34,009.01  
 $           
195.37  
transitionRevisionFullToNo1Less Obese 
 $    
33,815.27   $      34,006.53  
 $     
33,815.27  
 $   
34,006.53  
 $            
191.26  
transitionDeepRevisionToBest 
 $   
33,970.50  
 $        
33,811.86  
 $      
33,811.86  
 $   
33,970.50  
 $           
158.65  
transitionDeepBestToFail1Less Obese 
 $   
33,788.35  
 $       
33,928.41  
 $    
33,788.35  
 $    
33,928.41  
 $           
140.06  
complicationDeepSubsequentDeep 
 $   
33,826.74   $      33,955.42  
 $    
33,826.74  
 $   
33,955.42  
 $           
128.69  
qalyDeepSubsequentDeepDecrement 
 $    
33,869.31   $      33,995.67  
 $     
33,869.31  
 $   
33,995.67  
 $           
126.36  
complicationVTELess Obese 
 $   
33,844.46  
 $        
33,945.11  
 $    
33,844.46  
 $     
33,945.11  
 $           
100.64  
costsDeepRevisionLess Obese 
 $   
33,859.59   $      33,954.03  
 $    
33,859.59  
 $   
33,954.03  
 $             
94.43  
qalyDecWound 
 $   
33,883.20   $      33,973.35  
 $    
33,883.20  
 $   
33,973.35  
 $              
90.15  
tranistionToDeathLess Obese 
 $    
33,848.18   $      33,934.23  
 $     
33,848.18  
 $   
33,934.23  
 $             
86.05  
qalyDecObesity 
 $   
33,928.73   $      33,854.25  
 $    
33,854.25  
 $   
33,928.73  
 $             
74.48  
complicationDeepWound 
 $   
33,887.04  
 $       
33,961.48  
 $    
33,887.04  
 $    
33,961.48  
 $             
74.44  
qalyDecVTE 
 $   
33,883.72  
 $       
33,943.17  
 $    
33,883.72  
 $    
33,943.17  
 $             
59.45  
transitionDeepRevisionToBestLess Obese 
 $    
33,866.81  
 $       
33,904.13  
 $     
33,866.81  
 $    
33,904.13  
 $             
37.32  
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transitionDeepBestToFail2 
 $   
33,860.56   $      33,894.98  
 $    
33,860.56  
 $   
33,894.98  
 $             
34.42  
complicationDeepWoundLess Obese 
 $   
33,887.69  
 $       
33,912.23  
 $    
33,887.69  
 $    
33,912.23  
 $             
24.54  
transitionDeepBestToFail2Less Obese 
 $    
33,880.31   $      33,894.98  
 $     
33,880.31  
 $   
33,894.98  
 $              
14.67  
costsDeepContinuingBest 
 $    
33,886.21   $      33,900.79  
 $     
33,886.21  
 $   
33,900.79  
 $              
14.58  
costsDeepVTE 
 $   
33,888.64   $      33,895.94  
 $    
33,888.64  
 $   
33,895.94  
 $               
7.30  
costsDeepWound 
 $     
33,889.11   $      33,894.99  
 $      
33,889.11  
 $   
33,894.99  
 $               
5.87  
transitionDeepBestToFail3 
 $   
33,887.89  
 $       
33,891.48  
 $    
33,887.89  
 $    
33,891.48  
 $               
3.59  
transitionDeepBestToFail3Less Obese 
 $   
33,889.95  
 $       
33,891.48  
 $    
33,889.95  
 $    
33,891.48  
 $                
1.53  
complicationDeepVTELess Obese 
 $   
33,890.39  
 $       
33,891.86  
 $    
33,890.39  
 $    
33,891.86  
 $                
1.48  
qalyDeepWoundDecrement 
 $   
33,890.96   $      33,892.27  
 $    
33,890.96  
 $   
33,892.27  
 $                
1.32  
qalyDeepVTEDecrement 
 $   
33,890.96  
 $       
33,891.83  
 $    
33,890.96  
 $    
33,891.83  
 $               
0.87  
transitionDeepBestToFail4 
 $   
33,890.74  
 $         
33,891.11  
 $    
33,890.74  
 $      
33,891.11  
 $               
0.37  
transitionDeepBestToFail4Less Obese 
 $   
33,890.95  
 $         
33,891.11  
 $    
33,890.95  
 $      
33,891.11  
 $                
0.16  
transitionDeepBestToFail5 
 $    
33,891.04  
 $       
33,891.08  
 $     
33,891.04  
 $    
33,891.08  
 $               
0.04  
transitionDeepBestToFail5Less Obese 
 $    
33,891.06  
 $       
33,891.08  
 $     
33,891.06  
 $    
33,891.08  
 $               
0.02  
transitionDeepBestToFail6 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07  
 $               
0.00  
transitionDeepBestToFail6Less Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07  
 $               
0.00  
transitionDeepBestToFail7 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07  
 $               
0.00  
transitionDeepBestToFail7Less Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07  
 $               
0.00  
transitionDeepBestToFail8 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07  
 $               
0.00  
transitionDeepBestToFail8Less Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07  
 $               
0.00  
transitionDeepBestToFail9 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07  
 $               
0.00  
transitionDeepBestToFail10 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07  
 $               
0.00  
transitionDeepBestToFail9Less Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07  
 $               
0.00  
transitionDeepBestToFail10Less Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07  
 $               
0.00  
transitionOAtoTKA 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAtoFullNon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAtoFullMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAtoFullMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo1Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo1More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo1Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo2Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo2More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo2Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo3Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
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transitionTKAFullToNo3More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo3Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo4Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo4More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo4Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo5Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo5More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo5Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo6Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo6More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo6Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo7Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo7More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo7Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo8Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo8More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo8Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo9Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo9More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo9Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo10Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo10More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionTKAFullToNo10Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionToFullNon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionToFullMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionToFullMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo1Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo1More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo1Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo2Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo2More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo2Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo3Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo3More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo3Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo4Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
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transitionRevisionFullToNo4More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo4Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo5Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo5More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo5Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo6Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo6More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo6Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo7Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo7More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo7Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo8Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo8More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo8Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo9Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo9More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo9Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo10Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo10More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionRevisionFullToNo10Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
tranistionToDeath 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
tranistionToDeathNon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
tranistionToDeathMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
tranistionToDeathMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationVTENon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationVTEMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationVTEMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationWoundNon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationWoundMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationWoundMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepInfectionNon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepInfectionMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepInfectionMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
costTKANon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
costTKAMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
costTKAMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
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costRevisionNon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
costRevisionMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
costRevisionMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepVTENon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepVTEMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepVTEMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepWoundNon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepWoundMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepWoundMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepSubsequentDeepNon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepSubsequentDeepMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
complicationDeepSubsequentDeepMorbid 
Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepRevisionToBestNon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepRevisionToBestMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepRevisionToBestMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail1Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail1More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail1Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail2Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail2More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail2Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail3Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail3More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail3Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail4Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail4More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail4Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail5Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail5More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail5Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail6Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail6More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail6Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail7Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail7More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail7Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
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transitionDeepBestToFail8Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail8More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail8Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail9Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail9More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail9Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail10Non Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail10More Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
transitionDeepBestToFail10Morbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
costsDeepRevisionNon Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
costsDeepRevisionMore Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
costsDeepRevisionMorbid Obese 
 $    
33,891.07  
 $       
33,891.07  
 $     
33,891.07  
 $    
33,891.07   $                    -    
 
Table B-4 Full Univariate Sensitivity Analysis Results for Class II Obese Population 
Class II Obesity 
Base  $                                                                                  46,378.84  
Parameter Name Low High Min Max Gap 
qalyFull 
 $ 
(76,711.56) 
 $      
15,191.59  
 $ 
750,000.00  
 $       
15,191.59  
 $   
734,808.41  
transitionRevisionToFull 
 $ 
698,500.30  
 $   
33,560.76  
 $    
33,560.76   $ 698,500.30   $ 664,939.53  
transitionTKAtoFull 
 $    
305,261.61  
 $   
34,508.85  
 $    
34,508.85  
 $    
305,261.61   $ 270,752.77  
qalyOA 
 $      
41,521.07  
 $ 
288,083.10  
 $      
41,521.07  
 $   
288,083.10   $ 246,562.04  
complicationDeepInfectionMore Obese 
 $    
26,346.74  
 $   
243,132.13  
 $    
26,346.74  
 $    
243,132.13  
 $   
216,785.39  
complicationDeepInfection 
 $     
20,613.69  
 $    
161,751.67  
 $     
20,613.69  
 $     
161,751.67  
 $     
141,137.97  
costOATreatment 
 $    
76,709.77  
 $ 
(14,283.01) 
 $ 
(14,283.01) 
 $    
76,709.77  
 $    
90,992.78  
qalyDecRevision 
 $      
41,321.65  
 $   
119,526.47  
 $      
41,321.65  
 $    
119,526.47  
 $    
78,204.82  
costRevision 
 $    
24,399.73  
 $   
90,337.07  
 $    
24,399.73  
 $    
90,337.07  
 $    
65,937.33  
costTKA 
 $    
29,789.62  
 $   
79,557.28  
 $    
29,789.62  
 $    
79,557.28  
 $    
49,767.66  
transitionDeepLateToRevision 
 $    
46,378.84  
 $    
76,346.31  
 $    
46,378.84  
 $     
76,346.31  
 $    
29,967.47  
qalyDecTKA 
 $    
39,628.32  
 $   
68,922.20  
 $    
39,628.32  
 $    
68,922.20  
 $    
29,293.88  
transitionRevisionToFullMore Obese 
 $    
33,327.40  
 $   
58,039.07  
 $    
33,327.40  
 $    
58,039.07  
 $      
24,711.67  
transitionRevisionFullToNo1 
 $     
46,120.09  
 $   
67,755.64  
 $     
46,120.09  
 $    
67,755.64  
 $     
21,635.55  
costsDeepContinuingWorst 
 $    
39,753.70  
 $    
59,629.12  
 $    
39,753.70  
 $     
59,629.12  
 $     
19,875.42  
transitionTKAFullToNo10 
 $     
30,190.08  
 $   
50,027.86  
 $     
30,190.08  
 $    
50,027.86  
 $     
19,837.78  
transitionTKAtoFullMore Obese 
 $     
35,319.02  
 $   
53,048.87  
 $     
35,319.02  
 $    
53,048.87  
 $     
17,729.85  
qalyFailed 
 $     
58,031.48  
 $   
40,425.32  
 $    
40,425.32  
 $     
58,031.48  
 $      
17,606.16  
transitionRevisionFullToNo2 
 $      
46,114.72  
 $    
63,451.36  
 $      
46,114.72  
 $     
63,451.36  
 $     
17,336.64  
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transitionTKAFullToNo1 
 $     
45,389.13  
 $     
61,410.69  
 $     
45,389.13  
 $      
61,410.69  
 $      
16,021.56  
Discount Rate 
 $    
40,702.46  
 $    
55,880.17  
 $    
40,702.46  
 $     
55,880.17  
 $       
15,177.71  
transitionLateFailureToRevision 
 $    
58,972.85  
 $    
44,691.09  
 $     
44,691.09  
 $    
58,972.85  
 $      
14,281.77  
Age 
 $     
41,042.30  
 $   
55,297.29  
 $     
41,042.30  
 $    
55,297.29  
 $     
14,254.99  
transitionTKAFullToNo2 
 $    
44,549.63  
 $   
58,557.38  
 $    
44,549.63  
 $    
58,557.38  
 $     
14,007.75  
transitionRevisionFullToNo3 
 $    
45,830.34  
 $    
59,672.16  
 $    
45,830.34  
 $     
59,672.16  
 $      
13,841.82  
transitionTKAFullToNo3 
 $     
44,438.91  
 $     
56,631.10  
 $     
44,438.91  
 $      
56,631.10  
 $       
12,192.19  
transitionRevisionFullToNo4 
 $    
45,694.78  
 $    
56,763.14  
 $    
45,694.78  
 $     
56,763.14  
 $      
11,068.36  
transitionTKAFullToNo10More Obese 
 $     
41,644.77  
 $    
52,386.71  
 $     
41,644.77  
 $     
52,386.71  
 $      
10,741.94  
transitionTKAFullToNo4 
 $     
44,705.71  
 $   
55,234.96  
 $     
44,705.71  
 $    
55,234.96  
 $     
10,529.25  
qalyDeepWorstDecrement 
 $       
52,171.10  
 $    
41,744.22  
 $     
41,744.22  
 $       
52,171.10  
 $     
10,426.88  
costsDeepRevision 
 $     
43,301.72  
 $   
52,533.09  
 $     
43,301.72  
 $    
52,533.09  
 $        
9,231.37  
transitionTKAFullToNo5 
 $     
44,672.15  
 $    
53,685.01  
 $     
44,672.15  
 $     
53,685.01  
 $        
9,012.86  
transitionRevisionFullToNo5 
 $     
45,812.87  
 $   
54,637.70  
 $     
45,812.87  
 $    
54,637.70  
 $       
8,824.82  
transitionRevisionFullToNo10 
 $     
41,946.72  
 $    
50,401.24  
 $     
41,946.72  
 $     
50,401.24  
 $       
8,454.52  
transitionTKAFullToNo6 
 $    
44,632.79  
 $   
52,268.64  
 $    
44,632.79  
 $    
52,268.64  
 $       
7,635.85  
transitionRevisionFullToNo6 
 $    
45,849.37  
 $   
52,840.53  
 $    
45,849.37  
 $    
52,840.53  
 $         
6,991.16  
transitionDeepEarlyToRevision 
 $    
46,378.84  
 $   
52,864.26  
 $    
46,378.84  
 $    
52,864.26  
 $       
6,485.42  
transitionTKAFullToNo7 
 $    
43,984.69  
 $    
50,419.24  
 $    
43,984.69  
 $     
50,419.24  
 $       
6,434.56  
transitionRevisionFullToNo7 
 $    
45,869.89  
 $      
51,361.01  
 $    
45,869.89  
 $       
51,361.01  
 $         
5,491.13  
transitionTKAFullToNo8 
 $    
43,439.66  
 $   
48,823.38  
 $    
43,439.66  
 $    
48,823.38  
 $       
5,383.73  
tranistionEarlyFailureToRevision 
 $     
51,597.49  
 $   
46,378.84  
 $    
46,378.84  
 $     
51,597.49  
 $        
5,218.65  
costDeepInfection 
 $    
44,655.68  
 $    
49,825.16  
 $    
44,655.68  
 $     
49,825.16  
 $        
5,169.48  
transitionTKAFullToNo9 
 $      
42,815.31  
 $    
47,316.08  
 $      
42,815.31  
 $     
47,316.08  
 $       
4,500.77  
transitionRevisionFullToNo8 
 $    
45,962.26  
 $    
50,210.43  
 $    
45,962.26  
 $     
50,210.43  
 $        
4,248.16  
costFailure 
 $    
44,980.65  
 $    
49,175.22  
 $    
44,980.65  
 $     
49,175.22  
 $        
4,194.57  
costPostOpTKA 
 $    
45,097.78  
 $   
48,940.97  
 $    
45,097.78  
 $    
48,940.97  
 $        
3,843.19  
complicationDeepSubsequentDeepMore Obese 
 $    
45,639.44  
 $    
49,326.41  
 $    
45,639.44  
 $     
49,326.41  
 $       
3,686.96  
complicationDeepVTE 
 $    
46,362.33  
 $    
49,857.91  
 $    
46,362.33  
 $     
49,857.91  
 $       
3,495.58  
transitionTKAFullToNo9More Obese 
 $      
45,113.73  
 $   
48,450.00  
 $      
45,113.73  
 $    
48,450.00  
 $       
3,336.27  
transitionRevisionFullToNo9 
 $     
45,646.12  
 $   
48,966.88  
 $     
45,646.12  
 $    
48,966.88  
 $       
3,320.76  
transitionRevisionFullToNo10More Obese 
 $    
45,084.40  
 $   
47,947.73  
 $    
45,084.40  
 $    
47,947.73  
 $       
2,863.33  
complicationWound 
 $    
46,227.72  
 $   
49,024.40  
 $    
46,227.72  
 $    
49,024.40  
 $       
2,796.69  
transitionTKAFullToNo8More Obese 
 $    
45,337.87  
 $    
48,077.18  
 $    
45,337.87  
 $     
48,077.18  
 $        
2,739.31  
qalyDecDeepInfection 
 $    
45,996.48  
 $   
48,303.00  
 $    
45,996.48  
 $    
48,303.00  
 $       
2,306.53  
qalyDeepRevisionDecrement 
 $     
46,012.38  
 $   
48,302.50  
 $     
46,012.38  
 $    
48,302.50  
 $         
2,290.11  
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transitionTKAFullToNo7More Obese 
 $    
45,532.67  
 $   
47,755.25  
 $    
45,532.67  
 $    
47,755.25  
 $       
2,222.58  
complicationVTE 
 $     
45,740.61  
 $    
47,619.80  
 $     
45,740.61  
 $     
47,619.80  
 $        
1,879.20  
transitionTKAFullToNo3More Obese 
 $    
45,694.37  
 $   
47,489.52  
 $    
45,694.37  
 $    
47,489.52  
 $         
1,795.16  
transitionTKAFullToNo2More Obese 
 $    
45,733.70  
 $   
47,425.07  
 $    
45,733.70  
 $    
47,425.07  
 $         
1,691.37  
transitionTKAFullToNo6More Obese 
 $    
45,763.26  
 $   
47,376.62  
 $    
45,763.26  
 $    
47,376.62  
 $         
1,613.37  
transitionTKAFullToNo5More Obese 
 $    
45,777.22  
 $   
47,353.80  
 $    
45,777.22  
 $    
47,353.80  
 $        
1,576.58  
transitionTKAFullToNo4More Obese 
 $     
45,789.12  
 $   
47,334.35  
 $     
45,789.12  
 $    
47,334.35  
 $        
1,545.23  
costsDeepSubsequentDeep 
 $     
45,933.12  
 $   
47,270.30  
 $     
45,933.12  
 $    
47,270.30  
 $         
1,337.18  
costRevisionMore Obese 
 $    
45,952.06  
 $   
47,232.40  
 $    
45,952.06  
 $    
47,232.40  
 $        
1,280.34  
costTKAMore Obese 
 $    
46,056.72  
 $   
47,023.08  
 $    
46,056.72  
 $    
47,023.08  
 $          
966.36  
costVTE 
 $    
46,068.99  
 $   
46,998.55  
 $    
46,068.99  
 $    
46,998.55  
 $          
929.56  
transitionTKAFullToNo1More Obese 
 $     
46,030.91  
 $   
46,940.49  
 $     
46,030.91  
 $    
46,940.49  
 $          
909.58  
transitionRevisionFullToNo9More Obese 
 $      
46,119.06  
 $   
46,775.95  
 $      
46,119.06  
 $    
46,775.95  
 $          
656.89  
transitionDeepBestToFail1 
 $    
45,799.57  
 $   
46,453.22  
 $    
45,799.57  
 $    
46,453.22  
 $          
653.64  
transitionRevisionFullToNo4More Obese 
 $      
46,135.81  
 $    
46,751.45  
 $      
46,135.81  
 $     
46,751.45  
 $           
615.65  
qalyDeepSubsequentDeepDecrement 
 $    
46,279.27  
 $     
46,861.71  
 $    
46,279.27  
 $      
46,861.71  
 $          
582.44  
qalyDeepBestCase 
 $    
46,657.44  
 $    
46,103.55  
 $     
46,103.55  
 $    
46,657.44  
 $          
553.89  
transitionRevisionFullToNo5More Obese 
 $     
46,178.09  
 $   
46,685.94  
 $     
46,178.09  
 $    
46,685.94  
 $          
507.86  
transitionRevisionFullToNo3More Obese 
 $     
46,184.23  
 $   
46,676.65  
 $     
46,184.23  
 $    
46,676.65  
 $          
492.42  
transitionRevisionFullToNo6More Obese 
 $       
46,191.17  
 $   
46,665.65  
 $       
46,191.17  
 $    
46,665.65  
 $          
474.48  
transitionRevisionFullToNo7More Obese 
 $     
46,198.55  
 $    
46,654.14  
 $     
46,198.55  
 $     
46,654.14  
 $          
455.60  
complicationDeepSubsequentDeep 
 $     
46,157.47  
 $   
46,600.43  
 $     
46,157.47  
 $    
46,600.43  
 $          
442.96  
qalyDecObesity 
 $    
46,575.78  
 $    
46,187.46  
 $     
46,187.46  
 $    
46,575.78  
 $          
388.32  
transitionRevisionFullToNo8More Obese 
 $     
46,231.45  
 $    
46,603.51  
 $     
46,231.45  
 $     
46,603.51  
 $          
372.06  
transitionDeepRevisionToBest 
 $    
46,562.75  
 $    
46,195.90  
 $     
46,195.90  
 $    
46,562.75  
 $          
366.84  
transitionDeepBestToFail1More Obese 
 $     
46,174.34  
 $   
46,453.22  
 $     
46,174.34  
 $    
46,453.22  
 $          
278.87  
transitionRevisionFullToNo2More Obese 
 $    
46,285.44  
 $     
46,521.14  
 $    
46,285.44  
 $      
46,521.14  
 $          
235.70  
transitionRevisionFullToNo1More Obese 
 $    
46,287.34  
 $    
46,518.23  
 $    
46,287.34  
 $     
46,518.23  
 $          
230.90  
complicationWoundMore Obese 
 $     
46,303.12  
 $   
46,530.62  
 $     
46,303.12  
 $    
46,530.62  
 $          
227.49  
costWound 
 $    
46,306.20  
 $    
46,524.13  
 $    
46,306.20  
 $     
46,524.13  
 $           
217.93  
tranistionToDeathMore Obese 
 $    
46,288.63  
 $   
46,470.22  
 $    
46,288.63  
 $    
46,470.22  
 $            
181.60  
costsDeepRevisionMore Obese 
 $     
46,319.09  
 $   
46,498.34  
 $     
46,319.09  
 $    
46,498.34  
 $           
179.25  
qalyDecVTE 
 $    
46,360.06  
 $    
46,512.20  
 $    
46,360.06  
 $     
46,512.20  
 $            
152.14  
transitionDeepRevisionToBestMore Obese 
 $    
46,322.75  
 $   
46,409.04  
 $    
46,322.75  
 $    
46,409.04  
 $             
86.28  
complicationDeepWound 
 $    
46,374.93  
 $    
46,447.13  
 $    
46,374.93  
 $     
46,447.13  
 $              
72.19  
transitionDeepBestToFail2 
 $     
46,318.05  
 $   
46,386.63  
 $     
46,318.05  
 $    
46,386.63  
 $             
68.58  
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qalyDecWound 
 $    
46,372.99  
 $   
46,440.03  
 $    
46,372.99  
 $    
46,440.03  
 $             
67.04  
complicationVTEMore Obese 
 $    
46,359.27  
 $   
46,399.03  
 $    
46,359.27  
 $    
46,399.03  
 $             
39.76  
transitionDeepBestToFail2More Obese 
 $     
46,357.41  
 $   
46,386.63  
 $     
46,357.41  
 $    
46,386.63  
 $             
29.22  
costsDeepContinuingBest 
 $    
46,369.62  
 $   
46,397.30  
 $    
46,369.62  
 $    
46,397.30  
 $             
27.68  
costsDeepVTE 
 $    
46,370.83  
 $   
46,394.87  
 $    
46,370.83  
 $    
46,394.87  
 $             
24.04  
transitionDeepBestToFail3 
 $    
46,372.50  
 $   
46,379.66  
 $    
46,372.50  
 $    
46,379.66  
 $                
7.16  
complicationDeepWoundMore Obese 
 $    
46,376.88  
 $   
46,382.77  
 $    
46,376.88  
 $    
46,382.77  
 $               
5.88  
costsDeepWound 
 $    
46,376.96  
 $   
46,382.60  
 $    
46,376.96  
 $    
46,382.60  
 $               
5.64  
qalyDeepVTEDecrement 
 $    
46,378.36  
 $   
46,382.28  
 $    
46,378.36  
 $    
46,382.28  
 $               
3.93  
transitionDeepBestToFail3More Obese 
 $     
46,376.61  
 $   
46,379.66  
 $     
46,376.61  
 $    
46,379.66  
 $               
3.05  
qalyDeepWoundDecrement 
 $    
46,378.69  
 $   
46,380.42  
 $    
46,378.69  
 $    
46,380.42  
 $                
1.73  
complicationDeepVTEMore Obese 
 $    
46,378.34  
 $   
46,379.37  
 $    
46,378.34  
 $    
46,379.37  
 $                
1.03  
transitionDeepBestToFail4 
 $     
46,378.18  
 $   
46,378.93  
 $     
46,378.18  
 $    
46,378.93  
 $               
0.74  
transitionDeepBestToFail4More Obese 
 $     
46,378.61  
 $   
46,378.93  
 $     
46,378.61  
 $    
46,378.93  
 $               
0.32  
transitionDeepBestToFail5 
 $    
46,378.77  
 $   
46,378.85  
 $    
46,378.77  
 $    
46,378.85  
 $               
0.08  
transitionDeepBestToFail5More Obese 
 $    
46,378.82  
 $   
46,378.85  
 $    
46,378.82  
 $    
46,378.85  
 $               
0.03  
transitionDeepBestToFail6 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                
0.01  
transitionDeepBestToFail6More Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $               
0.00  
transitionDeepBestToFail7 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $               
0.00  
transitionDeepBestToFail7More Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $               
0.00  
transitionDeepBestToFail8 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $               
0.00  
transitionDeepBestToFail8More Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $               
0.00  
transitionDeepBestToFail9 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $               
0.00  
transitionDeepBestToFail10 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $               
0.00  
transitionDeepBestToFail9More Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $               
0.00  
transitionDeepBestToFail10More Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $               
0.00  
transitionOAtoTKA 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAtoFullNon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAtoFullLess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAtoFullMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo1Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo1Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo1Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo2Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo2Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo2Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
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transitionTKAFullToNo3Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo3Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo3Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo4Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo4Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo4Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo5Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo5Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo5Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo6Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo6Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo6Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo7Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo7Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo7Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo8Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo8Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo8Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo9Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo9Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo9Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo10Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo10Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionTKAFullToNo10Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionToFullNon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionToFullLess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionToFullMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo1Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo1Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo1Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo2Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo2Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo2Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo3Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo3Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo3Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
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transitionRevisionFullToNo4Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo4Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo4Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo5Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo5Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo5Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo6Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo6Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo6Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo7Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo7Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo7Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo8Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo8Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo8Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo9Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo9Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo9Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo10Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo10Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionRevisionFullToNo10Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
tranistionToDeath 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
tranistionToDeathNon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
tranistionToDeathLess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
tranistionToDeathMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationVTENon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationVTELess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationVTEMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationWoundNon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationWoundLess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationWoundMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepInfectionNon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepInfectionLess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepInfectionMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
costTKANon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
costTKALess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
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costTKAMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
costRevisionNon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
costRevisionLess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
costRevisionMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepVTENon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepVTELess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepVTEMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepWoundNon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepWoundLess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepWoundMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepSubsequentDeepNon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepSubsequentDeepLess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
complicationDeepSubsequentDeepMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepRevisionToBestNon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepRevisionToBestLess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepRevisionToBestMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail1Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail1Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail1Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail2Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail2Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail2Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail3Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail3Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail3Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail4Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail4Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail4Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail5Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail5Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail5Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail6Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail6Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail6Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail7Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail7Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
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transitionDeepBestToFail7Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail8Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail8Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail8Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail9Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail9Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail9Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail10Non Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail10Less Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
transitionDeepBestToFail10Morbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
costsDeepRevisionNon Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
costsDeepRevisionLess Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
costsDeepRevisionMorbid Obese 
 $    
46,378.84  
 $   
46,378.84  
 $    
46,378.84  
 $    
46,378.84  
 $                    
-    
 
Table B-5 Full Univariate Sensitivity Analysis Results for Class III Obese Population 
Class III Obesity 
Base  $                                                                                            80,670.88  
Parameter Name Low High Min Max Gap 
qalyFull  $ (97,999.80) 
 $       
24,206.66   $ 2,500,000.00  
 $       
24,206.66   $ 2,475,793.34  
qalyOA 
 $      
65,447.03  
 $ 
(1,522,558.19)  $ 2,500,000.00  
 $       
65,447.03   $ 2,434,552.97  
transitionRevisionToFull 
 $ 
2,109,925.01  
 $        
61,457.00  
 $         
61,457.00  
 $   
2,109,925.01  
 $   
2,048,468.01  
complicationDeepInfection 
 $       
25,296.31  
 $ 
1,009,654.42  
 $         
25,296.31  
 $ 
1,009,654.42  
 $       
984,358.11  
transitionTKAtoFull 
 $    
981,470.25  
 $        
61,494.83  
 $         
61,494.83  
 $     
981,470.25  
 $      
919,975.42  
complicationDeepInfectionMorbid Obese 
 $      
40,604.37  
 $       
568,115.45  
 $        
40,604.37  
 $      
568,115.45  
 $       
527,511.09  
qalyDecRevision 
 $       
70,919.20  
 $     
258,208.62  
 $         
70,919.20  
 $    
258,208.62  
 $      
187,289.42  
costOATreatment 
 $      
116,089.19  
 $          
9,834.27  
 $          
9,834.27  
 $       
116,089.19  
 $      
106,254.92  
costRevision 
 $      
54,538.25  
 $       
132,936.15  
 $        
54,538.25  
 $      
132,936.15   $        78,397.90  
transitionDeepLateToRevision 
 $      
80,670.88  
 $        
158,810.17  
 $        
80,670.88  
 $       
158,810.17  
 $         
78,139.29  
qalyDecTKA 
 $      
66,938.55  
 $       
133,100.32  
 $        
66,938.55  
 $      
133,100.32  
 $          
66,161.77  
costTKA 
 $      
59,528.60  
 $      
122,955.44  
 $        
59,528.60  
 $     
122,955.44   $        63,426.84  
transitionLateFailureToRevision 
 $     
120,321.80  
 $        
76,877.81  
 $         
76,877.81  
 $      
120,321.80   $        43,443.99  
costsDeepContinuingWorst 
 $      
67,537.35  
 $      
106,937.96  
 $        
67,537.35  
 $     
106,937.96   $        39,400.62  
qalyDeepWorstDecrement 
 $    
103,486.08  
 $        
66,098.41  
 $         
66,098.41  
 $     
103,486.08   $        37,387.66  
transitionRevisionToFullMorbid Obese 
 $         
61,110.69  
 $       
98,483.60  
 $           
61,110.69  
 $       
98,483.60  
 $         
37,372.91  
qalyFailed 
 $     
104,212.89  
 $       
69,204.73  
 $        
69,204.73  
 $      
104,212.89  
 $         
35,008.16  
transitionRevisionFullToNo1 
 $      
80,287.68  
 $        
112,774.41  
 $        
80,287.68  
 $       
112,774.41   $        32,486.73  
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transitionTKAtoFullMorbid Obese 
 $      
62,774.98  
 $        
91,856.69  
 $        
62,774.98  
 $        
91,856.69  
 $          
29,081.71  
transitionTKAFullToNo10 
 $      
57,483.76  
 $         
86,116.36  
 $        
57,483.76  
 $         
86,116.36  
 $         
28,632.61  
transitionTKAFullToNo1 
 $      
79,070.22  
 $      
105,729.65  
 $        
79,070.22  
 $     
105,729.65   $        26,659.42  
transitionRevisionFullToNo2 
 $       
80,281.48  
 $      
106,084.69  
 $         
80,281.48  
 $     
106,084.69  
 $         
25,803.21  
transitionTKAFullToNo2 
 $      
77,729.35  
 $      
100,767.05  
 $        
77,729.35  
 $     
100,767.05   $        23,037.70  
Discount Rate 
 $      
72,406.32  
 $        
94,775.16  
 $        
72,406.32  
 $        
94,775.16   $        22,368.84  
transitionRevisionFullToNo3 
 $       
79,866.19  
 $       
100,299.21  
 $         
79,866.19  
 $      
100,299.21   $        20,433.02  
transitionTKAFullToNo3 
 $      
77,565.75  
 $       
97,444.08  
 $        
77,565.75  
 $       
97,444.08  
 $         
19,878.33  
costsDeepRevision 
 $      
74,045.03  
 $       
93,922.58  
 $        
74,045.03  
 $       
93,922.58  
 $         
19,877.55  
Age 
 $       
75,010.93  
 $        
94,450.14  
 $         
75,010.93  
 $        
94,450.14  
 $         
19,439.22  
transitionTKAFullToNo4 
 $      
78,004.37  
 $       
95,046.93  
 $        
78,004.37  
 $       
95,046.93  
 $         
17,042.56  
transitionDeepEarlyToRevision 
 $      
80,670.88  
 $        
97,221.73  
 $        
80,670.88  
 $        
97,221.73  
 $         
16,550.85  
transitionRevisionFullToNo4 
 $      
79,672.39  
 $        
95,891.46  
 $        
79,672.39  
 $        
95,891.46  
 $          
16,219.07  
transitionTKAFullToNo10Morbid Obese 
 $      
73,736.53  
 $       
89,686.98  
 $        
73,736.53  
 $       
89,686.98  
 $         
15,950.46  
transitionTKAFullToNo5 
 $      
77,965.28  
 $        
92,431.39  
 $        
77,965.28  
 $        
92,431.39  
 $           
14,466.11  
transitionRevisionFullToNo5 
 $       
79,849.10  
 $       
92,693.44  
 $         
79,849.10  
 $       
92,693.44  
 $         
12,844.34  
transitionTKAFullToNo6 
 $       
77,919.06  
 $        
90,070.15  
 $         
77,919.06  
 $        
90,070.15  
 $            
12,151.10  
transitionRevisionFullToNo10 
 $       
74,667.01  
 $       
86,254.66  
 $         
74,667.01  
 $       
86,254.66  
 $          
11,587.66  
tranistionEarlyFailureToRevision 
 $       
91,466.04  
 $       
80,670.88  
 $        
80,670.88  
 $        
91,466.04  
 $          
10,795.15  
costDeepInfection 
 $       
77,164.72  
 $       
87,683.22  
 $         
77,164.72  
 $       
87,683.22  
 $           
10,518.51  
complicationDeepVTE 
 $      
80,622.96  
 $       
90,807.22  
 $        
80,622.96  
 $       
90,807.22  
 $          
10,184.26  
transitionTKAFullToNo7 
 $      
76,925.77  
 $       
87,055.55  
 $        
76,925.77  
 $       
87,055.55  
 $          
10,129.78  
transitionRevisionFullToNo6 
 $      
79,906.42  
 $        
90,014.32  
 $        
79,906.42  
 $        
90,014.32  
 $          
10,107.90  
complicationDeepSubsequentDeepMorbid 
Obese 
 $        
78,210.12  
 $       
87,997.32  
 $          
78,210.12  
 $       
87,997.32   $          9,787.20  
qalyDecDeepInfection 
 $      
79,329.06  
 $       
87,786.32  
 $        
79,329.06  
 $       
87,786.32   $          8,457.26  
qalyDeepRevisionDecrement 
 $      
79,384.43  
 $       
87,784.36  
 $        
79,384.43  
 $       
87,784.36   $          8,399.94  
transitionTKAFullToNo8 
 $       
76,109.82  
 $       
84,495.28  
 $         
76,109.82  
 $       
84,495.28   $          8,385.46  
transitionRevisionFullToNo7 
 $      
79,940.48  
 $       
87,826.65  
 $        
79,940.48  
 $       
87,826.65  
 $           
7,886.17  
transitionTKAFullToNo9 
 $       
75,189.42  
 $         
82,121.92  
 $         
75,189.42  
 $         
82,121.92   $          6,932.50  
transitionRevisionFullToNo8 
 $      
80,076.96  
 $        
86,135.90  
 $        
80,076.96  
 $        
86,135.90   $          6,058.94  
complicationVTEMorbid Obese 
 $      
79,804.82  
 $       
85,290.06  
 $        
79,804.82  
 $       
85,290.06   $          5,485.24  
transitionTKAFullToNo9Morbid Obese 
 $       
78,718.45  
 $       
83,882.68  
 $         
78,718.45  
 $       
83,882.68  
 $           
5,164.24  
costsDeepSubsequentDeep 
 $      
79,096.60  
 $        
83,819.46  
 $        
79,096.60  
 $        
83,819.46   $          4,722.86  
transitionRevisionFullToNo9 
 $       
79,633.81  
 $       
84,334.36  
 $         
79,633.81  
 $       
84,334.36   $          4,700.55  
costFailure 
 $        
79,110.35  
 $        
83,791.94  
 $          
79,110.35  
 $        
83,791.94  
 $           
4,681.59  
costPostOpTKA 
 $       
79,218.75  
 $        
83,575.15  
 $         
79,218.75  
 $        
83,575.15   $          4,356.40  
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transitionTKAFullToNo8Morbid Obese 
 $      
79,050.87  
 $       
83,324.88  
 $        
79,050.87  
 $       
83,324.88  
 $           
4,274.01  
transitionRevisionFullToNo10Morbid Obese 
 $      
78,902.36  
 $       
82,832.66  
 $        
78,902.36  
 $       
82,832.66   $          3,930.30  
qalyDeepSubsequentDeepDecrement 
 $      
80,062.50  
 $        
83,717.67  
 $        
80,062.50  
 $        
83,717.67  
 $           
3,655.18  
transitionTKAFullToNo7Morbid Obese 
 $       
79,344.01  
 $       
82,836.76  
 $         
79,344.01  
 $       
82,836.76   $          3,492.74  
complicationVTE 
 $      
79,604.25  
 $       
82,746.37  
 $        
79,604.25  
 $       
82,746.37  
 $             
3,142.11  
complicationWound 
 $        
80,511.34  
 $       
83,463.96  
 $          
80,511.34  
 $       
83,463.96   $          2,952.62  
transitionTKAFullToNo3Morbid Obese 
 $      
79,572.84  
 $       
82,458.36  
 $        
79,572.84  
 $       
82,458.36   $          2,885.53  
transitionTKAFullToNo2Morbid Obese 
 $       
79,631.20  
 $        
82,362.16  
 $         
79,631.20  
 $        
82,362.16   $          2,730.96  
transitionTKAFullToNo6Morbid Obese 
 $       
79,698.91  
 $       
82,250.46  
 $         
79,698.91  
 $       
82,250.46  
 $           
2,551.55  
transitionTKAFullToNo5Morbid Obese 
 $       
79,715.36  
 $       
82,223.47  
 $         
79,715.36  
 $       
82,223.47  
 $            
2,508.11  
transitionTKAFullToNo4Morbid Obese 
 $      
79,729.26  
 $       
82,200.66  
 $        
79,729.26  
 $       
82,200.66  
 $           
2,471.40  
costRevisionMorbid Obese 
 $        
79,711.89  
 $        
82,109.38  
 $          
79,711.89  
 $        
82,109.38   $          2,397.49  
qalyDecObesity 
 $         
81,701.14  
 $        
79,686.16  
 $         
79,686.16  
 $          
81,701.14  
 $           
2,014.98  
qalyDeepBestCase 
 $       
81,662.85  
 $       
79,702.73  
 $        
79,702.73  
 $        
81,662.85  
 $            
1,960.13  
costTKAMorbid Obese 
 $      
79,895.02  
 $        
81,834.68  
 $        
79,895.02  
 $        
81,834.68  
 $           
1,939.66  
complicationDeepSubsequentDeep 
 $       
79,831.82  
 $         
81,512.80  
 $         
79,831.82  
 $         
81,512.80  
 $           
1,680.98  
costVTE 
 $       
80,163.95  
 $        
81,684.75  
 $         
80,163.95  
 $        
81,684.75  
 $           
1,520.80  
transitionDeepBestToFail1 
 $      
79,347.80  
 $         
80,841.18  
 $        
79,347.80  
 $         
80,841.18  
 $           
1,493.38  
transitionTKAFullToNo1Morbid Obese 
 $       
80,107.50  
 $         
81,581.87  
 $         
80,107.50  
 $         
81,581.87  
 $           
1,474.37  
transitionDeepRevisionToBest 
 $       
81,230.08  
 $         
80,117.63  
 $          
80,117.63  
 $        
81,230.08  
 $             
1,112.45  
transitionRevisionFullToNo9Morbid Obese 
 $      
80,303.20  
 $        
81,232.95  
 $        
80,303.20  
 $        
81,232.95  
 $              
929.76  
transitionRevisionFullToNo4Morbid Obese 
 $       
80,316.08  
 $         
81,214.98  
 $         
80,316.08  
 $         
81,214.98  
 $              
898.90  
transitionRevisionFullToNo5Morbid Obese 
 $      
80,379.36  
 $          
81,116.89  
 $        
80,379.36  
 $          
81,116.89  
 $              
737.54  
transitionRevisionFullToNo3Morbid Obese 
 $      
80,385.33  
 $         
81,107.96  
 $        
80,385.33  
 $         
81,107.96  
 $              
722.63  
transitionRevisionFullToNo6Morbid Obese 
 $      
80,399.90  
 $        
81,085.04  
 $        
80,399.90  
 $        
81,085.04  
 $               
685.14  
transitionRevisionFullToNo7Morbid Obese 
 $        
80,412.13  
 $         
81,066.01  
 $          
80,412.13  
 $         
81,066.01  
 $              
653.88  
transitionDeepBestToFail1Morbid Obese 
 $       
80,203.13  
 $         
80,841.18  
 $         
80,203.13  
 $         
80,841.18  
 $              
638.05  
costsDeepRevisionMorbid Obese 
 $      
80,427.73  
 $         
81,035.61  
 $        
80,427.73  
 $         
81,035.61  
 $              
607.88  
transitionRevisionFullToNo8Morbid Obese 
 $      
80,460.74  
 $         
80,991.21  
 $        
80,460.74  
 $         
80,991.21  
 $              
530.47  
complicationWoundMorbid Obese 
 $      
80,560.80  
 $         
81,026.15  
 $        
80,560.80  
 $         
81,026.15  
 $              
465.35  
qalyDecVTE 
 $       
80,617.45  
 $         
81,051.07  
 $         
80,617.45  
 $         
81,051.07  
 $              
433.62  
tranistionToDeathMorbid Obese 
 $      
80,473.44  
 $       
80,872.78  
 $        
80,473.44  
 $       
80,872.78  
 $              
399.34  
transitionRevisionFullToNo2Morbid Obese 
 $       
80,533.16  
 $       
80,880.72  
 $         
80,533.16  
 $       
80,880.72  
 $              
347.56  
transitionRevisionFullToNo1Morbid Obese 
 $      
80,535.35  
 $       
80,877.37  
 $        
80,535.35  
 $       
80,877.37  
 $              
342.02  
transitionDeepRevisionToBestMorbid Obese 
 $      
80,500.94  
 $       
80,762.49  
 $        
80,500.94  
 $       
80,762.49  
 $               
261.55  
complicationDeepVTEMorbid Obese 
 $       
80,631.98  
 $       
80,877.72  
 $         
80,631.98  
 $       
80,877.72  
 $              
245.74  
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costWound 
 $      
80,596.33  
 $        
80,819.99  
 $        
80,596.33  
 $        
80,819.99  
 $              
223.66  
transitionDeepBestToFail2 
 $      
80,532.04  
 $       
80,688.68  
 $        
80,532.04  
 $       
80,688.68  
 $               
156.64  
complicationDeepWound 
 $      
80,663.72  
 $       
80,796.02  
 $        
80,663.72  
 $       
80,796.02  
 $               
132.30  
qalyDecWound 
 $      
80,660.43  
 $         
80,780.11  
 $        
80,660.43  
 $         
80,780.11  
 $                
119.68  
costsDeepVTE 
 $       
80,648.12  
 $         
80,716.41  
 $         
80,648.12  
 $         
80,716.41  
 $                
68.28  
transitionDeepBestToFail2Morbid Obese 
 $       
80,621.92  
 $       
80,688.68  
 $         
80,621.92  
 $       
80,688.68  
 $                
66.76  
costsDeepContinuingBest 
 $       
80,652.15  
 $       
80,708.36  
 $         
80,652.15  
 $       
80,708.36  
 $                 
56.21  
complicationDeepWoundMorbid Obese 
 $      
80,665.94  
 $       
80,686.83  
 $        
80,665.94  
 $       
80,686.83  
 $                
20.89  
qalyDeepVTEDecrement 
 $      
80,668.48  
 $       
80,687.88  
 $        
80,668.48  
 $       
80,687.88  
 $                 
19.39  
transitionDeepBestToFail3 
 $      
80,656.42  
 $       
80,672.74  
 $        
80,656.42  
 $       
80,672.74  
 $                 
16.32  
costsDeepWound 
 $      
80,667.54  
 $       
80,677.58  
 $        
80,667.54  
 $       
80,677.58  
 $                 
10.04  
transitionDeepBestToFail3Morbid Obese 
 $      
80,665.78  
 $       
80,672.74  
 $        
80,665.78  
 $       
80,672.74  
 $                   
6.95  
qalyDeepWoundDecrement 
 $       
80,670.41  
 $       
80,675.78  
 $         
80,670.41  
 $       
80,675.78  
 $                   
5.37  
transitionDeepBestToFail4 
 $      
80,669.38  
 $        
80,671.08  
 $        
80,669.38  
 $        
80,671.08  
 $                    
1.69  
transitionDeepBestToFail4Morbid Obese 
 $      
80,670.36  
 $        
80,671.08  
 $        
80,670.36  
 $        
80,671.08  
 $                   
0.72  
transitionDeepBestToFail5 
 $      
80,670.73  
 $       
80,670.90  
 $        
80,670.73  
 $       
80,670.90  
 $                    
0.17  
transitionDeepBestToFail5Morbid Obese 
 $      
80,670.83  
 $       
80,670.90  
 $        
80,670.83  
 $       
80,670.90  
 $                   
0.07  
transitionDeepBestToFail6 
 $      
80,670.87  
 $       
80,670.89  
 $        
80,670.87  
 $       
80,670.89  
 $                   
0.02  
transitionDeepBestToFail6Morbid Obese 
 $      
80,670.88  
 $       
80,670.89  
 $        
80,670.88  
 $       
80,670.89  
 $                    
0.01  
transitionDeepBestToFail7 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88  
 $                   
0.00  
transitionDeepBestToFail7Morbid Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88  
 $                   
0.00  
transitionDeepBestToFail8 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88  
 $                   
0.00  
transitionDeepBestToFail8Morbid Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88  
 $                   
0.00  
transitionDeepBestToFail9 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88  
 $                   
0.00  
transitionDeepBestToFail10 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88  
 $                   
0.00  
transitionDeepBestToFail9Morbid Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88  
 $                   
0.00  
transitionDeepBestToFail10Morbid Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88  
 $                   
0.00  
transitionOAtoTKA 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAtoFullNon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAtoFullLess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAtoFullMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo1Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo1Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo1More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo2Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo2Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
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transitionTKAFullToNo2More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo3Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo3Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo3More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo4Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo4Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo4More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo5Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo5Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo5More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo6Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo6Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo6More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo7Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo7Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo7More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo8Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo8Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo8More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo9Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo9Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo9More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo10Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo10Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionTKAFullToNo10More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionToFullNon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionToFullLess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionToFullMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo1Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo1Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo1More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo2Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo2Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo2More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo3Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo3Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
  
168 
transitionRevisionFullToNo3More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo4Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo4Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo4More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo5Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo5Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo5More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo6Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo6Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo6More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo7Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo7Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo7More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo8Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo8Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo8More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo9Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo9Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo9More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo10Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo10Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionRevisionFullToNo10More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
tranistionToDeath 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
tranistionToDeathNon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
tranistionToDeathLess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
tranistionToDeathMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationVTENon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationVTELess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationVTEMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationWoundNon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationWoundLess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationWoundMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepInfectionNon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepInfectionLess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepInfectionMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
costTKANon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
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costTKALess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
costTKAMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
costRevisionNon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
costRevisionLess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
costRevisionMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepVTENon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepVTELess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepVTEMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepWoundNon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepWoundLess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepWoundMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepSubsequentDeepNon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepSubsequentDeepLess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
complicationDeepSubsequentDeepMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepRevisionToBestNon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepRevisionToBestLess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepRevisionToBestMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail1Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail1Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail1More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail2Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail2Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail2More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail3Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail3Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail3More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail4Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail4Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail4More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail5Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail5Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail5More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail6Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail6Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail6More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail7Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
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transitionDeepBestToFail7Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail7More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail8Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail8Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail8More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail9Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail9Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail9More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail10Non Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail10Less Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
transitionDeepBestToFail10More Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
costsDeepRevisionNon Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
costsDeepRevisionLess Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
costsDeepRevisionMore Obese 
 $      
80,670.88  
 $       
80,670.88  
 $        
80,670.88  
 $       
80,670.88   $                        -    
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Verification of Population 
 
 
The population used in the ABM was synthetically created to match the US population on 
age, gender, obesity, and OA.  The 1995 population was created and allowed to age and die.  OA 
and obesity trends were also applied.  Given the available data, these model population 
demographics were periodically checked against the historical patterns.  The following graphs 
were used to verify that the population design reasonably reflected the population it was meant to 
represent (Figures C-1 - 12).   
Age and Gender 
Figure C-1 Female 1995 Population by Age: Census Expected versus Model Observed 
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Figure C-2 Male 1995 Population by Age: Census Expected versus Model Observed 
 
Figure C-3 Female 2010 Population by Age: Census Expected versus Model Observed 
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Figure C-4 Male 2010 Population by Age: Census Expected versus Model Observed 
 
Figure C-5 Female 2015 Population by Age: Census Expected versus Model Observed 
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Figure C-6 Male 2015 Population by Age: Census Expected versus Model Observed 
 
Obesity 
Figure C-7 Obesity Class by Age and Gender in 1995: NHANES Expected versus Model Observed 
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Figure C-8 Obesity Class by Age and Gender in 2003: NHANES Expected versus Model Observed 
 
Figure C-9 Obesity Class by Age and Gender in 2011: NHANES Expected versus Model Observed 
 
0
1000
2000
3000
4000
5000
6000
7000
Male 0-19 Male 20-39 Male 40-59 Male 60+ Female 0-19 Female 20-39 Female 40-59 Female 60+
2003 Obesity Class by Age and Gender
Class I and II are estimated evenly
Expected Non Observed Non Expected Class I Observed Class I
Expected Class II Observed Class II Expected Class III Observed Class III
0
1000
2000
3000
4000
5000
6000
7000
Male 0-19 Male 20-39 Male 40-59 Male 60+ Female 0-19 Female 20-39 Female 40-59 Female 60+
2011 Obesity Class by Age and Gender
Expected Non Observed Non Expected Class I Observed Class I
Expected Class II Observed Class II Expected Class III Observed Class III
  
176 
OA 
Figure C-10 Osteoarthritis Prevalence in Population Over Age 40 
 
Figure C-11 Osteoarthritis Prevalence in Population Over Age 40 by Obesity  
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Figure C-12 Osteoarthritis Prevalence in Population Over Age 40 by Gender  
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Database Implementation 
 
 
The model required extensive data processing before analysis.  Much of this was required 
due to the limitations of Excel in terms of maximum rows.  Processing the agents in smaller 
segments also significantly reduced model run time in AnyLogic.  This was a multiphase process 
requiring several pieces of software in several coding languages.  The process is described below 
and graphically represented in the attached figure (Figure D-1).   
Figure D-1 Schematic of Database Implementation from Raw Output to Final Analysis 
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AnyLogic has an internal database system.  On runtime, the output variables were stored 
to an internal dataset.  A total of 20 datasets, which are briefly described in the table below, are 
included in the AnyLogic database (Table D-1).  Each dataset follows the same structure – the 
name of the dataset, the agentName (a unique identifier for each agent), the time step, an index, 
and the numeric value recorded.   
Table D-1 AnyLogic Dataset Descriptions 
Category 
Name Description 
Static 
Demographics Female This shows value of 1 if female, 0 if male 
  Patient Birth Year Records the birth year of the agent based on age in 1995 
Annual 
Demographics 
Years in Current Health States Records the number of years spent in the current health state 
  Years in Failed Health States 
Records the number of years spent in the current health state 
if it is one of the three failed states 
  Age The current age based on starting age in 1995 
  
Alive 
This shows value of 1 if alive in the current year, 0 if patient 
has died 
  Health State (Numeric) 
Records which of the 12 health states the patient is in via 
numeric code 
  
Obesity Classification at time of 
surgery 
If a surgery occurred, the current obesity class (0-3) is 
recorded permanently 
  Number of Surgeries undergone 
A running count of the number of surgeries a patient has 
undergone 
  Obesity Classification Annual Records the current obesity class (0-3) 
  
Had Deep Infection Ever 
A permanent flag for anyone that has ever experienced a 
deep infection 
Event Flags Had Primary Surgery A onetime flag when primary surgery occurred 
  Had Revision Surgery A onetime flag when revision surgery occurred 
  Had Deep Revision Surgery A onetime flag when deep revision surgery occurred 
  Had Wound  
A onetime flag if a wound complication occurred in either a 
primary or revision surgery 
  Had VTE 
A onetime flag if a VTE complication occurred in either a 
primary or revision surgery 
  Had Deep Infection  
A onetime flag if a deep infection complication occurred in 
either a primary or revision surgery 
  
Had Wound from Deep Infection 
Surgery 
A onetime flag if a wound complication occurred in deep 
revision surgery 
  Had VTE From Deep Infection Surgery 
A onetime flag if a VTE complication occurred in deep revision 
surgery 
  Had Subsequent Deep Infection 
A onetime flag if a deep infection complication occurred in 
deep revision surgery 
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On each model run, the datasets were exported to an Excel workbook.  Each dataset was 
written to its own worksheet with the name of the dataset given to the worksheet.  Each 
workbook was saved with the run number attached as a suffix.  Due to the upper limit of rows in 
Excel, the AnyLogic runs had to be split into smaller batch sizes.   
For each scenario, a run of 10,000 agents was repeated 25 times for a total of 250,000 
agents.  All files were saved in a single folder with the name of the scenario.  Upon completion 
of the 25 runs, a VBA macro was run to extract the worksheets from the individual files as 
comma separated value (csv) files.  This macro was coded such that the name of the csv file was 
the name of the worksheet and the run number from the workbook name.  Each csv file then was 
named for the data type contained and the run number.  This created a total of 500 files.  The 
files were spot checked for fidelity to the original Excel output.  The csv files significantly 
reduced the file size and the processing time for the next step.   
The Spyder development environment for Python was used for the shaping of the data.  
In addition to basic Python, the panda’s library was used for data manipulation (pandas, n.d.).  
This is the Python Data Analysis Library and makes use of standard database techniques like 
inner and outer joins on specific values between data tables.  The Python was executed in two 
steps to accommodate the kernel timing out on the full process due to the file size.  In the first 
step, the 500 csv files were read into Python.  In this step, a run number field was added to the 
table with the run number value taken from the file name.  Additionally, the files corresponding 
to each dataset were merged into a single table.  Thus, on read in the Python code converts 500 
files to 20 tables with run number added as a field.  The new tables were also visually inspected 
for fidelity to the original data for both correctness of insertion of run numbers and for the values 
recorded.   
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Assistive tables were also read in at this time.  These files served to make the AnyLogic 
numeric output more readable.  The time step was converted to the real-world year it corresponds 
to and the binary female was changed to text labels.  Obesity class names were also added.   
With these tables created, the joining process with the panda’s library commenced.  Five 
tables were needed to deal with the variable nature of the data.  First, static demographics were 
grouped together.  This contains the unchanging year of birth and gender.  The composite key for 
this table was agent name and runs number.  Second, annual demographics made the largest 
table.  Every year, health state, age, obesity class and years in the current state were recorded for 
every agent who was alive.  Additionally, the number of surgeries received and a permanent flag 
if deep infection had ever been experienced were included.  Third, a series of three tables 
contained surgical and complication event flags organized by type of surgery: primary, revision 
and deep revision.  As appropriate the assistive tables were attached for clarity in the file dataset.  
The final four tables used a three-part composite key of agent name, run number, and time step.  
Samples from each of these five tables were then compared to raw output to ensure that the joins 
accurately reflected the original raw output.   
These five tables were then combined into a single flat table that was denormalized.  The 
ultimate goal for the data is as the basis of a PivotTable which requires such a format.  To 
accomplish this, the five tables created above were also joined on the three-part composite key.  
This table was written to a text file to be used in the second step of the Python process.   
In the second step of the Python data processing, the costs and QALYs associated with 
health states and events were attached to the flat table created in the first phase.  A series of 
tables containing specific cost and QALY events was attached based on the event flags or health 
state.  The final table was again exported as a txt file.  
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SQL Server Express was used as an intermediary between the Python output and the 
Excel PivotCache.  The file was imported to a database in SQL Server.  The file was otherwise 
unchanged.  Using several SELECT queries, the final table was tested against the raw output to 
ensure data fidelity for a final check of the extensive process of data manipulation.   
Finally, an ODBC bridge was created between Excel and the SQL Server database.  This 
link served as the basis of a PivotCache.  Various PivotTables were created based on this data 
link.  The data never comes into Excel itself because the Excel maximum row limit was still 
exceeded.  
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Cross Model Validation Results 
 
 
The model structure was validated by comparing results to the compartmental model that 
used the same design for the disease process.  The starting conditions were set to identical values 
and heterogeneity was removed from the ABM population design.  The outcomes tracked in the 
compartmental model focused on the costs and QALYs associated with two scenarios – no TKA 
and TKA occurring for an entire population in the first year – in four obesity classes.  For 
comparison, the total costs and total QALYs were compared on an annual basis between the two 
models for all 8 scenarios.  The results of those comparisons are presented below as 16 graphs – 
one for each scenario for costs and QALYs (Figures E-1 -16).  The output tracks closely across 
all groups in both measures.     
Figure E-1 Undiscounted Costs by Year: Nonobese – Year 1 TKA 
 
$0.00
$50,000,000.00
$100,000,000.00
$150,000,000.00
$200,000,000.00
$250,000,000.00
$300,000,000.00
$350,000,000.00
0 5 10 15 20 25
Undiscounted Costs by Year
Nonobese - Year 1 TKA
ABM Compartmental
  
184 
Figure E-2 Undiscounted QALYs by Year: Nonobese – Year 1 TKA 
 
Figure E-3 Undiscounted Costs by Year: Class I Obesity– Year 1 TKA 
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Figure E-4 Undiscounted QALYs by Year: Class I Obesity– Year 1 TKA 
 
Figure E-5 Undiscounted Costs by Year: Class II Obesity– Year 1 TKA 
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Figure E-6 Undiscounted QALYs by Year: Class II Obesity– Year 1 TKA 
 
Figure E-7 Undiscounted Costs by Year: Class III Obesity– Year 1 TKA 
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Figure E-8 Undiscounted QALYs by Year: Class III Obesity– Year 1 TKA 
 
Figure E-9 Undiscounted Costs by Year: Nonobese – No TKA 
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Figure E-10 Undiscounted QALYs by Year: Nonobese- No TKA 
 
Figure E-11 Undiscounted Costs by Year: Class I Obesity– No TKA 
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Figure E-12 Undiscounted QALYs by Year: Class I Obesity– No TKA 
 
Figure E-13 Undiscounted Costs by Year: Class II Obesity– No TKA 
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Figure E-14 Undiscounted QALYs by Year: Class II Obesity– No TKA 
 
Figure E-15 Undiscounted Costs by Year: Class III Obesity– No TKA 
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Figure E-16 Undiscounted QALYs by Year: Class III Obesity– No TKA 
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Calibration Results 
 
 
Calibration relied on three criteria all centered on the HCUP data as available.  The first 
and second rely on objective fit criteria.  The tables below show the parameter sets tried and the 
results of those criteria.  The first is the number of time points where the regressed model line 
was inside the HCUP Confidence Interval (Table F-1).  The second is the count of whether the 
confidence intervals overlapped (Table F-2).  The joint age and gender groups only have 3 years 
of data points and the rest are 15 years.  The final column shows the percent of the 108 data 
points that fit the criteria.  Figure F-13 shows the uptake rates over time for each group using the 
final parameter set.  While not used in the calibration, Table F-3 shows the MSE for each 
parameter set with the chosen parameters having the lowest total MSE.  In all three tables the 
yellow row or parameter scenario 10 is the final calibration set.   
The third criteria involved a visual inspection of the trend against the HCUP data.  This 
served as a final check of the parameter set’s suitability.  The graphs below show the 12 
demographics categories available with the HCUP and final parameter set along with their 
confidence intervals (Figures F-1 - 12).   
Overall, there is a good fit across all the data point types and time.  The HCUP 
confidence intervals have widely varying widths and the smallest were the least likely to contain 
the model trendline.  The joint estimates are also less likely to contain the trendline as they are 
only 3 years and have artificial confidence intervals which cause a sharp v shape.  A visual 
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inspection shows that even the worst group (Males 45-64) on the objective measures tracks 
nearly as well as the overall population estimate.  (Figure F-6)  
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Table F-1 Calibration Regression Lines Inside HCUP Confidence Intervals 
 
Scenario 
Parameter Set 95 % Confidence Intervals Overlap 
  
All 
Ages 
Both Genders 2000-2014 Relative to HCUP Discharges 
Base Trend 
Trend 
45-64 
Female 
RR-   
U45 
RR  
65-84 
RR-      
O85 
Female 
45-64 
Female 
65-84 
Female 
85+ 
Male 
45-64 
Male 
65-84 
Male 
85+ 
45-64 65-84 85+ Female  Male Overall Sum 
% 
Inside 
1 0.04 0.06 0.11 0.8 1 0.8 0.1           -    
           
3  
           
3  
          
-    
          
-    
          
-    
           
7  
          
-    
           
2  
           
5  
           
6            -    
        
26  24% 
2 0.038 0.07 0.11 0.8 1 1 0.2 
           
3  
           
3            -    
            
1  
          
-    
          
-    
         
10  
           
3  
          
-    
         
15  
           
5  
          
11  
         
51  47% 
3 0.038 0.08 0.11 0.8 1 1 0.15 
            
1  
           
3            -    
          
-    
            
1  
          
-    
          
11  
           
9  
            
1  
           
7  
           
7  
           
4  
        
44  41% 
4 0.04 0.075 0.11 0.75 1 1 0.1           -    
           
3            -    
          
-    
           
2  
          
-    
          
-    
           
6  
           
3  
         
15  
           
3  
          
11  
        
43  40% 
5 0.043 0.07 0.11 0.75 1 1.1 0.075           -    
           
3  
           
3  
          
-    
            
1  
          
-    
           
7  
           
8  
           
3  
         
10  
           
6  
         
15  
        
56  52% 
6 0.035 0.1 0.115 0.75 1 1.1 0.075 
            
1  
           
3  
            
1  
          
-    
           
3  
          
-    
          
11  
         
10  
           
2  
           
7  
            
1  
           
7  
        
46  43% 
7 0.035 0.1 0.115 0.7 1 1.1 0.07           -    
           
2            -    
          
-    
           
3  
          
-    
           
6  
           
7  
          
-    
           
4  
          
-    
           
4  
        
26  24% 
8 0.035 0.09 0.115 0.65 1 1.1 0.075           -    
           
3  
           
2  
          
-    
           
3  
          
-    
           
6  
         
15  
           
2  
           
6  
          
-    
           
9  
        
46  43% 
9 0.035 0.1 0.115 0.75 1 1.1 0.075 
            
1  
           
2  
            
1  
          
-    
           
3  
          
-    
         
12  
           
2  
           
3  
           
5  
          
-    
           
4  
        
33  31% 
10 0.03 0.09 0.115 0.75 0.09 1.1 0.07 
            
1  
           
3  
           
3  
          
-    
           
3  
          
-    
          
11  
         
15  
           
4  
           
9  
         
15  
         
13  
        
77  71% 
11 0.028 0.09 0.11 0.775 1 1.1 0.068 
           
3  
           
3  
           
2  
            
1  
           
3  
          
-    
            
1  
           
5  
           
5  
           
7  
         
15  
           
8  
        
53  49% 
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Table F-2 Calibration Regression HCUP Confidence Intervals Overlapping  
Scenario 
Parameter Set 95 % Confidence Intervals Overlap 
  
All 
Ages 
Both Genders 2000-2014 Relative to HCUP Discharges 
Base Trend 
Trend 
45-64 
Female 
RR-   
U45 
RR 
65-84 
RR-      
O85 
Female 
45-64 
Female 
65-84 
Female 
85+ 
Male 
45-64 
Male 
65-84 
Male 
85+ 
45-64 65-84 85+ Female  Male Overall Sum 
% 
Inside 
1 0.04 0.06 0.11 0.8 1 0.8 0.1 
           
3  
           
3  
           
3  
           
3  
          
-    
          
-    
          
15  
            
1  
          
15  
          
10  
          
12  
          
15  
         
80  74% 
2 0.0375 0.07 0.11 0.8 1 1 0.2 
           
3  
           
3            -    
           
3  
           
2  
           
3  
          
15  
           
6  
           
3  
          
15  
          
13  
          
15  
          
81  75% 
3 0.0375 0.08 0.11 0.8 1 1 0.15 
           
3  
           
3            -    
           
3  
           
3  
          
-    
          
15  
          
15  
           
6  
          
15  
          
15  
          
15  
         
93  86% 
4 0.04 0.075 0.11 0.75 1 1 0.1 
           
3  
           
3  
           
3  
          
-    
           
3  
           
3  
          
15  
           
9  
          
15  
          
15  
           
7  
          
15  
          
91  84% 
5 0.0425 0.07 0.11 0.75 1 1.1 0.075           -    
           
3  
           
3  
           
3  
           
3  
           
3  
          
15  
          
15  
          
15  
          
15  
          
15  
          
15  
       
105  97% 
6 0.035 0.1 0.115 0.75 1 1.1 0.075 
           
3  
           
3  
           
3  
           
3  
           
3  
           
3  
          
15  
          
15  
          
15  
          
15  
          
15  
          
15  
       
108  100% 
7 0.035 0.1 0.115 0.7 1 1.1 0.07 
            
1  
           
3  
           
3  
           
3  
           
3  
           
3  
          
15  
          
15  
          
15  
           
11  
          
15  
           
11  
         
98  91% 
8 0.035 0.09 0.115 0.65 1 1.1 0.075 
           
3  
           
3  
           
3  
           
3  
           
3  
           
3  
          
15  
          
15  
          
15  
          
10  
           
2  
          
15  
         
90  83% 
9 0.035 0.1 0.115 0.75 1 1.1 0.075 
           
3  
           
3  
           
3  
           
3  
           
3  
          
-    
          
15  
           
5  
           
9  
           
8  
            
1  
           
6  
         
59  55% 
10 0.03 0.09 0.115 0.75 0.09 1.1 0.07 
           
3  
           
3  
           
3  
          
-    
           
3  
           
3  
          
15  
          
15  
          
15  
          
15  
          
15  
          
15  
       
105  97% 
11 0.0275 0.09 0.11 0.775 1 1.1 0.0675 
           
3  
           
3  
           
3  
           
3  
           
3  
          
-    
           
7  
          
15  
          
15  
          
10  
          
15  
          
15  
         
92  85% 
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Table F-3 Calibration Regression MSE Results 
Scenario 
Parameter Set MSE Values 
  All Ages Both Genders 
2000-2014 Relative to HCUP Discharges 
Base Trend 
Trend 
45-64 Female 
RR-
U45 
RR  65-
84 RR-O85 45-64 65-84 85+ Female  Male Overall Sum 
1 0.04 0.06 0.11 0.8 1 0.8 0.1 
     
522,288,882  
  
3,796,724,268  
        
48,003,427  
    
4,040,719,515  
        
119,378,128  
  
3,844,822,294  
      
12,371,936,515  
2 0.0375 0.07 0.11 0.8 1 1 0.2 
     
662,525,205  
  
3,262,034,730  
      
418,424,697  
         
464,011,311  
    
1,903,422,157  
   
2,669,276,185  
      
9,379,694,285  
3 0.0375 0.08 0.11 0.8 1 1 0.15 
    
1,806,257,014  
    
1,830,235,215  
        
161,256,551  
   
3,137,629,548  
     
1,361,079,198  
   
7,023,130,428  
     
15,319,587,954  
4 0.04 0.075 0.11 0.75 1 1 0.1 
  
2,056,403,039  
      
650,563,316  
         
76,297,184  
    
1,555,776,371  
    
3,291,977,163  
   
5,139,666,066  
     
12,770,683,140  
5 0.0425 0.07 0.11 0.75 1 1.1 0.075 
     
835,878,665  
  
2,544,982,767  
         
72,384,715  
     
1,439,015,371  
    
2,181,562,550  
  
3,998,548,855  
     
11,072,372,924  
6 0.035 0.1 0.115 0.75 1 1.1 0.075 
    
1,156,957,886  
  
2,440,685,768  
         
57,950,981  
      
599,214,879  
   
2,801,726,293  
    
5,018,133,848  
    
12,074,669,655  
7 0.035 0.1 0.115 0.7 1 1.1 0.07 
      
622,981,397  
    
2,895,801,901  
         
56,914,056  
   
2,674,035,918  
  
2,458,428,060  
  
4,993,389,640  
      
13,701,550,971  
8 0.035 0.09 0.115 0.65 1 1.1 0.075 
   
1,005,030,686  
   
1,223,933,035  
        
44,993,747  
   
2,921,740,299  
   
2,053,197,798  
   
1,850,564,782  
      
9,099,460,348  
9 0.035 0.1 0.115 0.75 1 1.1 0.075 
     
320,404,048  
      
964,015,243  
           
21,102,441  
      
308,861,482  
    
1,304,324,412  
   
1,926,947,723  
      
4,845,655,349  
10 0.03 0.09 0.115 0.75 0.09 1.1 0.07 
       
386,907,711  
     
225,096,557  
        
22,387,369  
     
939,857,063  
     
272,045,885  
      
524,693,414  
      
2,370,988,000  
11 0.0275 0.09 0.11 0.775 1 1.1 0.0675 
      
710,304,954  
   
1,443,860,739  
        
32,785,672  
  
2,309,097,994  
       
115,502,993  
  
2,954,289,365  
        
7,565,841,718  
 
 
  
197 
Figure F-1 Final Calibration Against HCUP - Overall 
 
Figure F-2 Final Calibration Against HCUP – Females- All Ages 
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Figure F-3 Final Calibration Against HCUP – Males- All Ages  
 
Figure F-4 Final Calibration Against HCUP – Both Genders- 45-64 Year Olds 
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Figure F-5 Final Calibration Against HCUP – Female- 45-64 Year Olds 
 
Figure F-6 Final Calibration Against HCUP – Males- 45-64 Year Olds 
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Figure F-7 Final Calibration Against HCUP – Both Genders- 65-84 Year Olds 
 
Figure F-8 Final Calibration Against HCUP – Females- 65-84 Year Olds 
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Figure F-9 Final Calibration Against HCUP – Males- 65-84 Year Olds 
 
Figure F-10 Final Calibration Against HCUP – Both Genders- 85 Years and Older 
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Figure F-11 Final Calibration Against HCUP – Females- 85 Years and Older 
 
Figure F-12 Final Calibration Against HCUP – Males- 85 Years and Older 
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Figure F-13 TKA Uptake Rates by Group Using Final Calibration Values 
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